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Abstract 
The human brain is one of the most exquisite structures in nature, featuring 
extreme functional complexity and capacities that allow for advanced cognitive abilities. 
During the development of the human brain, neural progenitors undergo massive 
proliferation, which is known to inevitably result in spontaneous mutations; yet the 
degree of somatic mosaicism within the human brain is unexplored. Several hypotheses 
have been proposed that various types of somatic mosaicism may serve as an adaptive 
mechanism to diversify neurons and thereby promote the functional complexity of human 
brains. Previously proposed mechanisms to increase somatic mosaicism within the brain 
include elevated somatic LINE-1 element retrotransposition, and the creation of somatic 
aneuploidy during neurogenesis. On the other hand, genomic diversity needs to be 
balanced by genomic stability, in order to protect against deleterious mutations that 
reduce the fitness of the cells, or oncogenic mutations that might promote cancers. In fact, 
brain-specific somatic mutations have also been proposed to contribute to the 
unexplained burden of neurological diseases. To directly study genomic variability from 
cell-to-cell within the human brain, we developed a method to isolate and amplify single 
neuronal genomes from postmortem and surgically resected human brain tissues. We 
quantified the frequency of somatic LINE-1 retrotransposition events and aneuploidy in 
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human cortical neurons, and found that the frequencies of both are low, with no sign of 
brain-specific elevation, arguing against the hypotheses that these two mutational sources 
are obligate generators of neuronal diversity. Additionally, aneuploidy analysis was 
performed on bulk and single cortical cells from a hemimegalencephaly brain. 
Hemimegalencephaly is an asymmetrical brain overgrowth syndrome caused by somatic 
mutations in brain. Single-cell analysis identified an unexpected mosaic tetrasomy of 
chromosome 1q, affecting both neuronal and glial populations, as a genetic cause of 
hemimegalencephaly. These results demonstrate that single-neuron sequencing allows 
systematic assessment of genomic diversity in the human brain and the identification and 
characterization of pathogenic somatic mutations underlying neurological disorders.
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Overview of Current Knowledge on Human Brain Development and 
Unanswered Questions 
Evolution of human brain 
The evolution of the human brain somehow resulted in the exceptional cognitive 
abilities that make us human. It is generally believed that the enormous expansion in 
human brain size compared to other closely related primate species directly enabled the 
exquisite complexity and diversity of neural cell types and connections that characterize 
the human brain (Rakic, 2009; Lui et al., 2011). Historically, studies on human brain 
development have been mainly descriptive at the anatomical and histological level. 
However, recent technological advances finally allow studies of human brain-specific 
features at the molecular and cellular level. These studies have revealed human-specific 
gene compositions, transcriptional networks and cell types, and have further elucidated 
the uniqueness of the human brain, yet also raise challenges to assessing the functional 
significance of these distinctive features in contributing to human cognitive capacities 
(Konopka et al., 2009; Hawrylycz et al., 2012; Konopka et al., 2012; Zeng et al., 2012). 
Notably, the prefrontal cortex was identified to have the most prominent human-specific 
expression profile as opposed to other brain regions (Konopka et al., 2012), consistent 
with its primary role in higher cognitive functions and its prominent expansion in surface 
area relative to total brain volume during human brain evolution (Rakic, 2009). 
 
Neocortical development 
Human cerebral cortex has been extensively characterized based on gross 
anatomy, cytoarchitecture, and topography. Neocortex, defined by its six-layer 
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cytoarchitecture, is the most recently evolved cortical region, is distinctive in mammals, 
and is the center of higher cognitive functions (Rakic, 2009). Compared to other brain 
regions, the structure of the neocortex is relatively uniform. It is organized into a six-
layer structure, specified by neuronal cell types and connections (Rakic, 2009). To date, 
hundreds of neuronal subtypes have been identified in the neocortex, based on their 
morphological and molecular features, as well as their projection patterns. These 
neuronal subtypes can be categorized into two major classes: excitatory pyramidal 
neurons derived from the dorsal ventricular epithelium, and inhibitory interneurons 
derived from the ventral and possibly also the dorsal ventricular epithelium (Molyneaux 
et al., 2007; Zecevic et al., 2011). The distinctive origin of the two major neuronal cell 
types reflects an important rule of cortical development, such that brain cells derived 
from distant cell lineages tend to have different functions. However, how much these 
distinct cell lineage relationships contribute to the generation of the enormously 
diversified cortical neuronal subtypes remains largely unknown (Molyneaux et al., 2007).   
The regionalization of the neocortex is initiated by patterning centers that secrete 
signaling factors such as FGFs, WNT and BMP at the neural tube stage before the onset 
of neurogenesis (Kiecker and Lumsden, 2012). The maintenance and fate specification of 
neural progenitor cells are further regulated by a series of cell autonomous and non-
autonomous mechanisms during neurogenesis. Based on current knowledge, there are 
two major neurogenic germinal zones: the ventricular zone (VZ), which is conserved 
from primates through rodents; and the outer subventricular zone (OSVZ), which is much 
more prominent in gyrencephalic animals (Breunig et al., 2011; Lui et al., 2011) (Figure 
1-1). It has been hypothesized that the massive expansion of the OSVZ is responsible for 
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Figure 1-1. Expansion of OSVZ progenitors in human compared to rodents. Adapted from Lui et 
al. (2011) 
(A) Current view of rodent corticogenesis. The germinal zone is made up by the ventricular zone (VZ), 
populated by radial glial cells (RG) and subventricular zone (SVZ), populated by intermediate 
progenitors (IP). Very few outer radial glia (oRG) are observed from rodent brains. 
(B) Current view of human corticogenesis. In addition to the VZ and SVZ, a prominent outer 
subventricular zone (OSVZ) populated by oRG and OSVZ IP cells are observed in developing human 
cortex. The expansion of OSVZ population is thought to account for the tangential expansion of human 
cortex surface area.  
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the elaboration of cortical gyri, and the tangential expansion of neocortical surface area in 
primates and human (Hansen et al., 2010; Lui et al., 2011; Reillo et al., 2011), but this remains 
unproven. Both the VZ and OSVZ contain heterogeneous progenitor cell populations, which can 
be broadly classified into self-renewing radial glia (RG and oRG) and transit-amplifying 
neurogenic intermediate progenitors (IP). Understanding of the cell lineage relationship between 
different OSVZ progenitor cell types and their extremely diversified neuronal progenies remains 
a major challenge in understanding human cortical development and evolution.  
 
Open questions and challenges 
The recent discoveries on OSVZ progenitors, human specific neuronal subtypes and 
human specific patterns of gene expression have begun to shed some light on the cellular and 
molecular mechanism of human brain evolution (Lui et al., 2011; Hawrylycz et al., 2012; 
Konopka et al., 2012; Zeng et al., 2012). It is conceivable that new classes of neurons allow the 
formation of new patterns of connections, which increases the capacity and flexibility of 
cognitive abilities. It is tempting to ask whether the expansion of OSVZ progenitor pool in 
human brain contribute to its increased neuronal diversity, and whether there exists human 
specific progenitor cell populations that give rise to particular neuronal subtypes enabling our 
higher cognitive functions. Development of new cell lineage tracing techniques in human brain 
will help to start addressing these questions. 
 
Brain malformations as an avenue to study brain development 
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Our increasing knowledge of human brain development helps us to understand the 
disease mechanisms of common neurodevelopmental disorders, such as autism spectrum 
disorders (ASD), schizophrenia (SCZ), intellectual disability (ID) and epilepsy (LaMonica et al. 
2012). Meanwhile, human neurodevelopmental disorders provide great opportunities to study 
normal brain development at the molecular level. Brain malformations are rare and severe forms 
of neurodevelopmental disorders with anatomical alteration of brain structures that are easily 
identified radiographically.  Brain malformations are often caused by the disruption of key 
aspects of brain development, such as neurogenesis, neuronal migration, and axon guidance. 
Therefore, brain malformations are often associated with one or multiple neurological conditions 
such as ID, ASD and epileptic seizures. On the other hand, more common and milder 
neurological and neuropsychiatric conditions, such as non-syndromic ASD, non-lesional 
epilepsy (epilepsy conditions without radiographically identifiable lesions), SCZ and bipolar 
disorder (BIP), are associated with more subtle defects of neurological function, such as synaptic 
function and ion channels (Sullivan et al. 2012; State & Sestan 2012). Therefore, studies of 
severe brain malformation disorders often lead to understanding of the more fundamental aspects 
of brain development. For instance, genetic disorders resulting in abnormal brain size provide 
tremendous insights into the regulation of neurogenesis that ultimately determines brain size 
(Gilmore & Walsh 2012).  
 
Microcephaly 
Human autosomal recessive primary microcephaly (meaning “small brain”) (MCPH) is a 
genetically heterogeneous neurodevelopmental disorder defined by marked reduction in brain 
size with grossly preserved brain architecture at birth. Clinical features of MCPH also include 
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intellectual disability with variable severity and occasional seizures (Thornton & Woods 2009). 
To date, more than ten genes have been identified to cause this rare genetic disorder; and 
remarkably, most of these genes encode proteins associated with centrosomal and microtubule-
related cellular functions, with a few exceptions that are involved in DNA damage repair 
(Gilmore & Walsh 2012; Shen et al. 2010). The centrosome plays multiple roles in regulating 
cell divisions and cytoskeletal reorganization (Bettencourt-Dias et al. 2011) (Figure 1-2). The 
functional convergence between centrosome and DNA damage repair is cell cycle regulation, 
which empirically confirms the speculation that brain size is largely regulated by proliferation of 
neural progenitor cells during neurogenesis. It is interesting to note that despite their ubiquitous 
expression and expected cellular function throughout the body, most MCPH-associated 
centrosomal mutations cause brain-specific defects, with a few exceptions such as PCNT, and 
some cases in CEP152 and CENPJ (Al-Dosari et al. 2010; Kalay et al. 2011; Griffith et al. 2008), 
suggesting that brain is more susceptible to cell proliferation defects. This is presumably due to 
the extremely high demand in progenitor pool expansion within the small timeframe of 
neurogenesis. 
 
Lissencephaly 
Lissencephaly (meaning “smooth brain”) is another genetic neurodevelopmental disorder 
characterized by simplified gyrification that leads to a smooth cerebral surface, mental 
retardation and seizures, as a consequence of severe defects in neuronal migration (Wynshaw-
Boris et al. 2010). Mutations of a number of genes have been identified as the genetic causes of 
lissencephaly, including LIS1, DCX, TUBA1A and RELN, all of which are involved in 
cytoskeletal organization and thereby are essential for proper neuronal migration (Wynshaw-
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Boris et al. 2010; Manzini & Walsh 2011). Although it was originally thought that microcephaly 
and lissencephaly are separate disorders with distinct cellular processes being affected during 
neurodevelopment, the identification of WDR62 mutations causing both profound microcephaly 
and simplified gyrification blurs the boundary of the two disorders and suggests cellular 
pathways that intersect neural progenitor proliferation and neuronal migrations (Nicholas et al. 
2010; Yu et al. 2010; Bilguvar et al. 2010). Most lissencephaly cases are caused by mutations 
involving LIS1 or DCX. Human LIS1 mutations are mostly de novo dominant mutations, 
involving the heterozygous deletion of 17p13.3, which leads to haploinsufficiency of the LIS1 
gene. DCX mutations are the major genetic causes of X-linked lissencephaly. Hemizygous males 
show classic lissencephaly phenotype, whereas heterozygous females show mosaic phenotype of 
an extra subcortical band, referred as “double cortex syndrome” (Walsh & Engle 2010; Gleeson 
et al. 1998). 
 
Hemimegalencephaly 
Hemimegalencephaly (HME) is a sporadic epileptic disorder characterized by the 
enlargement and malformation of one cerebral hemisphere (Flores-Sarnat et al. 2003). Two 
emerging studies have pinpointed somatic hyperactivation of the PI3K-AKT-mTOR pathway to 
be a major genetic cause of this disorder (Poduri et al. 2012; Lee et al. 2012). PI3K-AKT-mTOR 
pathway has been extensively characterized as a signaling pathway that responds to external 
growth factors to regulate cell proliferation, growth and survival; hyperactivation of the pathway 
is frequently observed in human cancers (Engelman et al. 2006) (Figure 1-3). 
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Figure 1-2 Summary of centrosomal genes involved in microcephaly. Adapted from Bettencourt-
Dias et al. (2011). 
Mutation involving multiple aspects of centrosome biology including procentriole duplication, elongation 
and centrosome maturation/separation were all identified, suggesting the convergence of a molecular 
pathway in causing a particular disorder.  
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Figure 1-3. PI3K/AKT/mTOR molecular pathway regulates cell growth, survival and proliferation. 
Adapted from Engelman et al. (2006). 
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These findings independently demonstrated how misregulation of neural progenitor cell 
proliferation can directly alter the brain size and consequently disrupt cognitive function. 
Notably, HMG and other megalencephaly/macrocephaly disorders are often associated 
with secondary anomalies in neuronal migration, whereas the primary microcephaly 
disorders often show no obvious brain anomalies other than simplification of the gyral 
pattern (Barkovich et al. 2012). This suggests that neuronal production and migration are 
highly synchronized processes during corticogenesis, and thereby the normal neuronal 
migration machineries cannot accommodate the misregulated excessive neuronal 
production. Such difference may partially explain why HMG patients exhibit much more 
prominent epileptic symptoms than MCPH patients (Flores-Sarnat 2002). 
 
Genetic Mutational Mechanisms of Neurodevelopmental Disorders 
From inherited to de novo mutations 
Historically, conventional human genetics studies have primarily focused on 
inherited germline mutations as the basis of Mendelian diseases. Many rare and severe 
brain malformations are caused by autosomal recessive mutations carried by both healthy 
parents in the heterozygous state. Therefore, linkage analysis on the family pedigree has 
led to tremendous success in the identification genetic causes underlying these severe 
developmental disorders, with discoveries of essential genes involved in critical aspects 
of cortical development (Walsh & Engle 2010).  In contrast, for more prevalent and 
milder conditions such as ASD, the genetic causes of the majority of cases (75-80%) 
remain unidentified following traditional methods (Miles 2011). Recent technological 
advances in high-resolution genomic microarrays and next-generation sequencing (NGS) 
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allow the identification of de novo or spontaneous germline mutations as important 
contributors of complex and sporadic neurodevelopmental disorders (Sanders et al. 2011; 
Levy et al. 2011; Sanders et al. 2012; State & Sestan 2012; Kong et al. 2012). Even more 
recently, the identification of several “brain-specific” somatic mosaic mutations as the 
genetic cause of brain malformations has further extended the spectrum of the mutational 
mechanisms of neurodevelopmental disorders (Poduri et al. 2012; Rivière et al. 2012; Lee 
et al. 2012). 
 
De novo CNVs and SNVs 
De novo mutations are defined as “new” genetic variants that are not present in 
either of the parents. They can arise in the germline of either parents, or post-zygotically 
during embryogenesis (Veltman & Brunner 2012; Vadlamudi et al. 2010). It has been 
widely speculated that rare sporadic genetic diseases are often caused by extremely 
deleterious de novo mutations, which would otherwise be under strong negative selective 
pressure due to the reproductive disadvantage of the patients (Eyre-Walker & Keightley 
2007). More recently, a pioneering study carried out by Sebat, et al. (2007) show that the 
occurrence of de novo copy number variations (CNVs) is considerably elevated in 
patients with sporadic autism compared to healthy controls, suggesting de novo germline 
mutations as significant genetic contributors of complex diseases, particularly in 
neurodevelopmental disorders (Sebat et al. 2007).  
With the widespread application of high-resolution genomic microarrays and 
next-generation sequencing in the recent years, a number of subsequent studies confirmed 
and refined the role of de novo mutations, including de novo CNVs and de novo single 
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nucleotide variants (SNVs), as important genetic risk factors of sporadic 
neurodevelopmental disorders (Vissers et al. 2010; O'Roak et al. 2011; Levy et al. 2011; 
Sanders et al. 2011; Gilman et al. 2011; Girard et al. 2011; Xu et al. 2011; Sanders et al. 
2012; O'Roak et al. 2012; Neale et al. 2012; Iossifov et al. 2012; Mefford et al. 2010). 
Based on these large-scale genome-wide studies, the average de novo mutation rate for 
SNVs was estimated to be 1.2 X 10-8 per nucleotide per generation, resulting in 74 de 
novo germline SNVs in each individual’s genome (Kong et al. 2012; Conrad et al. 2011). 
Additionally, de novo SNVs are found be predominately paternal in origin and age-
dependent, suggesting replication errors as the major contributor to these mutations 
(Kong et al. 2012). De novo small indels and large CNVs (>100kb) are thought to occur 
at much lower frequency, estimated to be 3 per genome per generation and 1 out of 50 
genomes per generation, respectively (Itsara et al. 2010; Fu et al. 2010). Despite their low 
frequency, large de novo CNVs collectively alter a larger fraction of the genome and are 
usually more deleterious and relevant to disease. 
Neurodevelopmental disorders, including ID, ASD, SCZ and epilepsy, often 
manifest overlapping phenotypes, presumably as a consequence of general impairment of 
nervous system development. Remarkably, these disorders also share a highly similar 
large CNV landscape, with a number of recurrent CNVs being observed across diverse 
neurological phenotypes (Xu et al. 2008; Sharp et al. 2008; Mefford et al. 2008; de Vries 
et al. 2005; Sanders et al. 2011). These observations lead to a hypothesis that large CNVs 
tend to disrupt the homeostasis of normal neuronal development, which accounts for the 
increased CNV burden in a wide spectrum of neurodevelopmental and neuropsychiatric 
conditions (Coe et al. 2012). Rare and recurrent CNVs can be both inherited and de novo, 
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with CNV size positively correlated to the probability of arising de novo (Itsara et al. 
2010). The molecular mechanisms underlying the formation of CNVs and structural 
variants (SVs) are currently under vigorous investigations and remain controversial. 
Three major mechanisms have been shown to account for the majority of CNVs: non-
homologous end joining (NHEJ); replication-based mechanisms including fork stalling 
and template switching (FoSTeS) and microhomology mediated break-induced 
replication (MMBIR); and non-allelic homologous recombination (NAHR) (Zhang et al. 
2009; Conrad et al. 2010; Mills et al. 2011; Kidd et al. 2010; Chiang et al. 2012). Each 
mechanism generates breakpoints with distinctive features and is associated with 
characteristic mutational “hotspots” that lead to the formation of recurrent CNVs (Fu et al. 
2010; Itsara et al. 2009; Mills et al. 2011). Several large recurrent CNVs associated with 
neurological phenotypes are thought to occur at meiotic recombination hotspots with 
segmental duplications (SD) by NAHR (Turner et al. 2008; Itsara et al. 2012; Zhang et al. 
2009; Veltman & Brunner 2012); and therefore, they primarily arise de novo during 
germline development. However, in rare cases, recurrent de novo CNVs can also happen 
at post-zygotic stage, resulting in special conditions named germline and somatic 
mosaicism (Koolen et al. 2012).  
 
From germline to somatic mutations  
De novo (meaning “new”) mutations are operationally defined by as “new” 
genetic variants that are not detected in either of the parents. In fact, there are three 
different types of new mutations that fit under the umbrella term “de novo.” Type I 
mutations arise in the germline of the parents due to either meiotic or mitotic errors to 
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give a single or a small number of mutated gametes. This type of mutation is transmitted 
to the child through a parent but the siblings are unlikely to be affected because the 
mutation would only present in a very limited number of gametes from the affected 
parent. Type II mutation arises at the post-zygotic stage during early embryonic 
development of the affected child, due to mitotic errors. This type of mutations is not 
transmitted from the parents and thereby is not detectable from the parents and is not 
recurrent among siblings. Depending upon when a type II mutation arises, it may affect 
only a fraction of cells from the whole body, a condition named as “somatic mosaicism” 
(Figure 1-4). Type III mutation arises during the post-zygotic development of the 
affected parent, resulting in a portion of germline cells carrying the mutation, and the 
mutation being transmitted to the child through an affected gamete. This condition is 
named as “germline mosaicism.” Although the parent carries the mutation at a mosaic 
state, they are often misdiagnosed as non-affected due to the limitation of standard 
genetic testing on minor alleles that present at low level. Type III mutations are the only 
type of de novo mutations that lead to occasional recurrence among the siblings. Current 
studies on “de novo” mutations have primarily focused on type I mutations by identifying 
mutations not shared with the parents from simplex (non-recurrent) families (Sanders et 
al. 2012; Sanders et al. 2011; Iossifov et al. 2012; O'Roak et al. 2011; Xu et al. 2011; 
Levy et al. 2011). Type II and III mutations can also be occasionally detected and 
misclassified as type I mutations in these studies. The major 
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Figure 1-4. Schematic for the generation somatic mosaicism. Adapted from Youssoufian et al. 
(2002).  
The percent of cells affected by a somatic mutation depends on its functional consequence on fitness as 
well as the time point when the mutation occurs.  
 
 
	  
17	  
focus of this dissertation is to develop effective methods to detect type II somatic 
mutations and to explore their contribution in the development of normal and diseased 
human brains. 
Type II somatic mutations can be further classified into mutations arising during 
embryonic development and mutations arising postnatally throughout adulthood. 
Although with some overlap, the mutational mechanisms and functional consequences of 
somatic mutations arising at these two distinct developmental stages can be drastically 
different.  
During embryogenesis, the single fertilized zygote is programmed to generate ~10 
trillion cells that compose the human body through trillions of cell divisions (Erickson 
2010). Genetic errors are inevitably introduced with each cell division due to the 
imperfections of DNA polymerases and the DNA damage repair machinery; therefore, 
we would expect our body to carry a tremendous number of somatic mutations and every 
cell in the body is likely to be different (Frumkin et al. 2005). Theoretical calculation 
predicts that every gene in the genome mutates many times throughout any individual’s 
lifespan based on an estimated somatic mutation rate on the order of magnitude 10-7 -10-6 
(Frank 2010). Despite the large number of somatic mutations present in our body, their 
functional consequences remain mostly uncharacterized. Similar to germline mutations, 
somatic mutations can be functionally neural, deleterious or advantageous. It is also 
important to note that for any given somatic mutation to have a significant functional 
effect at the organismal level, such mutation needs to be shared by a sufficient number of 
cells. Therefore, a somatic mutation with functional significance would either occur in a 
progenitor cell at very early stage of embryogenesis or result in a proliferative advantage 
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to the founder cell leading to its preferential clonal expansion (Erickson 2010). 
Additionally, deleterious mutations arising at early stages of embryogenesis are likely to 
be eliminated or diluted out during development. Several recent studies of chromosomal 
mosaicism in human preimplantation embryos highlight the prevalence of these early 
mutational events, suggesting that frequent somatic chromosomal instability may largely 
contribute to spontaneous miscarriages and constitutional chromosomal disorders, which 
were previously thought to originate primarily from the parental germline as type I de 
novo mutations (Vanneste et al. 2009; van Echten-Arends et al. 2011). On the other hand, 
despite the high prevalence of chromosomal mosaicism at the blastocyst stage, the 
noticeable preferential development of a diploid fetus from a mosaic embryo 
demonstrates that aneuploid cells at early embryonic stages are under strong negative 
selection, consistent with the predicted deleterious effect of aneuploidy (Eggan et al. 
2002; van Echten-Arends et al. 2011). Taken together, the functional consequence of any 
somatic variant depends on both the time point at which it arises and its functional effect 
on the founder cell and its immediate progeny. The phenotypic manifestations of somatic 
mutations range from benign (e.g. birthmarks) to some most aggressive forms of human 
diseases (e.g. overgrowth syndromes and cancers). 
Somatic mutations continue to arise postnatally, throughout individuals’ lifespan. 
Similar to somatic mutations generated during embryo development, most postnatal 
somatic mutations arise through mitotic errors during tissue turnovers. Therefore, the 
abundance of somatic mutations generated postnatally highly depends on the tissue types 
and their turnover rates. For instance, skin epithelium and hematopoietic cells undergo 
rapid self-renewal, whereas the neurons that constitute 30% of the brain are strictly post-
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mitotic with the exception of the hippocampus and olfactory system (Pellettieri & 
Alvarado 2007). Therefore, a much higher rate of replication-driven somatic mutations is 
expected in skin and hematopoietic system compared to brain. Examples of somatic 
mutations in normal individuals include moles growing on the skin, while recent studies 
confirm that somatic CNVs present at different frequencies between different tissues and 
they tend to accumulate with aging (Jacobs et al. 2012; Laurie et al. 2012; O’Huallachain 
et al. 2012). Somatic mutations can also occur in post-mitotic and quiescent cells due to 
flawed DNA damage repair. Neurons are the most unique type of post-mitotic cells, 
surviving for decades throughout our lifespan; therefore, it is expected that neurons 
would potentially accumulate more post-mitotic somatic mutations than other cells in the 
body. The genome instability of post-mitotic neurons is highlighted by observations that 
the CAG repeats causing Huntington’s Disease (HD) continue to expand in post-mitotic 
neurons with focal somatic expansion of the CAG repeats often leading to early-onset of 
HD (Gonitel et al. 2008). The prevalence of age-related somatic mutation in normal brain, 
and its contribution to age-related neurological conditions, are important but technically 
challenging to explore with current technologies.  
 
Somatic Mutations and Diseases 
Although not commonly recognized, somatic mutations may contribute to a 
substantial portion of sporadic genetic diseases that are enriched for type I de novo 
germline mutations. In fact, many of the recurrent de novo mutations associated with 
neurodevelopmental disorders also arise as somatic mutations. For instance, heterozygous 
mutations in SCN1A, gene encoding the α1-subunit of the type I neuronal voltage-gated 
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sodium channel, are the primary genetic cause of Dravet syndrome, a severe, sporadic 
epileptic syndrome of infancy that is also associated with ID and ASD. 95% of SCN1A 
mutations identified are regarded as de novo (Vadlamudi et al. 2010; Gennaro et al. 2006). 
However, study of monozygotic twins with Dravet syndrome demonstrated that the de 
novo mutations could occur both in the parental germline—leading to concordant twins—
or at post-zygotic stages resulting in discordant twins (Vadlamudi et al. 2010). Moreover, 
it is predicted that many of the most severely deleterious mutations can only exist as 
mosaic somatic mutations affecting a subset of cells in a human body, since they would 
be incompatible with life if affecting the whole body (Happle 1987). Therefore, somatic 
mutations exhibit a wider mutational spectrum than germline mutations, and may explain 
many disorders with unidentified genetic causes. This prediction is well supported by the 
observation that a number of chromosomal aneuploidy disorders other than trisomy 13, 
18, 21 could only be tolerated as somatic mosaics (Erickson 2010). More recently, the 
genetic cause of Proteus syndrome, characterized by local overgrowth of skin, connective 
tissue and brain, was identified as a mosaic activating mutation in the AKT1 gene, which 
results in a significant proliferative advantage of affected cells (Lindhurst et al. 2011). It 
is predicted that such mutation would otherwise be lethal in a non-mosaic state. This 
inspiring finding directly stimulated a number of additional studies identifying somatic 
activation mutations targeting the PI3K-AKT-mTOR pathway as the genetic causes of 
similar overgrowth syndromes (Hussain et al. 2011; Poduri et al. 2012; Lee et al. 2012; 
Rivière et al. 2012). In particular, our group identified the first “brain-only” somatic 
activating mutation in AKT3 as one of the genetic causes of a brain overgrowth syndrome, 
hemimegalencephaly (HMG) (see previous section “Hemimegalencephaly”). Focal 
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lesions are a common characteristic feature of these somatic overgrowth syndromes; 
therefore, we hypothesize that additional brain malformation conditions involving focal 
lesions with unidentified genetic causes, such as focal cortical dysplasia (FCD)—an 
epileptic developmental brain lesion with neuropathological abnormalities suggestive of 
an early disruption of the normal brain development—are also likely to be ultimately 
explained by somatic mutations.  
To further extend the importance of somatic mutation in the context of 
neurodevelopment, somatic mutations that do not confer proliferative advantages have 
also been previously identified, leading to local perturbations of normal brain 
development. For example,  dominant mutation of LIS1 and X-linked mutation in DCX in 
males can occur in a mosaic state to perturb the neuronal migration of a subset of neurons, 
resulting in the “double cortex” pattern, a milder form of lissencephaly (Sicca et al. 2003; 
Gleeson et al. 2000). Both the LIS1 and DCX1 somatic mutations were detectable from 
tissues outside of the brain, suggesting that the mutation occurred early in embryogenesis, 
before the neural lineage was specified. More importantly, the phenotypic manifestation 
of the disease depends on the percent mosaicism, consistent with the previous prediction 
that the earlier a somatic mutation arises during development, the more likely it is to 
cause a pathogenic condition (Gleeson et al. 2000; Erickson 2010). Furthermore, somatic 
mutations disrupting neurodevelopment or neuronal functions do not necessarily result in 
anatomically visible lesions. They could potentially also account for the complex 
idiopathic forms of neurological conditions, including non-syndromic ID and ASD, non-
lesional epilepsy, and SCZ. As previously mentioned, de novo mutations in genes 
encoding ion channel subunits, such as SCN1A and SCN2A, are recurrently identified in 
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both syndromic and idiopathic (non-syndromic) forms of epilepsy and ASD, arising 
either at post-zygotic stage or in parental germline (O'Roak et al. 2011; Gennaro et al. 
2006; O'Roak et al. 2012; Sanders et al. 2012). Similar to point mutations, recurrent 
CNVs that are known to arise de novo also occur both at post-zygotic stages and in the 
parental germline (Koolen et al. 2012). It is expected that mutations altering neuronal-
specific functions, such as ion channels and neurotransmitter receptors, can severely 
impair cognitive functions while gross brain structure may remain intact. Mutations 
regulating neural-specific functions would not be under negative selection pressure 
during embryogenesis and would therefore be expected to be preserved if they occur 
early in development. However, the contribution of somatic mutations to sporadic 
neurodevelopmental and neuropsychiatric conditions is as of yet largely unexplored and 
should be a high priority of the field. It would also be interesting to determine whether 
the percent mosaicism of a somatic mutation correlates with the severity of the patient 
phenotype and the penetrance of a particular mutation. These studies will definitely add 
insight into the genetic heterogeneity as well as the variable penetrance and expressivity, 
of recurrent mutations identified in complex neurodevelopmental disorders. The major 
technical hurdle of addressing these question remains the limitation of current sequencing 
methods in detecting low-level mosaic somatic mutations. 
The major challenge of detecting somatic variants from bulk samples (i.e. DNA 
extracted from a pool of affected and non-affected cells) is that the signal of the somatic 
variants is severely diluted out from the normal alleles present in the non-affected cells in 
the same sample. This problem becomes more pronounced when the percent mosaicism 
of the somatic variants gets low in the tissue being sampled. Current mutation detection 
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models assume that a mutant allele accounts for at least 50% of the signal, whereas 
somatic variants would only account for a much smaller fraction and would be likely 
regarded as signal noise that does not trigger a variant call. Tissue accessibility is the 
other major challenge for the detection of somatic mutations since the affected tissue, 
which presumably is most enriched for the mutation, may not always be available for 
genetic testing. For most neurological disorders, DNA specimens derived from blood are 
studied and brain tissues are largely unavailable; therefore it is predicted that most 
somatic mutations present in the brain but absent (or present at low-level) in blood would 
be missed. The development and implementation of non-invasive tissue sampling would 
be essential to address this issue.  
Given the challenges, specific experimental designs are often required for studies 
of somatic mutations. For instance, studies that systematically survey a variety of tissue 
types led to the identification of somatic variants in both normal and diseased individuals 
(O’Huallachain et al. 2012; Kurek et al. 2012).With growing interest on studying low-
level mosaic CNVs, several groups have recently developed bioinformatic tools to detect 
mosaic large CNVs from SNP/CNV hybrid microarrays by combining the subtle logRR 
change (log2 ratio measuring the copy number) with allelic imbalance indicated by the 
deviation of BAF score (B-Allele-Fraction) from expected heterozygous state (Jacobs et 
al. 2012; Laurie et al. 2012; Vattathil & Scheet 2013). These studies have shown that 
somatic mosaic CNVs exist in the blood of normal individuals and expand clonally. More 
interestingly, the frequency of detectable clonal mosaicism increases with age and is 
positively correlated with the risk of developing hematopoietic cancers (Jacobs et al. 
2012; Laurie et al. 2012). Although these studies were able to detect large somatic CNVs 
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down to <10% percent mosaicism from bulk DNA, they are limited to a single class of 
mutation and are limited to the SNP chip platforms which are slowly getting replaced by 
next-generation sequencing (NGS) platforms. Compared to SNP chips, NGS allows the 
assessment of a full spectrum of mutations, including SNP, CNV/SV at higher resolution 
than SNP chips, retrotransposition insertions (L1, Alu and SVA) and microsatellites (MS) 
mutations; however, the tools available for studying somatic mutations from NGS data 
are still extremely lacking and have been barely applied to the detection of somatic 
mosaicism from normal tissues outside of cancers (Dewal et al. 2012). Furthermore, there 
will always be a technical detection limit of somatic mutations with low percent 
mosaicism from bulk samples when the signal level falls below the spontaneous 
sequencing error rate with the current sequencing technologies. 
It is also important to note that somatic mutations arising postnatally are 
significantly more challenging to detect than those occurring at early embryonic stages 
because of their relative lack of clonality. Cells undergoing postnatal turnover are mostly 
terminally differentiated; therefore a somatic mutation acquired at a late stage will only 
affect a small number of cells with two exceptions: 1) if the mutation results in a 
proliferative advantage, which may lead to clonal expansion and often the development 
of benign tumors; 2) if a progenitor cell responsible for tissue turnover carries a somatic 
mutation either originating during embryonic development or acquired through flawed 
DNA damage repair during its quiescent stage, such a somatic mutation can be expanded 
clonally and become detectable by current technologies. Therefore, we choose to focus 
on somatic mutation arisen during embryonic development since they are technically 
easier to detect and highly relevant to neurodevelopmental disorders. 
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Somatic mosaic syndromes were first described by cytogeneticists decades ago 
using karyotyping to identify mosaic chromosomal disorders. The major advantage of 
karyotyping is its single cell resolution, which allows definitive separation and 
characterization of the small proportion of cells carrying the somatic mutations. However, 
this method is limited to the identification of large, microscopically visible chromosomal 
abnormalities. In order to systematically identify and quantify somatic mutations, whole 
genome sequencing of single cells would be necessary. Substantial progress has been 
made in single cell genomics in the past a few years, yielding valuable insight into the 
genetic heterogeneity of cancers and providing exciting future directions in characterizing 
somatic mosaicism of normal and disease human brains (Navin et al. 2011; Hou et al. 
2012; Xu et al. 2011). These recent advances will be reviewed in the following section 
“Overview of Recent Advances in Single-Cell Sequencing Technology and Applications.” 
 
Somatic variants in normal brains 
There are ~100 billions neurons in the human brain, comprising by different 
neuronal subtypes that are specified by morphology, gene expression, and patterns of 
connections. Furthermore, each neuron is estimated to form thousands of synapses with 
other neurons, and these synapses are responsible for each neuron’s distinctive activities 
and functions, leading to the speculation that within each neuronal subtype, functional 
diversity further exists at the level of single neurons (Singer et al. 2010). Such an 
exquisite functional diversity has been proposed to account for our exceptional cognitive 
capacities. One of the major questions remains in neuroscience remains to understand the 
molecular basis of this functional diversity, which is together defined by intrinsic and 
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extrinsic factors. The proposed intrinsic attributes of neuronal diversity include the 
diversified expression patterns, epigenetic modifications, as well as genetic mosaicism 
(Muotri & Gage 2006).  Although it is intriguing to propose that somatic variants 
positively contribute to the functional diversity of neurons, such a mechanism has to be 
balanced by the need for genome stability, as evident by the pathogenic somatic 
mutations causing neurological disorders (see previous section “Somatic mutations and 
diseases”). 
There have been long-standing hypotheses about the potential contribution of 
genetic variability in neurons to neuronal diversity but this topic remains highly 
controversial. In the 60’s and 70’s, several studies showed that Purkinje cells were 
tetraploid, which was further speculated to contribute to their distinct morphology and 
functions (Lapham 1968). However, these findings were later challenged and corrected in 
the late 70’s and 80’s as technical inconsistencies on DNA quantification (Mann et al. 
1978; Swartz & Bhatnagar 1981). In the 90’s, a series of studies suggested the potential 
involvement of the V(D)J recombination mechanism in the central nervous system (CNS) 
for genome diversification analogous to the immune system, stemming from the 
observation of brain expression of the recombination activating protein RAG-1, a key 
factor of the V(D)J recombination machinery (Chun et al. 1991). Furthermore, some 
human syndromes as well as mice mutants with DNA damage repair (DDR) defects only 
affect the immune and nervous system, suggesting some functional similarities between 
the two (Gao et al. 1998). However, studies of potential genetic recombination in brain 
were not thoroughly followed up or were proven otherwise using different experimental 
systems (Abeliovich et al. 1992).  Extensive DNA rearrangements in neuronal genomes 
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were also hypothesized followed by the initial failure of cloning of viable mice from 
post-mitotic neurons (Hochedlinger & Jaenisch 2002). However, this was again disputed 
by the later success of cloning of a functionally normal mouse from an olfactory neuron 
(Eggan et al. 2004). Mechanisms of genetic diversity in the CNS continued to be 
explored and led to two recent hypotheses that somatic L1 retrotransposition and somatic 
aneuploidy may serve as somatic mutational mechanisms during neurogenesis to generate 
somatic variation and diversity (Singer et al. 2010; Rehen et al. 2005).  
Human-specific LINE-1 (L1Hs) retrotransposons comprise the only known active 
autonomous transposon family in humans, with ~80-100 active L1Hs elements per 
individual (Hancks & Kazazian 2012). The activities of L1Hs have been mostly 
characterized in the germline, with a few recent reports of the occurrence of somatic 
L1Hs insertions in cancerous and normal cells (Miki et al. 1992; van den Hurk et al. 2007; 
Iskow et al. 2010; E. Lee et al. 2012a). However, a systematic characterization of L1Hs 
activity in somatic tissues is still lacking. Recent studies observed rare retrotransposition 
events of a L1Hs reporter gene in rodent brain in vivo, suggesting that L1Hs are active 
somatically during neurogenesis at some level in rodents (Muotri et al. 2005; Muotri et al. 
2010). Furthermore, in vitro study of human neural progenitors estimated the rate of 
somatic L1Hs insertions to be around 10-5 events/cell based on the same L1Hs GFP-
reporter used the in vivo studies on rodents (Coufal et al. 2009). However, an independent 
qPCR-based method on bulk DNA extracted from primary human brain tissues indirectly 
estimated a much higher rate of retrotransposon insertion of around 80-100 events/cell in 
hippocampus (Coufal et al. 2009). One additional study found evidence for widespread 
somatic L1Hs insertions in the human brain by targeted capture and deep sequencing 
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from bulk DNA (Baillie et al. 2011). However, these authors were unable to estimate a 
insertion rate due to the method limitation.  Although intriguing, these studies are not 
entirely consistent with each other and are not direct proof of somatic retrotransposition 
activity since they failed to identify bona fide somatic insertions with their biological 
hallmark, namely target site duplication (TSD). Furthermore, the large discrepancy 
between the estimation of the retrotransposition rates in vitro and in vivo urges the use of 
an independent method that allows direct estimation of the insertion rate from human 
brain. Single cell analysis would achieve both goals by systematically identifying and 
quantifying somatic insertions from neurons directly isolated from human brains.  
Aneuploidy defines a condition where the chromosome number within a cell 
deviates from the wildtype by part of a chromosome set. For instance, the human euploid 
genome contains 46 chromosomes, and the most common aneuploid condition in human 
is trisomy 21, the genetic cause of Down syndrome, which contains 47 chromosomes 
with an extra chromosome 21. Aneuploidy arises from chromosome mis-segregation 
during either mitosis or meiosis due to various mechanisms, including spindle-assembly 
checkpoint (SAC) defects, kinetochore and microtubule defects, and multipolar spindles 
(Siegel & Amon 2012). The functional consequence of aneuploid cells often includes 
slower proliferation, energy and proteotoxic stress, and genomic instability (Siegel & 
Amon 2012). Although generally detrimental, aneuploidy can also serve as a fast 
adaptive mechanism to improve fitness under selective pressure (Yona et al. 2012; Siegel 
& Amon 2012). Naturally occurring somatic aneuploidies have been reported from liver 
and brain, both resulted by multipolar mitoses (Rehen et al. 2001; Rehen et al. 2005; 
Duncan et al. 2010). Within human liver hepatocytes, greater than 25% were shown to be 
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aneuploid based on karyotyping; and the prevalence of aneuploid cells appears to 
associate with stress and increases with aging in mouse models (Duncan, Hanlon Newell, 
Smith, et al. 2012b; Duncan, Hanlon Newell, Bi, et al. 2012a). An increased rate of 
aneuploid cells has also been claimed in mice and human brain. It was initially observed 
in mouse neural progenitors of which ~33% were showed to be aneuploid, by spectral 
karyotyping (SKY). This rate substantially decreased in mature neurons, assayed by 
interphase FISH targeting the sex chromosomes, suggesting that the observed aneuploidy 
of progenitors confer proliferative disadvantages, premature differentiation or cell death 
(Rehen et al. 2001). Follow-up studies were carried out by the same group showing that 
the aneuploid progenitors arise from multipolar mitoses and that the aneuploid neurons 
observed in mice were functionally integrated into the neuronal circuitry (Yang et al. 
2003; Kingsbury et al. 2005). A similar study was carried out to quantify the prevalence 
of aneuploidy in human brains; both neurons and glial cells from human brain tissue 
showed a slight increase in aneuploid frequency (5%) compared to lymphocytes control 
(0.6%) based on interphase FISH against chromosome 21 (Rehen et al. 2005). The 
authors further argued that this might be a significant underestimation of aneuploid cell 
frequencies since they only assayed for a single chromosome. These studies taken 
together generated a hypothesis that elevated levels of somatic neuronal aneuploidy may 
serve as a mechanism to generate genetic diversity within the human brain, analogous to 
the increased level of somatic retrotransposition (Muotri & Gage 2006).  
Studies of neuronal aneuploidy in brain are subject to several technical concerns. 
First of all, interphase FISH is known to be prone to false positive results since the probes 
being used are usually targeting the alpha-satellite regions of different chromosomes and 
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they can falsely hybridize to other chromosomes due to rare variants shared by other 
chromosomes (Collin et al. 2009; Winsor et al. 1999). In fact, several follow-up studies 
from different groups failed to generate consistent results on the frequency of aneuploid 
neurons in human brain using interphase FISH targeting different genomic regions 
(Westra et al. 2008; Yurov et al. 2007; Thomas & Fenech 2008). An independent 
quantification method would be necessary to confirm the initial observations. Secondly, 
only a small subset of the genome (one or a few chromosomes) was assayed in the 
previous studies; therefore, the studies were unable to provide an accurate genome-wide 
representation of the “aneuploid” cells. For example, does an “aneuploid” neuron 
identified in these studies only have copy number gain or loss of the assayed 
chromosome, or is the neuron grossly aneuploid with gains or losses on multiple 
chromosomes? Single-cell copy number profiling from human brains provides a mean to 
address all these questions definitively. 
All these studies on somatic variants in normal human brains are highly 
interesting and potentially high impact if they are proven to contribute to the functional 
diversification of neurons. However, several steps need to be taken to test the hypothesis. 
First of all, somatic variants are expected in every single somatic cell including neuron 
based on the previous discussion (see section “From germline to somatic mutations”). 
Therefore, identification of a certain type of somatic variant is not succifient to support 
the hypothesis that somatic variants are active generators of neuronal genetic diversity. A 
demonstration of significantly elevated levels of somatic variants compared to other 
tissues by more direct and quantitative means would be required to support the 
hypothesis. To date, V(D)J recombination in the immune system is the only known 
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mechanism to actively generate somatic genetic diversity through DNA rearrangement in 
lymphocytes, allowing a rapid adaptive response to new antigens (Jung et al. 2006). Such 
a mechanism is required for the proper function the of the immune system as evident by 
the immune-deficiency associated with V(D)J recombination defects (Jung et al. 2006). 
Therefore, if an analogous mechanism exists in the central nervous system, the disruption 
of it would be expected to lead to adverse effects on neuronal function. However, the 
identification of mammalian species that appear to have lost all L1 activity suggests that 
L1 retrotransposition may not be a universal requirement for mammalian neuronal 
function (Cantrell et al. 2008). Secondly, both retrotransposition and aneuploidy are 
regarded as stochastic mutational forces that generate random and mostly deleterious 
mutations as opposed to targeted V(D)J recombination. Both somatic retrotransposition 
and somatic aneuploidy are prevalent in cancer cells, highlighting the adverse effects of 
these two mutational forces on genome stability (E. Lee et al. 2012a; Weaver et al. 2007). 
Furthermore, the frequency of aneuploid neurons appears to increase in 
neurodegenerative diseases such as Alzhermier’s disease (AD) and Ataxia-Telangiectasia 
(AT), further suggesting that aneuploidy may lead to cognitive dysfunction as opposed to 
beneficial functional diversity (Iourov et al. 2009).  
 
Overview of Recent Advances in Single-Cell Sequencing Technology 
and Applications 
Single-cell analysis is performed to understand cell-to-cell variability. Such 
variability has been systematically overlooked at the genomics level as most previous 
studies assumed an identical genome within the cells of an individual. With recent 
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technical advances, researchers have started to appreciate cell-to-cell differences at the 
genomic level and the biological significance of such genetic heterogeneity in the 
development of human diseases such as cancers (Frumkin et al. 2008; Navin et al. 2011; 
Xu et al. 2011; Hou et al. 2012). Significant progress has also been made on studies of 
embryonic development using a single-cell genomics approach to understand the genetic 
variability of early stage embryos (Vanneste et al. 2009; Yin et al. 2013). Studies on the 
hemizygous genome of human single sperms have reveal remarkable insight into 
germline development regarding the homologous recombination patterns as well as de 
novo point mutation rates (Wang et al. 2012; Lu et al. 2012). Moreover, single-cell 
genomics has benefitted tremendously microbial biology by identifying uncultivable new 
microbial species as a mean to study ecosystem evolution (Blainey & Quake 2011; Swan 
et al. 2011). In addition to single-cell genomics, remarkable progress has also been made 
in gene expression analyses and transcriptome studies at the single-cell level, revealing 
complex biological regulatory networks and identifying new cell types (Ramsköld et al. 
2012; Hashimshony et al. 2012). Despite all this recent progress, all current single cell 
studies are limited because they rely on a secondary amplification step because of the 
difficulty of directly analyzing the extremely tiny amount (6pg) of genetic material from 
a single cell. The secondary amplification inevitably introduces biases and artifacts, 
setting limitations on the applications of these methods. 
The two major challenges to single-cell genomic analysis are: 1) the isolation of 
single cells with specific phenotypes of interest; and 2) whole-genome or whole 
transcriptome amplification from the isolated single cells. Current means for single cell 
isolation include fluorescence-activated cell sorting (FACS), laser-capture 
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microdissection (LCM) and microfluidics. FACS has been the most reliable method for 
single cell isolation, featuring the highest throughput and allowing for the use of various 
immunofluorescent markers to isolate specific cell populations. However, FACS relies 
heavily on the availability and quality of antibodies and requires a relatively large 
number of cells to start with, making it difficult to study rare and/or unknown cell 
populations (Navin & Hicks 2011; Kalisky et al. 2011). LCM is robust in permitting the 
identification of specific cell populations based on both morphology and a wider 
spectrum of antibodies (Tietjen et al. 2003). However, LCM is low-throughput, and 
therefore not easily applicable to studies of large numbers of cells. Microfluidic systems 
have been recently developed and incorporated into single-cell -omics studies and 
promise a few major advantages. First of all, as closed systems, microfluidic systems 
effectively minimizes the risk of external contamination, and allows for the isolation of 
cells and amplification of genetic material to take place in the same chamber, greatly 
simplifying the work flow (Tietjen et al. 2003; Zare & Kim 2010). Secondly, microfluidic 
systems allow an extremely small volumes for secondary amplification, which 
significantly brings down the cost and helps to reduce amplification bias (Marcy et al. 
2007). The major limitation of exsiting microfluidic systems is their accessibility, as it 
requires certain expertise for its operation and maintenance. However, with commercially 
available microfluidic systems now being installed at a growing number of research 
institutes, this drawback is expected to be overcome in a near future.  
A second important challenge of single-cell -omics studies is amplification bias. 
All currently used amplification methods introduce amplification artifacts such as errors, 
chimeras and false-positive copy number changes to varying degrees (Wang et al. 2012; 
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Blainey & Quake 2011; Lasken & Stockwell 2007); therefore, careful characterization of 
each method and its limitations is essential for critical analysis and interpretation of any 
single-cell -omics datasets. Depending upon the applications, different amplification 
methods may be applied (Bergen et al. 2005); therefore, careful evaluation and 
comparison of currently available amplification methods are important for achieving the 
best results. Eventually, more advanced single cell amplification methods that amplify 
the genome linearly with higher fidelity will need to be developed.  
With the expansion of next generation sequencing technologies, an increasing 
number of clinical applications have also been proposed for the use of single-cell 
sequencing. Preimplantation genetic diagnosis (PGD) for IVF has pioneered the use of 
single-cell genomics to screen for cell aneuploidy, first using array-based methods and 
now moving to next-generation sequencing based (Vanneste et al. 2009; Yin et al. 2013). 
In the near future, it is expected that single-cell sequencing technology would be widely 
applied to noninvasive prenatal diagnosis through analyzing circulating fetal cells from 
maternal plasma. Additionally, single cell haplotyping techniques are being actively 
developed, providing tremendous power for the understanding of germline meiotic 
recombinations (Fan et al. 2011).  Similarly, single-cell sequencing can be applied to the 
identification and analysis of circulating cancer cells (CTC), providing valuable 
information on cancer diagnosis, prognosis as well as treatments (Navin & Hicks 2011). 
The major technical challenges of these clinical applications remains the cost and 
consistency of current methods. With the further reduction of sequencing cost in the near 
future and the maturation of single-cell technology, we would expect rapid advances in 
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medical applications allowing for more sensitive diagnosis using the single-cell 
technology. 
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This chapter contains work from the manuscript “Human Mutations in NDE1 Cause Extreme 
Microcephaly with Lissencephaly”, published in American Journal of Human Genetics, May 13, 
2011; 88:536-547. The text and figures were modified to fit the format of this dissertation. Xuyu 
Cai was co-first author of the manuscript with Fowzan Alkuraya. One of the two families studied 
(Family 1) was contributed by collaborator Fowzan Alkuraya. Clinical characterization was done 
by Ganesh Mochida, Brenda Barry and Jennifer Partlow. Homozygosity mapping and Sanger 
sequencing was done with help from Sean Hill and Jillian Felie. Functional characterization of 
both mutant alleles was solely done by Xuyu Cai. Immunocytochemistry of Nde1-/- MEFs was 
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Summary 
Genes disrupted in human microcephaly (“small brain”) define key regulators of 
neural progenitor proliferation and cell fate specification. In comparison, genes mutated 
in human lissencephaly (lissos, “smooth,” cephalos, “brain”) highlight critical regulators 
of neuronal migration. Here we report two families with extreme microcephaly and 
grossly simplified cortical gyral structure, an entity referred to as microlissencephaly, and 
show that they carry homozygous frameshift mutations in NDE1. NDE1 encodes a 
multidomain protein that localizes to the centrosome and mitotic spindle poles. Both 
human mutations in NDE1 truncate the C-terminal domains of NDE1, which are essential 
for interactions with cytoplasmic dynein to regulate cytoskeletal dynamics in mitosis, and 
for phosphorylation of NDE1 by CDK1 in a cell cycle-dependent fashion. We show that 
the patient NDE1 proteins are unstable, cannot bind cytoplasmic dynein and do not 
localize properly to the centrosome. The role of NDE1 in cell cycle progression likely 
contributes to the profound neuronal proliferation defects evident in Nde1 null mice and 
patients with NDE1 mutations, demonstrating the essential role of NDE1 in human 
cerebral cortical neurogenesis. 
 
Introduction 
The exquisitely organized formation of cerebral cortical neurons from the cortical 
neuroepithelium has provided an important system for studying the control of cell 
proliferation and cell fate. Cortical progenitors, forming a pseudostratified epithelium 
with nuclei in the ventricular germinal zone, have the capacity for symmetrical cell 
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divisions to form two dividing daughter cells, or asymmetrical cell divisions to generate 
one dividing daughter as well as post-mitotic neurons that populate the developing cortex. 
After exiting the cell cycle, post-mitotic neurons migrate away from the ventricular zone 
to the incipient cerebral cortical layers to establish the highly organized cortical 
architecture. Human autosomal recessive primary microcephaly (MCPH, [MIM251200]), 
or microcephaly vera, manifests with small but architecturally fairly normal brains. 
Multiple human genes mutated in MCPH encode proteins that localize to the centrosome 
and/or mitotic spindle poles (Thornton & Woods 2009). Many of them have been 
implicated in regulating progenitor cell cycle progression and the decision of progenitors 
to continue proliferating or to differentiate into post-mitotic neurons (Thornton & Woods 
2009). In contrast to microcephaly, human lissencephaly manifests with a simplified 
cortical gyration pattern reflecting abnormal histological organization of the cortical 
layers, but normal brain volume, and most often reflects disruption of neuronal migration 
(Wynshaw-Boris et al. 2010). Identified genetic causes of lissencephaly include 
mutations in LIS1 [MIM 601545], DCX [MIM 300121], RELN [MIM 600514] and 
TUBA1A [MIM 602519] (Dobyns et al. 1993; Gleeson et al. 1998; Hong et al. 2000; 
Poirier et al. 2007). Recently, mutations in WDR62 [MIM613583] have been associated 
with microcephaly with a variety of architectural defects of the cortex as well (Nicholas 
et al. 2010; Yu et al. 2010; Bilguvar et al. 2010), suggesting additional overlap in the 
genes that regulate proliferation and migration. But there have long been rare cases of a 
reduction in brain size typical of microcephaly that is also associated with simplification 
of cerebral cortical gyration that falls within the spectrum of lissencephaly. These two 
findings together have been referred to as “microlissencephaly”, but the genetic and 
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mechanistic causes of microlissencephaly are unknown (Norman et al. 1976; Dobyns et 
al. 1984). 
Nuclear distribution E (NudE) was originally identified in Aspergillus nidulans as 
an essential regulator of a common nuclear migration pathway, which also involves 
NudC (DYNC1H1, [MIM600112]) and NudF (LIS1) (Efimov & Morris 2000). The 
mammalian orthologues of NudE include NDE1 [MIM 609449] and NDE1-Like 1 
(NDEL1, [MIM 607538]). Mouse Nde1 is highly expressed in cortical neural progenitors 
and encodes a protein that localizes to the centrosome and mitotic spindle poles. It is also 
known to physically interact with the cytoplasmic dynein complex and Lis1 (Feng et al. 
2000; Feng & Walsh 2004; McKenney et al. 2010). The dynein-Lis1-Nde1 complex has 
an essential role in cytoskeleton dynamics in a wide range of cellular processes, including 
mitosis, nuclei positioning, and cell migration (Wynshaw-Boris et al. 2010; Wynshaw-
Boris 2007). Loss of Nde1 in mouse models causes profound defects in cerebral 
corticogenesis but only modest defects in neuronal migration (Feng & Walsh 2004). 
Nde1-null cortical progenitors showed defects in centrosome duplication and mitotic 
spindle assembly, which resulted in severe mitotic arrest/delay, spindle mis-orientation 
and mis-positioning of the mitotic chromosomes. These mitotic defects were thought to 
account for the premature depletion of progenitor cells in Nde1-null brains through 
impaired cell cycle progression, and pre-mature cell cycle exit by progenitors to form 
neurons (Feng & Walsh 2004). 
In this study, we demonstrate that human NDE1 mutations cause a severe 
microlissencephaly syndrome, resembling that described by Norman and Roberts 
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(Norman et al. 1976; Dobyns et al. 1984). The identified frameshift mutations result in 
truncation of the C-terminal domains and disruption of several key functions of NDE1.  
 
Results 
Clinical Characterization of Microlissencephaly 
Ongoing efforts to characterize the genetic bases of microcephaly by a large 
collaborative effort known as the Microcephaly Collaborative identified two families 
whose children share remarkably severe microcephaly (head circumferences more than -
11 to -13 standard deviations below the mean for age), abnormal cortical gyration, short 
stature (more than -2 and -4 standard deviations below the mean for age), microsomia 
(weight more than -2 and -5 standard deviations below the mean for age) and a prominent 
broad nasal bridge (Figure 1; see Supplementary Clinical Information). 
Family 1 originates from Eastern Saudi Arabia. The parents are healthy and are 
reported to be first cousins. They have two daughters affected with extreme microcephaly 
(Figure 2-1a). The first affected daughter (08DG00535; Family1, IV-1 in Figure 2-1a) 
was first evaluated at the age of 33 months, at which time her head circumference was 
34.4cm, length was 81.4 cm and weight was 8.6 kg (8.9, 3 and 3.8 standard deviations 
below the mean respectively). Physical examination at that time was notable for marked 
hypertonia and global developmental delay. MRI imaging revealed severe microcephaly, 
with proportionate reduction in the size of most other brain structures, including the 
cerebellum and brain stem, associated with agenesis of the corpus callosum. The gyral 
folding of the cerebral cortex was extremely simplified, with almost no detectable sulci 
other than the Sylvian fissure. At the age of seven years, she displayed extreme
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Figure 2-1. Pedigrees and radiographic features of the two consanguineous families 
with microlissencephaly. 
(A) Both families are from Saudi Arabia. Parents of Family 1 are first cousins and have two affected 
female children (08DG00535, IV-1; 08DG00536, IV-2). Whole blood DNA from both parents and 
both affected children was obtained and analyzed (indicated by asterisk). Parents of Family 2 are first 
cousins with seven reported pregnancies, producing one affected male (MC-14901, II-7), one affected 
female (II-4) (not available for analysis), two unaffected males and three pregnancies that resulted in 
fetal demise. Whole blood DNA from both parents and the affected male (MC-14901, II-7) was 
obtained and analyzed (indicated by asterisk). 
(B) Representative MRI images of 08DG00536 (family 1, IV-2) from Family 1 at 4.5 years of age, 
demonstrating the drastic reduction in brain size, agenesis of the corpus callosum, and abnormal gyral 
pattern compared to a normal 2 year old child. Sagittal T1 and axial T2 sections are shown (scale 
bar=5cm). 
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microcephaly with head circumference of 35 cm (13.4 standard deviations below the 
mean) and evidence of retarded growth with a length of 105 cm and weight of 10 kg (3.1 
and 4.7 standard deviations below the mean respectively). She remained seizure-free but 
was only able to roll over, and her social and cognitive development was limited to 
spontaneous smiling. The second affected daughter (08DG00536; Family 1, IV-2 in 
Figure 2-1a) was first evaluated at birth, at which time her length and weight were 
normal, head circumference was 26.5 cm (5.6 standard deviations below the mean), and 
her anterior fontanel was almost closed. Her neurological course was static and 
characterized by marked hypertonia with virtually no gain of any milestone beyond 
spontaneous smiling and rolling over by the age of 5.5 years, but with no seizures. 
At that time her head circumference was 34 cm, length was 85 cm, and weight was 8.9 kg 
(12.7, 5.5 and 4.8 standard deviations below the mean respectively). Laboratory 
investigations including plasma acylcarnitines, carnitine, and amino acids, urine organic 
acids, ammonia, lactic acid, and high-resolution karyotype were all normal. MRI scans 
showed microcephaly, severe simplification of the gyral pattern (lissencephaly), agenesis 
of the corpus callosum, and colpocephaly (enlargement of the posterior lateral ventricles, 
often associated with corpus callosum defects), features that have been described in 
microlissencephaly (Figure 2-1b). 
Family 2 originates from Western Saudi Arabia. The parents are healthy and are 
reported to be first cousins. They have a daughter and son with extreme microcephaly, 
two healthy sons, and had three additional pregnancies that resulted in spontaneous 
abortion (Figure 2-1a). The affected daughter was reported to have microcephaly without 
seizures but no additional information was available (Family 2, II-4 in Figure 2-1a). The 
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affected son (MC-14901; Family 2, II-7 in Figure 2-1a) displayed microcephaly and 
dysmorphic features at birth but growth parameters are not available. A head CT at that 
time revealed small brain size. Seizures began at two months of age and were described 
to start on the left side and progress to full-body convulsions with up-rolling of the eyes. 
He was first evaluated at 9 months of age, at which time he could not roll or 
control his head and a neurologic exam revealed increased reflexes, decreased tone, 
normal power and positive Babinski signs. MR imaging at 11 months of age showed a 
marked decrease in the size of both cerebral hemispheres with a large midline fluid filled 
structure and dilatation of the right lateral ventricle, a small cerebellum, and agenesis of 
the corpus callosum. The thalami were not fused and a midline falx was noted. 
Laboratory investigations included a normal karyotype (46, XY) and an unremarkable 
acylcarnitine profile and amino acid analysis by tandem mass spectrometry. An 
evaluation at 3.5 years of age recorded his head circumference as 32 cm (11.1 standard 
deviations below the mean), length as 88 cm (2.8 standard deviations below the mean) 
and weight as 13 kg (6th percentile). 
Identification of Homozygous NDE1 Mutations 
All patients were born to consanguineous marriages, suggesting autosomal 
recessive inheritance and allowing homozygosity mapping, which identified only one 
common homozygous region larger than 1Mb--at chromosome 16p13.11--shared by all 
three affected children (DNA from the second affected child in Family 2 was 
unavailable). The maximal LOD scores of the two pedigrees at the homozygous region 
are 1.8 and 1.2, respectively. The homozygous locus is 4.6Mb in size and contains 
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Figure 2-2. Homozygosity analysis of both pedigrees identified a 4.6-Mb region on chromosome 
16 that is homozygous in all three affected children. 
All homozygous SNPs are represented as blue and heterozygous 
SNPs are represented as yellow. The maximal LOD scores of the two pedigrees at the homozygous 
region are 1.8 and 1.2, respectively. The shared region of homozygosity contains approximately 35 
annotated genes, including NDE1. 
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approximately 35 annotated genes, including NDE1 (Figure 2-2). NDE1 was selected as 
the top candidate given that the mouse Nde1 mutations strongly affected neural 
progenitor proliferation, and that defects of both proliferation and neuronal migration 
were observed in mice deficient for both Nde1 and Lis1 (Feng & Walsh 2004; Pawlisz et 
al. 2008; Yingling et al. 2008). Direct sequencing of NDE1 revealed frameshift mutations 
in both families (Figure 2-3a,b). Family 1 showed a c.684_685del mutation in exon 6 
that creates a translational frameshift at codon 229 of the normal 335 amino acid protein 
sequence (p.Pro229TrpfsX85), and predicts a protein that consists of 312 amino acids, 
terminating after the addition of 84 abnormal amino acids (Figure 2-3a,b). Family 2 
showed a c.733dup mutation in exon 7 that creates a frameshift mutation at codon 245 
(into the same abnormal reading frame as the mutation in Family 1) creating a predicted 
protein truncated after the addition of 69 abnormal amino acids (p.Leu245ProfsX70). 
Both mutations were homozygous in affected individuals, segregated perfectly 
with disease in each family, and were absent from more than 200 normal individuals, 
including 96 Saudi Arabian controls, and not seen in the 1000Genomes, strongly 
suggesting that they are bona fide mutations. This conclusion was further supported by 
identification of additional NDE1 alleles in patients sharing similar clinical features by 
Bakircioglu et al. (2011). 
Characterization of the Mutant NDE1 Proteins 
Based on data from NDE1 and its paralogue, NDEL1, the truncated NDE1 
proteins, if stable, would lack critical protein domains (Figure 2-3a). The C-terminus of 
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Figure 2-3. Two framshift homozygous mutations identified from NDE1. 
(A)	  The human NDE1 gene consists of 9 exons (8 coding exons), which encode a protein with 335 
amino acids, harboring multiple protein-interaction domains. Two frameshift mutations were identified 
in exon 6 and 7 respectively, both predicted to disrupt the CENP-F, dynein interaction domain, 
centrosomal localization domain, and at least two conserved phosphorylation residues implicated in 
mitotic progression (T246 and S250) at the C-terminus. The black bar shows noncoding exons; open 
bar, coding exon; red dot indicates potential phosphorylation sites. 
(B) Representative Sanger sequencing traces indicating the two base-pair deletion identified in patient 
08DG00536 (Family 1, IV-2 in Figure 2-1a) and the one base-pair duplicated identified in patient 
MC-14901 (Family 2, II-7 in Figure 2-1a. 
(C) NDE1 protein was undetectable in the whole cell lysates collected from lymphoblasts of both 
patients (IV-1&2 in Figure 2-1a) in Family 1 harboring the c.684_685del 
(p.Pro229TrpfsX85) mutation. The protein levels of NDE1 from the parents (III-1&2 in 
Figure 2-1a) were reduced by roughly 50% compared to the wildtype control, consistent with their 
known heterozygous carrier status. Immunoblotting (IB) was performed with antibody against NDE1 
and actin as a loading control. 
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NDE1 includes a domain required for interaction with CENP-F, which directs NDE1 to 
kinetochores (Vergnolle & Taylor 2007), and another domain that regulates binding to 
the cytoplasmic dynein complex and to Su4823, which was found recently to regulate 
centrosomal localization of NDE1 (Sasaki et al. 2000; Stehman et al. 2007; Hirohashi et 
al. 2006). Although RT-PCR using patient lymphoblasts from Family 1 suggested equal 
abundance of NDE1 transcripts between patients and controls (data not shown), western 
blot analysis of patient lymphoblasts showed no detectable NDE1 protein in the two 
affected patients (Family 1, IV-I and IV-II) carrying the p.Pro229TrpfsX85 mutation 
(Figure 2-3c), while heterozygous parents showed ≈50% reduction in protein level. 
These data suggest that the frameshift mutation caused instability of the protein and 
subsequent degradation. Thus, the severe reduction of brain volume seen in these patients, 
which is far more severe than the dramatic ASPM-associated microcephaly (Bond et al. 
2005; Bond et al. 2002; Desir et al. 2008), appears to be associated with loss of NDE1 
protein, though some mutant protein in some tissues cannot be ruled out. 
In order to further study the functional role of the C-terminus of NDE1, we 
engineered cDNAs corresponding to the p.Pro229TrpfsX85 and p.Leu245ProfsX70 
alleles, tagged with FLAG (Figure 2-3a). Despite the instability of endogenous mutant 
proteins, overexpression allowed recovery of enough protein to study the effects of the 
two mutations on NDE1 binding to LIS1 and to dynein. Wild-type FLAG-NDE1 can be 
easily co-immunoprecipitated with the dynein complex (Figure 2-4a), and both 
frameshift mutants completely abolished dynein binding (Figure 2-4b). NDE1 also binds 
LIS1, but through the coiled-coil domain at the amino terminus of NDE1 (Feng et al. 
2000; Derewenda et al. 2007), 
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Figure 2-4. Both mutant alleles disrupt the interaction of NDE1 with the cytoplasmic dynein 
complex. 
(A)	  WT FLAG-NDE1 interacts with the dynein complex. Immunoprecipitation was performed using 
anti-FLAG M2 beads. Cells transfected with empty 3XFLAG-CMV vector was labeled as “-” and used 
as the negative control; cells transfected with WT FLAG-NDE1 vector was labeled as “+”. (DIC: 
dynein intermediate chain 74.1; DHC: dynein heavy chain) 
(B) The interaction with dynein complex was abolished in both mutant NDE1 proteins, confirming the 
disruption of dynein-binding domain by both mutant alleles. However, the interaction with LIS1 was 
preserved or even slightly enhanced in both mutant proteins. 
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Figure 2-5. The centrosomal localization of NDE1 was abolished in the mutants proteins. 
(A)	  Wild-type EGFP-NDE1-WT was transfected into 293T cells and localized to the centrosome. 
(B) Mutant EGFP-NDE1-p.Leu245ProfsX70 was transfected into 293T cells and did not localize to the 
centrosome. It either formed non-centrosomal aggregates, or localized diffusely in the cytoplasm. 
Centrosomes labeled by Pericentrin are indicated by the arrowhead and magnified in the upper right 
inlets (scale bar=10µm). 
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and LIS1 binding was normal or even enhanced (Figure 2-4b) in the FLAG-tagged 
mutant proteins. Since the cytoplasmic dynein complex has profound roles in 
neurogenesis, including mitotic spindle organization, interkinetic nuclear migration, and 
neuronal migration, the loss of an important dynein regulator could impact multiple 
aspects of neurogenesis.  
Both mutations are also predicted to abolish the centrosomal localization domain 
located at the C-terminus of NDE1 (Figure 2-3a). To examine the effects of mutations on 
NDE1 subcellular localization, GFP tagged wild-type or p.Leu245ProfsX70 mutant were 
transfected in 293T cells. Wildtype GFP-NDE1 localized to the centrosome, consistent 
with previous findings (Figure 2-5a), whereas mutant GFP-NDE1-p.Leu245ProfsX70 
(c.733dup) failed to target the centrosome but either presented as non-centrosomal 
aggregates or diffusely in the cytoplasm. (Figure 2-5b). Similar results were reported by 
analyzing the p.Pro229TrpfsX85 (c.684_685del) allele by Bakircioglu et al. (2011). 
Therefore both NDE1 mutations disrupt at least two key functions of NDE1, suggesting 
that the developmental defects seen in the patients are likely caused by the loss of NDE1 
function. 
Loss of NDE1/Nde1 Disrupts Mitotic Progression in Both Human and Mice 
Mouse embryonic fibroblasts with Nde1 mutations (Figure 2-6) showed defects 
in mitotic progression evident by increased mitotic index despite growing more slowly in 
culture (Figure 2-6a), and abnormal spindle structures such as multipolar spindles and 
chromosome misalignment (Figure 2-6b). Similarly, patient-derived lymphoblast cells 
(Figure 2-7) also show defects in spindle structure, including tripolar spindles, 
misaligned mitotic chromosomes, nuclear fragmentation, and abnormal microtubule 
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Figure 2-6. Nde1 deficiency leads to increased mitotic index and abnormal mitotic spindles in 
early passage (P0-3) primary MEFs. 
(A)	  Mitotic index increased by approximately 50% in Nde1-/- MEFs compared to Nde1+/+ MEFs at 
passage 1 (p-value <.01, Chi-square test of homogeneity for two independent samples). 
(B) Primary MEFs derived from wild type (Nde1+/+) and mutant (Nde1-/-) embryos were analyzed 
directly for the structure of mitotic spindles by staining with monoclonal antibody to tubulin (in green) 
and Hoechst for chromosomal DNA (in blue). Examples of normal Nde1+/+ M-phase cell, an abnormal 
Nde1-/- M-phase cell with tripolar mitotic spindle and mis-aligned mitotic chromosomes, and an 
abnormal Nde1-/- mitotic cell with discordant mitotic spindle and chromosome alignments are shown 
(scale bar=10µm). 
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Figure 2-7. NDE1 patient lymphoblasts exhibit defects in mitotic spindle organization. 
(A)	  Control lymphoblasts showed normal looking nuclei and normal alpha-tubulin staining. Examples 
of a NDE1+/+ interphase cell and a NDE1+/+ M-phase cell are shown. 
(B) Patient lymphoblasts showed condensed/fragmentized nuclei and disorganized alpha-tubulin. g, 
Examples of an abnormal NDE1-/- interphase cell with nuclear fragmentation and an abnormal NDE1-/- 
M-phase cell with multipolar and disorganized spindles (scale bar=10µm) are shown. The percentage 
of mitotic cells found with abnormal spindles was 7% in patient lymphoblasts, compared to 0% found 
in control lymphoblasts (P<0.02, two-tailed Chi-squared test). 
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organization, further supporting that NDE1’s is essential role in normal mitotic spindle 
function. Patient lymphoblast cultures also showed excessive dying cells (not shown), 
which could also contribute to the developmental defects. 
 
Discussion 
Our data indicate that loss of NDE1 produces profound defects in cerebral cortical 
size and organization, as well as less profound defects in somatic size. Both of the 
identified NDE1 mutations truncate the C terminus of the NDE1 protein, preventing 
normal dynein binding. Whereas the overexpressed proteins are somewhat unstable, they 
retain LIS1 binding activity, and so in principle could act as dominant-negative proteins. 
However, the absence of a genetically dominant phenotype, the absence of detectable 
mutant protein in patient cells, and the similarity of phenotype in the three patients 
described here (as well as additional patients and an additional mutant allele described by 
Bakircioglu et al., 2011) all argue strongly that the mutations act as simple null alleles. 
The C-terminus of NDE1 is also mutated by the recurrent inversions of 16p that 
are associated with acute myelogenous leukemia (AML), which disrupts exon 8 of NDE1, 
encoding the extreme C-terminus of the protein (Van der Reijden et al. 2010). Existing 
pedigree analysis and medical follow-up of Families 1 and 2, while somewhat limited, 
has so far not suggested the presence of AML or other leukemia in homozygous or 
heterozygous carriers of NDE1 mutations, though more extensive analysis of additional 
families is needed. On the other hand, our biochemical analysis suggests that the AML 
disruptions, if they create a stable truncated protein, could potentially create abnormal 
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proteins with preserved LIS1 binding but abnormal dynein binding, which might 
contribute to leukemogenesis.  
Although mice lacking Nde1 show about a one-third reduction in brain mass 
(Feng & Walsh 2004), neuronal migration is only moderately deficient, whereas human 
NDE1 mutations cause >50% decrease in cortical volume, and striking architectural 
disturbances that suggest severely abnormal neuronal migration. The more striking brain 
defects seen in humans harboring NDE1 mutations, especially the marked architectural 
defects, could reflect morphological or quantitative defects in the radial glial cells in 
human NDE1 deficiency that normally act as guides for migrating neurons, or may 
merely reflect the larger human brain with more profound defects in neurogenesis. 
Alternatively, the differences could reflect a greater role for NDE1 in migrating neurons 
in humans than in mice, parallel to the much more profound defects in neuronal 
migration in humans versus mice after removal of one allele of LIS1. The Nde1 
paralogue, Ndel1, is highly similar structurally to Nde1, more highly expressed in post-
mitotic neurons, and appears to have larger roles in cell proliferation outside the brain, 
mitotic spindle orientation, and neuronal migration (Wynshaw-Boris 2007; Derewenda et 
al. 2007; Mori et al. 2007; Shu et al. 2004; Lam et al. 2010; Sasaki et al. 2005; Toyo-Oka 
et al. 2005; Yamada et al. 2008). The details of potential genetic redundancy between 
NDE1 and NDEL1 may also contribute to these mouse-human differences.  
Humans with NDE1 mutations show modestly reduced height and weight as well 
as cerebral cortical size, though the defect in head circumference (typically -10 to -14 SD 
below the mean) was more marked statistically than defects in height and weight 
(typically -2 to -5 SD below mean). The decreased body size could reflect roles of NDE1 
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in other tissues, although more specific hypothalamic defects, or nutritional explanations 
related to the patients’ poor neurological function, cannot be ruled out. Mice with Nde1 
mutations show at most a slight, statistically insignificant, reduction in body mass (Feng 
& Walsh 2004). Since NDE1, like many other microcephaly genes, is expressed in many 
developing tissues (Feng et al. 2000), the more severe involvement of brain is generally 
regarded as reflecting the more limited ability of the brain to regulate its size, given that 
most brain cells are post-mitotic, but other mechanisms may also contribute to this tissue 
specificity. 
Finally, although analysis of archived DNA samples from the original 
microlissencephaly family of Norman and Roberts (Norman et al. 1976) did not reveal a 
detectable mutation in NDE1 (data not shown), the similarity of the NDE1 phenotype to 
the “Norman-Roberts” syndrome is striking, and some other cases of microlissencephaly 
also do not show NDE1 mutations. Hence, this classical form of microlissencephaly may 
ultimately reflect defects in proteins of this highly conserved centrosomal pathway that 
function in close concert with NDE1. 
Since the manuscript was published in 2011, an additional mutant allele of NDE1 
have been identified, leading to a slightly different neurodevelopmental disorder, named 
microhydranencephaly, characterized by extreme microcephaly with ventricular 
dilatation but without obvious lissencephaly (Guven et al. 2012). This additional allele 
was identified from a Turkish family with a 4.3kb homozygous deletion that 
encompasses the start codon in exon 2, and therefore is predicted to be a null allele 
(Guven et al. 2012). Its identification widens the spectrum of brain malformations caused 
by NDE1 mutations, highlighting a multifunctional role of NDE1 in brain development. 
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Although we are accustomed to think that alternate alleles within a given gene are likely 
to cause similar phenotypes, more and more cases studied recently have started to 
challenge this paradigm. In addition to the example of NDE1 we observed here, brain 
malformations caused by WDR62 (i.e. the MCPH2 gene) mutations showed broad 
phenotypic diversity involving both neurogenesis and neuronal migration defects, 
suggesting potential functional convergence of these two cellular processes (Nicholas et 
al. 2010; Yu et al. 2010; Bilguvar et al. 2010). In fact, mutations in the physical 
interaction partners of NDE1, such as LIS1, dynein heavy chain (DHC) and katanin p80 
(unpublished data from Walsh lab) also seem to be involved in a wide range of cellular 
processes, and have all been identified to cause related brain malformations, further 
suggesting that genetic interactions can serve as a mean to map molecular regulatory 
networks for key developmental processes such as neurogenesis and neuronal migration 
(Walsh & Engle 2010). More interestingly, both LIS1 and DHC mutations are identified 
as single-hit de novo mutations, consistent with their critical roles in multiple 
fundamental cellular functions ranging from spindle formation during mitosis, 
cytokinesis, cellular polarity, nucleokinesis and leading process extension.   
 
Materials and Methods 
Human studies 
The human studies protocols were reviewed and approved by the institutional 
review boards of the Children’s Hospital Boston and the King Faisal Specialist Hospital 
and Research Centers at Riyadh and Jeddah, and human research was performed in 
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accordance with the ethical standards with proper informed consent obtained. Standard 
protocols were used for blood draw and DNA extractions. 
Genome-wide linkage analysis 
Family 1 was genotyped using the Affy 250K StyI SNP Chip as per the 
manufacturer’s protocol. Family 2 was genotyped using the Illumina660W-Quad Chip at 
the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University. 
Single and multipoint LOD scores were calculated using Allegro assuming a recessive 
mode of disease inheritance, full penetrance, and a disease allele frequency of 0.0001. 
Nucleotide numbers are in reference to cDNA (RefSeq NM_017668.2, where A of the 
ATG translational start site is designated as +1) coordinates, and amino acid numbers are 
in reference to protein (RefSeq NP_001137451.1) coordinates, all following HGVS 
guidelines. 
Sanger sequencing 
Coding NDE1 exons as well as flanking intronic sequences were amplified by 
PCR, followed by bidirectional sequencing using ABI 3730XL DNA Analyzer or 
submitted to Polymorphic DNA Technologies for Sanger capillary electrophoresis. 
Sequencing of >200 neurologically normal control samples and 96 unaffected individuals 
from Saudi Arabian families with unrelated disorders failed to identify either mutant 
variant. 
Cell culture, transfection, cell synchronization and flow cytometry 
293T cells were cultured in DMEM containing 10% fetal bovine serum (FBS). 
Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 Nde1-/- mice and their 
littermates, and were cultured in Dulbecco’s Modified Earle Medium (DMEM) with 10% 
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FBS for 2 passages or fewer. Human lymphoblasts from normal individuals, NDE1-/-
individuals, and heterozygous NDE1-/+ parents were transformed using Epstein-Barr virus 
and cultured in RPMI medium supplemented with 15% fetal calf serum (FCS). For 
FLAG-NDE1 overexpression, 293T cells were transfected with specified plasmids 
(empty FLAG-containing vector, FLAG-NDE1-WT, FLAG-NDE1-delAC and 
FLAGNDE1-dupC) using Fugene6® (Roche).  
Western blotting and immunoprecipitation 
Cell lysates were prepared either using lysis buffer (for immunoprecipitation) 
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.4% NP-40, 1 mM NaF, 10 mM b-
glycero-phosphate, 10 nM calyculin A, 1 mM Na3VO4, 1 mM PMSF and protease 
inhibitor cocktail mix (Roche) or RIPA buffer (50 mM Tris-HCl 7.4, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitor cocktail mix 
(Roche) for direct western blotting. Protein concentrations were normalized using the 
BCA assay (Thermo Scientific). For immunoprecipitation, cell lysates were incubated 
with anti-FLAG M2 affinity gel (Sigma) for 2 hours at 4°C, followed by three-times 
wash using the same lysis buffer. Protein samples were then eluted using 3XFLAG 
peptides (150 ng/µl) for 1 hour at 4°C. For western blotting, cell lysates or 
immunoprecipitation elution were boiled in LDS sample buffer (Invitrogen), followed by 
electrophoresis on 4-12% Bis-Tris or 7% Tris-Acetate SDS-PAGE (Invitrogen) and 
transfer onto PVDF membrane (Millipore). Membranes were blocked in TBST 
containing 5% non-fat milk or Odyssey Blocking Buffer (LICOR Biosciences) at room 
temperature for 30 minutes, and incubated with primary antibodies according to the 
antibody manufacture’s instruction, followed by incubation with HRP-conjugated 
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secondary antibodies (Cell Signaling Technology) or fluorescent-dye-conjugated 
secondary antibodies (LICOR Biosciences). Immunosignals were detected by 
SuperSignal West Pico Chemiluminescent (Pierce) or the Odyssey® Infrared Imaging 
System (LICOR Biosciences). 
The rabbit antibody against total Nde1 was used as previously described (Feng & 
Walsh 2004). In addition, the following antibodies were purchased and used according to 
the manufacturer’s instructions: mouse anti-FLAG (M2) antibody and beads (Sigma); 
rabbit anti-DYKDDDDK (FLAG) (Cell Signaling Technology); rabbit anti-LIS1 (Bethyl 
Laboratory); mouse monoclonal anti-dynein intermediate chain (clone 74.1) (Millipore); 
rabbit anti-dynein heavy chain (Santa Cruz Biotechnology); mouse monoclonal anti-
Cdk1 (Millipore). 
For the FLAG-NDE1 construct, human NDE1 cDNA (RefSeq NM_017668.2, 
starting from ATG) was PCR amplified and subcloned into the p3XFLAG-CMV-10 
vector (Sigma); the two mutant constructs were generated by site-directed mutagenesis to 
delete 684_685AC (c.684_685del) or duplicate 733C (c.733dup), respectively.  
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Chapter 3: Whole-genome amplification of single neurons 
from human brain and identification of somatic L1 
insertions 
 
 
 
 
 
 
 
 
This chapter contains work from the manuscript “Single-Neuron Sequencing Analysis of L1 
Retrotransposition and Somatic Mutation in the Human Brain”, published in Cell, October 26, 
2012; 151(3):483-496. The text and figures were modified to fit the format of this dissertation. 
Xuyu Cai was co-first author on this manuscript with Gilad Evrony, and all experiments and data 
analyses in this chapter were carried out jointly by Gilad Evrony and Xuyu Cai. 
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Summary 
This chapter summarizes the methods development of single-cell genomic 
sequencing from fresh frozen human brain tissues. Single neuronal and non-neuronal 
nuclei, from postmortem or surgically removed brain tissues, were obtained by 
successive nucleus purification, immunostaining and fluorescence-activated cell sorting 
(FACS). Two independent whole-genome amplification methods were applied to the 
isolated nuclei to amplify genomes from single cells for downstream analyses. Extensive 
quality controls were performed to ensured sorting and amplification success, as well as 
assessing the genotype concordance and genome coverage at various scales. The 
development of such methods allows us to systematically assess the genomic variance for 
a wide spectrum of somatic mutation types between single neurons from human brains. 
Potential future applications and limitations of the methods are also discussed. 
 
Introduction 
Isolation and amplification of single neuronal genome has been technically 
challenging due to the extremely small DNA content of a single cell (~6pg). No current 
sequencing technology is sensitive enough to sequence such a small amount of input 
material; therefore, extensive whole-genome amplification is required. Whole-genome 
amplification is known to introduce technical artifacts that complicate the analyses; 
therefore, a careful survey and comparison of different cell isolation and whole-genome 
amplification technique was carried out prior to the launch of the project. 
Isolation of single cells 
 
	  
73	  
The first challenge of the study is to isolate a large number of single cells of the 
cell type of interest (e.g. neurons vs. glia) free of external contamination. The methods 
available for single cell isolation include: fluorescence-activated cell sorting (FACS), 
microfluidics, laser-capture microdissection (LCM) and related robotic and manual 
micro-manipulation tools (Navin & Hicks 2011). Each of these methods has their pros 
and cons, which were taken into consideration before choosing the most suitable method 
for our purpose. Among them, FACS is the most widely used technology for cell type 
isolation based on fluorescence labeling, particularly in the field of immunology. It also 
has the highest throughput allowing the sorting thousands of cells within minutes. A 
number of studies have successfully applied FACS to isolate neuronal versus non-
neuronal nuclei based on immunoreactivity to the pan-neuronal marker NeuN (Spalding 
et al. 2005; Rehen et al. 2005; Matevossian & Akbarian 2008). However, FACS 
technology was primarily designed for bulk sorting; therefore, although it’s capable of 
single cell sorting, its ability to consistently deposit the desired small number of cells into 
96-well or 384-well PCR plates for downstream processing remained questionable.  
LCM and related techniques allow isolation of single cells from thin-sectioned 
tissue specimens. Compared to FACS, LCM not only allows the identification of desired 
cell types based on immunofluorescence labeling, but also on the histology. This 
represents a big advantage in the isolation of rare cell populations that might lack reliable 
immunofluorescence markers. On the other hand, LCM requires extensive tissue 
manipulations including tissue sectioning, fixation and staining prior to the procedure.  
These procedures significantly lengthen the preparation time and pose risks to the 
genome integrity of processed tissues. For instance, tissue fixation with aldehydes (e.g., 
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formalin, parafaormaldehyde) is known to denature, modify, and fragment the genomic 
DNA and thereby affects the downstream whole-genome amplification. Additionally, 
sectioning tissue into 10-20µm slices may destroy the nuclear integrity of targeted cells, 
resulting in incomplete recovery of their genome. Moreover, LCM is a low-throughput 
method that takes hours to process up to 10-20 cells.  
Microfluidic systems are an emerging technology that allows accurate isolation of 
single cells or even single chromosomes into small chambers in nanoliter size (Zare & 
Kim 2010; Fan et al. 2011). Small volumes of reaction cocktail can be subsequent flowed 
into the chambers for whole-genome amplification. Such a setup provides significant 
advantages over the other two technologies in preventing external contamination, and this 
has been critical for single bacterial genomics studies (Blainey & Quake 2011; Zhang et 
al. 2006). Moreover, the small nanoliter reaction volume appears to improve 
amplification bias compared to standard microliter reactions, as well as greatly reducing 
the reagent costs for large-scale studies (Marcy et al. 2007). Despite all the advantages, 
isolation of fluorescence-labeled cells can be tricky with microfluidic systems as it 
requires manual calls on whether to include a cell under the microscope. In contrast, 
FACS can analyze tens of thousands cells at a time to build statistical signal intensity 
distributions for clearer separation of positive versus negative cells. Moreover, 
microfluidic systems are difficult to set up and require expertise in usage and 
maintenance. Only recently, bench-top microfluidic systems for single cell analysis 
became commercially available (e.g. Fluidigm C1 Single-cell system), which are 
expected to significantly improve the accessibility of the technology to non-expert end 
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users. However, to date, the system only accommodates single cell RNA amplification 
instead of whole-genome DNA amplification.  
After considering the above concerns, we decided to use FACS to isolate single 
neurons given its high throughput, accessibility, and previous successful examples of 
isolating neuronal nuclei (Spalding et al. 2005; Matevossian & Akbarian 2008). 
Meanwhile, we are aware of its technical limitations, including its questionable accuracy 
on sorting single cells and potential risk of introducing external contamination during the 
process. These concerns were carefully evaluated while developing the methods.  
Single cell whole-genome amplification 
The second challenge of this study is to consistently amplify single genomes for 
downstream analyses. A variety of technical artifacts and biases can be introduced by the 
currently available whole-genome amplification; these potential artifacts need to be 
carefully evaluated and considered in the development of methods. There are two major 
methods for whole-genome amplification from single cells.  
The first method, named multiple displacement amplification (MDA), is an 
isothermal reaction using a phi29 polymerase, which has a strong displacement activity 
that allows the polymerase to displace double-strand DNA to continuously create free 
single-strand DNA for further reaction at the same temperature. The reaction starts with 
alkaline lysis and denaturation of the original template, followed by random hexamer 
annealing and amplification at 30C (Dean et al. 2002). In additional to its displacement 
activity, phi29 shows a robust proof-reading activity that limits the error rate down to 10-7, 
as well as its great processivity which leads to the generation of overlapping amplicons 
up to ~30kb in size (Hou et al. 2012). Recent studies showed that single cancer cells can 
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be amplified by MDA to recover up to 90% of the genome in a fashion that was suitable 
for studies of single-nucleotide variants (SNV) via whole-genome and whole-exome 
sequencing (Hou et al. 2012; Xu et al. 2012). However, MDA is known to suffer from 
non-linear amplification such that different regions of the genome stochastically get 
under or over-amplified (Dean et al. 2002). Additionally, a small fraction of the genome 
is consistently under-amplified or completely “dropped out” from MDA presumably due 
to high GC content or secondary structures of these regions (Evrony et al. 2012). The 
non-linear amplification and regional dropouts are expected to complicate the analysis of 
copy number variants (CNVs) from the amplified single cells. Lastly, MDA is known to 
create chimera sequences due to polymerase slippage and branch migration; these 
chimeras can be falsely classified as structural variants (SVs) during downstream 
analyses.  
A second amplification method, named GenomePlex WGA4 (licensed by Sigma, 
later referred as “WGA4”), is a PCR-based method that starts with denaturation and 
fragmentation of the single cell genome, followed by universal adaptor ligation and PCR 
amplification. Since the genome is fragmented into ~400bp fragments prior to 
amplification, the amplification is generally more linear and produces higher quality copy 
number profiles from amplified single cells. This approach was successfully applied to 
the first human single cell study, which performed copy number profiling via low 
coverage sequencing to study the evolution of breast cancer cells (Navin et al. 2011). 
However, due to the initial fragmentation of the genome, only ~10% of the single cell 
genome is recovered by this method. Moreover, the fragmentation results in non-
overlapping amplicons, which makes PCR-based secondary validation impossible. Taken 
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together, although WGA4 is a better method for CNV analysis, MDA is required for 
study other types of genetic variants, including SNVs, structural variants (SV) and 
retrotransposition. Both methods were tested in this chapter and their performance and 
applications will be discussed later in the chapter. 
 
Results 
Isolation of single neuronal nuclei from human brain tissue 
We purified nuclei from post-mortem human frontal cortex and caudate nucleus 
and labeled them with a neuron-specific antibody (NeuN) for sorting using fluorescence-
activated cell sorting (FACS) (Figure 3-1A) (Matevossian & Akbarian 2008; Spalding et 
al. 2005). Large nuclei with neuronal nuclear morphology were readily apparent by 
microscopy (Figure 3-1B) (Parent & Carpenter 1995). NeuN immunoreactivity (Figure 
3-1C) labels essentially all neuronal nuclei in cortex and caudate, corresponding to 25-
35% of all nuclei (population I; Figures 3-2) (Mullen et al. 1992; Wolf et al. 1996). 
Consistent with their increased size on microscopy (Figure 3-1B), NeuN+ nuclei also had 
larger forward (FSC) and side (SSC) scatter (correlates of size) by flow cytometry 
compared to NeuN- nuclei (Figures 3-2C). Whereas for nuclei isolated from the caudate 
we performed a simple sort of the NeuN+ population (population I, Figures 3-2B), we 
further enriched nuclei from the cortex for pyramidal neuronal nuclei. Since neighboring 
cortical pyramidal neurons tend to have shared clonal origins due to their primarily radial 
migration (Magavi et al. 2012), enriching for pyramidal neuronal nuclei increases the 
chance of identifying clonal somatic mutations shared by multiple neurons. The largest 
neuronal nuclei in cortex correspond primarily to pyramidal projection neurons 
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Figure 3-1. Isolation of neuronal nuclei from human brains. 
(A)	  Schematic of single neuron isolation and whole-genome amplification.  
(B) Purified nuclei from post-mortem human frontal cortex. Nuclei with neuronal nuclei morphology 
(large, prominent nucleolus) can be readily observed (arrowheads). Pyramidal shape in some large 
nuclei is reminiscent of pyramidal neuronal nuclei shape. 
(C) NeuN (green) and Hoechst (blue) staining of cortical nuclei by fluorescent microscopy. White 
arrowheads indicate neuronal nuclei. 
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Figure 3-2. Fluorescence-activated cell sorting (FACS) of purified nuclei labeled with NeuN. 
(A)	  FACS of cortical nuclei stained with NeuN shows two separable populations: NeuN+ (population 
I) and NeuN- (population II). A subset of population I (Ia) consisting of large neuronal nuclei was 
sorted and reanalyzed, confirming sort purity. Two populations of nuclei are sometimes apparent 
without NeuN staining, due to the increased background staining of the larger population I nuclei. 
Fluorescence decrease of the sorted population on reanalysis is always observed due to photobleaching 
and washing of non-specific staining in the first sort. 
(B) FACS of NeuN-labeled caudate nuclei. The entire NeuN+ population (population I) was sorted and 
reanalyzed. 
(C) Forward (FSC) and side (SSC) scatter backgating analysis of flow cytometry of human brain 
cortical nuclei. Red dots indicate events out of all events recorded (gray dots) from the specified 
population (I, Ia, and II). Population I nuclei have a distinct size distribution larger than population II, 
and population Ia nuclei are larger nuclei within population I. 
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 (Gittins & Harrison 2004; Mills 2002), and indeed their nuclei often show a pyramidal 
shape (Figures 3-2A). We therefore sorted cortical nuclei within the top 25% NeuN/FL-2 
fluorescence of population I (population Ia), which were the largest nuclei in population I 
(Figures 3-2A). We confirmed the neuronal and non-neuronal identities of the sorted 
populations by reverse transcriptase PCR (RT-PCR) and western blot analysis of 
additional neuronal (SNAP25 and SYT1) and non-neuronal (GFAP, AQP4, and Olig2) 
markers (Figures 3-3). For every sort, a portion of the sorted nuclei was reanalyzed by 
FACS, confirming that nuclei remained intact during sorting and that sort purity 
was >98% (Figures 3-2). 
 
Whole-genome amplification using MDA and GenomePlex WGA4 
We first optimized MDA reaction condition for increased yield with varying 
concentrations of random hexamer, dNTP and phi29 polymerase. We found that dNTP is 
the most important limiting factor of reaction yield; and with sufficient dNTP present, 
increase of phi29 units improves the yield (Figure 3-4A). To balance between yield and 
the enzyme cost, we chose to follow the condition that produced the second-highest yield 
(15-20ug) at 50uM random hexamer, 2mM dNTP and 40U phi29 (Figure 3-4A). We 
then measured exogenous (non-human) DNA contamination in the reagents of the MDA 
reaction, finding negligible (< 1fg) exogenous DNA (Figures 3-4B,C) (Blainey & Quake 
2011). Additional controls (see following section “Genome-wide coverage and 
amplification dropout rates of single neuronal genomes”) excluded operator human DNA 
contamination. Quantitative MDA (qMDA) reactions further showed that, as the number 
of nuclei sorted in a well increased, the time-to-threshold-amplification decreased in a  
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Figure 3-3. Post-FACS quality control on cell identity of sorted populations. 
(A)	  RT-PCR confirming the neuronal and non-neuronal identities of populations Ia and II, 
respectively, by assaying for expression of nuclear RNA for two neuronal (SNAP25 and SYT1), two 
astroglial (GFAP and AQP4), and input control (RPL37A) genes. RT-PCR and western blot 
experiments (Figures 1C and 1D) were performed with NeuN/Mef2c double labeling in which all 
NeuN+ nuclei were Mef2c+ (data not shown). 
(B) Western blot analysis of NeuN and Olig2 (an oligodendrocyte marker), confirming neuronal and 
non-neuronal identity, respectively, of populations Ia and II. 
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Figure 3-4. Optimization of single-cell MDA. 
(A) MDA reaction yields of control human DNA amplified with varying hexamer, dNTP and phi29 
polymerase concentrations (error bars ±1SD, n=2 per condition). Arrow indicates chosen reaction 
conditions for single neuron genome amplification. 
(B) Real-time quantitative MDA monitoring of amplification reactions with varying lambda DNA 
input. 
(C) A semi-log standard curve was fit to data from amplification curves in Figure 3-4B (TimeT, time 
to threshold amplification). No-input DNA reactions have ~0.8 femtograms of non-human exogenous 
DNA, negligible compared to 6.5 picograms of DNA in a single human nucleus (error bars ±1SD, n=2 
per condition). 
(D) Quantitative MDA reactions monitored in real-time confirm accurate sorting of the desired number 
of nuclei. The time to amplify to a threshold above background (TimeT, analogous to qPCR CT value) 
is plotted on the y-axis (error bars ±1SD, n=7 or 8 reactions per condition). Points were fit to a semi-
log line of slope -4.3, corresponding to 1.7-fold amplification per unit time. 
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step-wise manner (p <0.01 for each additional nucleus) (Figure 3-4D) (Zhang et al. 
2006), confirming that the desired number of nuclei was correctly sorted in each well. 
Because of concern that MDA would amplify the genome non-linearly, 
preventing analysis of aneuploidy and large segmental CNVs, we also explored the 
GenomePlex WGA4 method used by Navin et al. (2011) to profile copy numbers from 
single cancer cells. WGA4 starts with initial fragmentation and adaptor ligation of the 
single cell genome, followed by PCR amplification (Figure 3-5A). The fragmentation 
leads to non-lapping amplicions, and thereby PCR-based quality control assessments 
cannot be appiled to WGA4 amplified samples. Instead, per manufacturer’s 
recommendation, we ran a small fraction of amplified samples on 1.5% agorase gel to 
examine the fragment size distribution and relative yield (Figure 3-5B) and quantified 
the final yield by nanodrop (data not shown) to confirm the successful amplification of 
each sample and the absence of external contamination of each preparation from the 0 
cell negative control.  
We concluded that our procedure can sort and amplify single neuronal genomes 
from human brains with high purity and in a high-throughput manner. For the analysis of 
SNPs, SVs and retrotransposon insertions, MDA amplified single cells were used. For the 
analysis of aneuploidy and segmental CNVs, both WGA4 and MDA amplified cells were 
used and compared (see detailed analysis and discussion in section “Amplification 
linearity of single cell genomes” in Chapter 4). 
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Fragmentation/adaptor ligation
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Figure 3-5. Quality assessment of GenomePlex WGA4 single cell whole-genome amplification. 
(A) Schematic of the method. 
(B) Agorose gel of amplified products from 0 cell, 1 cell and 10 cells, confirming succeussful 
amplification with fragments ranging between 150-1000bp, and free of external contamination based 
on 0-cell negative control. 
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Genome-wide coverage and amplification dropout rates of MDA single neuronal 
genomes 
To be able to study a wide variety of mutational types from amplified single cell 
genome, it is important to determine what fraction of the genome has been consistently 
amplified by the method. We took multiple approaches, including multiplex PCR, low 
coverage sequencing, SNP-chip array, Identifiler fingerprinting and retrotransposon 
screening to estimate the allelic and locus dropout rates of single cell MDA at different 
scales ranging from single nucleotide from SNP-chip to ~500kb regions from low 
coverage sequencing. These results are largely consistent with each other and lead us to 
conclude that the single cell MDA method we developed recovers >90% of the single cell 
genome and thereby is suitable for studies of a wide spectrum of somatic mutational 
events (application on L1 retrotranspositon prolifing, aneuploidy analysis, and whole-
genome sequencing for SNPs and SVs that will be discussed later in the chapter and in 
chapter 4). 
We first evaluated the genome-wide coverage and reproducibility of our MDA 
single cell genome amplification. In an initial 4-locus multiplex PCR quality control, 
97% of sorted single neurons showed amplification of at least 3 of the 4 loci, indicating 
that their genomes were successfully amplified and suitable for further experiments 
(Figure 3-6A). Low-coverage sequencing of MDA samples that failed the mutiplex PCR 
quality control confirmed that they were not suitable for downstream analysis because 
many genomic regions were amplified poorly, while a small fraction of the genome was 
overamplified up to 50-fold (Figure 3-6B). We then performed low-coverage whole-
genome sequencing (Figure 3-7A) of eight randomly chosen single neurons (0.35x 
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Figure 3-6. Multiplex PCR quality control on MDA amplified single cell samples. 
(A) Multiplex PCR on 4 randomly selected loci from the human genome. 0 cell controls gave no 
amplified bands, confirming that the preparations are free of human DNA contamination. >80% of the 
sorted wells give at least 1 band, indicating a sorting success rate greater than 80%. Among the sorted 
wells, 97% give 3 or 4 bands, indicating a high success rate of MDA whole-genome amplification. 
Samples that yielded only 1 or 2 bands are regarded as poorly amplified and were excluded from 
further analysis. Red square marks wells with no cells sorted. 
(B) Histograms of relative copy number ratio to euploid genome (normalized by read depth and GC 
content) of 6,000 equal-read bins across the whole genome. A representative sample passing the 
multiplex QC (left) shows a normal distribution with median = 1 (expected for euploid genome); a 
representative sample that failed the multiplex QC (right) shows a skewed distribution with most bins 
(~90%) showing copy number ratio close to 0 and the rest of the bins showing copy number ratio up to 
50-fold. 
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Figure 3-7. Whole-chromosome copy number analysis of MDA amplified single neurons. 
(A) Schematic of the low-coverage whole-genome sequencing method. 
(B) Chromosome copy numbers of single cortical neurons from normal (UMB1465, 46XY) and 
trisomy 18 (UMB866, 47XY,+18) individuals. Copy numbers are normalized to the median copy 
number of each chromosome across the 8 single neurons, with autosomes adjusted to a median copy 
number of 2. Orange lines denote ±1 copy. 
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average coverage), six from a normal male individual (46XY) and two from a male 
trisomy of chromosome 18, as well as unamplified and MDA-amplified bulk reference 
samples. The two neurons from the trisomy 18 individual showed the expected increase 
in chromosome 18 copy number, and the six single neurons from the normal individual 
were all euploid, confirming that intact nuclei can be sorted and that all chromosomes 
were amplified and that MDA is sensitive enough detect copy number changes at the 
chromosomal level despite previous concerns about its amplification linearity (Figure 3-
7B). Counting sequencing reads across the genome in bins ~500kb in size (Navin et al. 
2011; Baslan et al. 2012) revealed a systematic, regional amplification bias for all MDA 
samples, compared to unamplified bulk DNA, regardless of the number of nuclei 
amplified (Figure 3-8A). This regional bias in MDA amplification could be controlled 
for using any of the MDA samples as a reference (Figure 3-8C), indicating that most of 
the regional variability in amplification is inherent to MDA rather than reflecting the 
number of nuclei amplified. The rate of locus dropout (LD) rate at ~500kb resolution was 
estimated by counting the percentage of low-coverage sequencing bins with less than 
1/16 of the copy number relative to an unamplified DNA reference, and was 2.0% for 1-
neuron samples (Figure 3-8B). When using 100-neuron samples as a reference, LD in 1-
neuron samples was lower at 0.05%, consistent with the finding that most regional 
amplification bias is inherent to MDA (Figure 3-8B). GC content partially accounts for 
the regional bias such that regions with high GC content are systematically under-
amplified by MDA (Figure 3-9A). Regional bias resulting from GC content imbalance 
can be corrected by GC-normalization (see details in Methods) (Figure 3-9B). 
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Figure 3-8. Low cov rage whole-genome sequencing of MDA amplified single neuronal genome. 
(A) Copy number profiling in 6,000 equal-read bins of ~500kb in size, relative to an unamplified DNA 
reference, shows that MDA bias is consistent and reproducible regardless of the number of nuclei 
amplified. Correlations (R2) between 50×103-nuclei, 100- and 1-neuron samples are shown. Purple 
points represent off-scale bins. 
(B) Genomic locus dropout (LD) estimates from low-coverage sequencing normalized to the indicated 
amplified and unamplified references (left panel) (error bars ±SD, n=4 for 50×103 nuclei, n=2 for 100-
neuron, and n=6 for 1-neuron groups).  
(C) Higher-resolution copy number profiling in 6,000 equal-read bins of ~500kb in size shows that 
MDA bias can be corrected by normalization to an MDA-amplified reference. Orange lines denote ±1 
copy, and purple points indicate off-scale bins. 
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Figure 3-9. Normalization of MDA amplification bias by GC contents.  
X-axis represents the GC content of the 6,000 equal-read bins across the genome; y-axis represents to 
the log2 ratio of relative copy number to euploid reference genome of each bin.  
(A) Before GC-normalization, GC content negatively correlates to the log2 ratio suggesting that high 
GC regions are systematically under amplified by MDA. 
(B) GC bias of the amplification can be corrected by GC-normalization (see details in Methods 
section). 
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Figure 3-10. SNP-chip analysis on 3 MDA amplified single neurons. 
(A) Allelic dropout (AD) rates of 3 single neurons against unamplified bulk DNA from the same 
individual at single base pair resolution. 
(B) Fraction of genotypes by SNP microarray that are concordant between 3 single neurons and bulk 
DNA confirms the single neurons derive from the correct individual. 
A
 
B
 
 
	  
92	  
* * *
* *
* *
0 nuclei
n = 8
n = 92
1 neuron
n = 10
10 / 100 neurons
n = 4
1000 neurons
n = 15
Unamplified DNA
n = 4
10×103 or 50×103
unsorted nuclei
* * *
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
Balanced amplification
Preferential amplification
Low amplification
Allele drop-out
Concordant
genotype} Discordant allele
0.
0
0.
5
1.
0
1.
5
2.
0
35% 40% 45% 50% 55%
0.
0
0.
5
1.
0
1.
5
2.
0
0.
0
0.
5
1.
0
1.
5
2.
0
N
or
m
al
iz
ed
 re
ad
 d
ep
th
GC content
Amplified 1 neuron
Amplified 100 neurons
Amplified 50×103 unsorted nuclei
D
A B
C
vs. Unamplified DNA
vs. Amplified 100 neurons
15%
10%
5%
0
SN
P 
m
icr
oa
rra
y a
lle
lic
 d
ro
po
ut
 (A
D)
1 ne
uron
 #6
1 ne
uron
 #2
1 ne
uron
 #3
Re
lat
ive
 co
py
 n
um
be
r (
log
2 r
at
io)
R2=
0.92
R2=
0.82
1 2 3 4 5 XY6 7 8 910
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
Sa
m
ple
Reference
Amplified
50×103
unsorted nuclei
(sample #5)
(sample #2)
(neuron #3)
Unamplified DNA
Amplified
100
neurons
Amplified
1 neuron
R2=
0.90
4%
3%
2%
1%
0
500kb bins
50k
 uns
orte
d
nuc
lei
100
 neu
rons
1 ne
uron
Ge
no
m
e 
se
qu
en
cin
g 
loc
us
 d
ro
po
ut
 (L
D)
(L
og
2 R
at
io 
< 
-4
)
* * *
* *
* *
0 nuclei
n = 8
n = 92
1 neuron
n = 10
10 / 100 neurons
n = 4
1000 neurons
n = 15
Unamplified DNA
n = 4
10×103 or 50×103
unsorted nuclei
* * *
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
Balanced amplification
Preferential amplification
Low amplification
Allele drop-out
Concordant
genotype} Discordant allele
0.
0
0.
5
1.
0
1.
5
2.
0
35% 40% 45% 50% 55%
0.
0
0.
5
1.
0
1.
5
2.
0
0.
0
0.
5
1.
0
1.
5
2.
0
N
or
m
al
iz
ed
 re
ad
 d
ep
th
GC content
Amplified 1 neuron
Amplified 100 neurons
Amplified 50×103 unsorted nuclei
D
A B
C
vs. Unamplified DNA
vs. Amplified 100 neurons
15%
10%
5%
0
SN
P 
m
icr
oa
rra
y a
lle
lic
 d
ro
po
ut
 (A
D)
1 ne
uron
 #6
1 ne
uron
 #2
1 ne
uron
 #3
Re
lat
ive
 co
py
 n
um
be
r (
log
2 r
at
io)
R2=
0.92
R2=
0.82
1 2 3 4 5 XY6 7 8 910
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
Sa
m
ple
Reference
Amplified
50×103
unsorted nuclei
(sample #5)
(sample #2)
(neuron #3)
Unamplified DNA
Amplified
100
neurons
Amplified
1 neuron
R2=
0.90
4%
3%
2%
1%
0
500kb bins
50k
 uns
orte
d
nuc
lei
100
 neu
rons
1 ne
uron
Ge
no
m
e 
se
qu
en
cin
g 
loc
us
 d
ro
po
ut
 (L
D)
(L
og
2 R
at
io 
< 
-4
)
* * *
* *
* *
0 nuclei
n = 8
n = 92
1 neuron
n = 10
10 / 100 neurons
n = 4
1000 neurons
n = 15
Unamplified DNA
n = 4
10×103 or 50×103
unsorted nuclei
* * *
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
AM
EL
D8
S1
17
9
D2
1S
11
D7
S8
20
CS
F1
PO
D3
S1
35
8
TH
01
D1
3S
31
7
D1
6S
53
9
D2
S1
33
8
D5
S8
18 FG
A
D1
9S
43
3
vW
A
TP
OX
D1
8S
51
0.0
0.5
1.0
Balanced amplification
Preferential amplification
Low amplification
Allele drop-out
Concordant
genotype} Discordant allele
0.
0
0.
5
1.
0
1.
5
2.
0
35% 40% 45% 50% 55%
0.
0
0.
5
1.
0
1.
5
2.
0
0.
0
0.
5
1.
0
1.
5
2.
0
N
or
m
al
iz
ed
 re
ad
 d
ep
th
GC content
Amplified 1 neuron
Amplified 100 neurons
Amplified 50×103 unsorted nuclei
D
A B
C
vs. Unamplified DNA
vs. Amplified 100 neurons
15%
10%
5%
0
SN
P 
m
icr
oa
rra
y a
lle
lic
 d
ro
po
ut
 (A
D)
1 ne
uron
 #6
1 ne
uron
 #2
1 ne
uron
 #3
Re
lat
ive
 co
py
 n
um
be
r (
log
2 r
at
io)
R2=
0.92
R2=
0.82
1 2 3 4 5 XY6 7 8 910
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
Sa
m
ple
Reference
Amplified
50×103
unsorted nuclei
(sample #5)
(sample #2)
(neuron #3)
Unamplified DNA
Amplified
100
neurons
Amplified
1 neuron
R2=
0.90
4%
3%
2%
1%
0
500kb bins
50k
 uns
orte
d
nuc
lei
100
 neu
rons
1 ne
uron
Ge
no
m
e 
se
qu
en
cin
g 
loc
us
 d
ro
po
ut
 (L
D)
(L
og
2 R
at
io 
< 
-4
)
Normalize
to referenceAmplified DNA
Unamplified
DNA
Samples
Amplified DNA
Reference
Unamplified DNA
Reference
Low coverage
whole-genome
sequencing
Re
lat
ive
 co
py
 n
um
be
r (
log
2 r
at
io)
1 2 3 4 5 XY6 7 8 910 1 2 3 4 5 XY6 7 8 910 1 2 3 4 5 XY6 7 8 910
Sa
m
ple
Reference
Amplified
50×103
unsorted nuclei
(sample #5)
(sample #2)
(neuron #3)
Amplified
100
neurons
Amplified
1 neuron
Amplified 1 neuronAmplified 100 neuronsAmplified 50×10
3
unsorted nuclei
(pooled reads samples #1-4) (sample #1) (pooled reads neurons #4-6)
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
0
1
2
3
4
-1
-2
-3
-4
Balanced amplification
Preferential amplification
Low amplification
Allele drop-out
Concordant
genotype}
Discordant allele
Reference genotype
of individual:
Example locus
Allele
A
Allele
B
Microsatellite Identity Fingerprinting
M
ea
n 
pe
rc
en
t a
cr
os
s
al
l l
oc
i a
nd
 s
am
pl
es
Un
am
plif
ied
DN
A
10 
/ 10
0 n
eur
ons
1 n
eur
on
0 n
ucl
ei
10×
10
3 or 
50×
10
3
uns
orte
d n
ucl
ei
100%
90%
9.5%
0.6%
99% 100% 100%
AD DA
LA
PA
BA
0
50%
100%
Number of Samples:
(11-14 loci per sample)
8 92 10 4 15
146
5-c
orte
x
463
8-c
orte
x
464
3-c
orte
x
#6 #2 #3
1465-cortex
U
na
m
pl
ifi
ed
4638-cortex
4643-cortex
1465-cortex-1 neuron
#6
#2
#314
65
-c
or
te
x
1 
ne
ur
on
Unamplified
1.00
0.70 1.00
0.70 0.70 1.00
0.95 0.68 0.68 1.00
0.95 0.68 0.68 0.96 1.00
0.95 0.68 0.68 0.96 0.96 1.00
A
C
D E
B
Chromosome
Co
py
 n
um
be
r
Normal (46XY) cortex Trisomy 18 (47XY) cortex
Trisomy 18
1-Neuron #2
1-Neuron #11-Neuron #1
1-Neuron #2
1-Neuron #3 1-Neuron #6
1-Neuron #5
1-Neuron #4
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y
0
1
2
3
A
 
B
 
Figure 3-11. Identifiler fingerprinting analysis on bulk and MDA amplified samples. 
(A) Identifiler fingerprinting confirms the single neurons derive from the correct individuals, and 
measures allele preferential amplification (PA), low amplification (LA), allele dropout (AD), and 
discordant allele (DA) rates.  
(B) Per-locus Identifiler results for different sample types. Asterisks mark consistently under-
performing loci, indicating that they reside in regions that do not amplify well by MDA. 
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In order to use single-neuron sequencing for somatic mutation detection, 
amplified genomes must reflect the diploid genotype (both alleles) of genomic loci. We 
therefore quantified the fraction of genomic loci that failed to amplify one (allelic 
dropout, AD) or both alleles (locus dropout, LD). Loss of one allele, AD, was measured 
by SNP microarray genotyping (Figure 3-10B) and with a panel of 16 highly 
polymorphic microsatellite markers (Identifiler fingerprinting) (Figure 3-11A). AD 
measured by SNP microarray (for >60,000 loci that are heterozygous in the bulk DNA 
and called with high confidence in both the reference and sample) was 8-9% in 3 single 
neurons (Figure 3-10B), and AD of 92 single neurons measured by Identifiler of 92 
single neurons across 1,183 heterozygous loci, was 9.5% (Figure 3-11A), consistent with 
previous estimates (Hou et al. 2012). Some dropout tended to recur at specific loci even 
in MDA-amplified 100- and 1000-neuron samples (Figure 3-11B), reflecting the 
systematic bias of MDA for amplification of specific loci. Loss of both alleles, LD (locus 
dropout), was approximately 2.3% in the 92 single neurons assayed by Identifiler.  
These low rates of AD (~10%) and LD (~2%) at various scales demonstrate 
comprehensive and reproducible amplification of single neuronal genomes by MDA, and 
suggest that genome-wide profiling of specific types of mutational events such as L1 
insertions in single neurons could capture up to 90% of retrotransposon insertions per cell. 
These genotyping controls also excluded operator contamination, since all amplified 
single neuronal genomes tested were concordant with the bulk reference (Figure 3-10B 
and 3-11).  
Identification of somatic L1 retrotransposon insertion from single neurons 
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We carried out genome-wide L1 retrotransposition profiling on 300 MDA 
amplified single neurons from cortex and caudate of three neurologically normal 
individuals to identify somatic L1 insertions and to quantify the insertion rate (the 
estimation of somatic insertion rate is discussed in detail in Gilad Evrony’s thesis). A 
method named L1Hs insertion profiling (L1IP) adapted from Ewing and Kazazian (2010), 
was used to profile L1Hs insertions genome-wide. L1Hs is the only retrotransposon 
subfamily that remains self-autonomously active in the human genome. There are 800-
850 copies of L1Hs in each individual, of which ~600 copies are fixed in the human 
population (referred to later as known reference, KR) and 100-200 copies are population 
polymorphic (referred to later as known non-reference, KNR) (Ewing & Kazazian 2010; 
Iskow et al. 2010; Stewart et al. 2011; Hancks & Kazazian 2012). 
We confirmed that we are able detect the expected absolute number of insertions: 
the mean number of KR, KNR and unknown insertions (UNK) per bulk DNA sample 
was 689, 113, and 43, respectively, compared to 628 KR and 152 KNR/UNK insertions 
found on average in a previous study (Ewing & Kazazian 2010). 605, 87 and 47 KR, 
KNR, and UNK insertions were found on average in the 300 single neurons profiled, 
reflecting a technical sensitivity >80% from the single neuron genomes. Furthermore, 
only 4 out 300 neurons profiled were poor quality outliers, demonstrating the high quality 
and consistency of the method (Figure 3-12).  
In order to validate L1-IP predicted insertions, we optimized a 3’ junction PCR 
validation method (3’PCR) (Figure 3-13A), and further used it to directly measure allelic 
dropout (AD) and locus dropout (LD) of L1Hs insertions in amplified single neurons. 
The technical sensitivity of the 3’PCR validation method (i.e. 3’PCR detection rate of 
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Figure 3-12. Box plot of number of L1IP insertion per chromosome, for all 1-neuron samples in 
the study. 
Outliers are represented by black dots. 4 consistent outlier low-quality samples are colored. 
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Figure 3-13. Estimation of AD and LD based on PCR validation of L1Hs insertions from single 
neurons. 
(A) Schematic of the method.  
(B) Representative gel images of 3’PCR of 20 different germline insertions (8 KR, 8 KNR, and 4 
UNK). 
(C) Representative gel images of 3’PCR and FL-PCR of 1 homozygous and 1 heterozygous L1Hs 
germline insertion in 8 different single neurons. The upper band in FL-PCR of the heterozygous 
insertion is the allele with the transposon insertion, and the lower band is the allele with no transposon 
insertion. Although the majority of cells have both alleles evenly amplified, AD of the insertion allele 
can be seen in some cells (e.g. neuron #4), which correlates with absence of 3’PCR product in the 
same cell. AD of the allele with no insertion can be seen in neuron #5. Neuron #8 had preferential 
amplification of the insertion allele. 
(D) 3’PCR quantification of AD and LD in 1-neuron samples (n=83), of 3 heterozygous and 3 
homozygous L1Hs insertions. AD and LD are quantified for heterozygous and homozygous insertions, 
respectively. BA, balanced amplification; LA, low amplification; AD, allelic-dropout; LD, locus-
dropout. 
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 true germline insertions) was important to determine first, in order to estimate at what 
rate true insertions found by L1-IP fail to validate by 3’PCR. This was assayed by 3’PCR 
of 64 known germline insertions (33 KR and 31 KNR) in unamplified bulk DNA, and in 
amplified, unsorted 50,000-nuclei and 1-neuron samples. In 1-neuron samples, 3’PCR 
detected 94% of known germline insertions with the first primer pair attempted, and the 
remainder were validated successfully with redesigned primers, This detection rate was 
not significantly different between amplified and unamplified samples (Figures 3-13B). 
3’PCR can therefore sensitively detect L1Hs insertions in amplified single neuronal 
genomes. 3’PCR also successfully validated, in both bulk and 1-neuron samples, 12 out 
of 12 unknown (UNK) germline candidate insertions that we tested (Figures 3-13B), 
confirming that L1-IP can identify unknown insertions. AD of L1Hs insertions was then 
estimated by 3’PCR of 3 heterozygous insertions in a larger number of 83 single neurons 
(Figures 3-13C), finding 8.0% AD (20/249 alleles), consistent with previous estimates 
(Figures 3-13D). LD estimated by 3’PCR of 3 homozygous insertions in the same cells 
was 1.2% (3/249 alleles) (Figures 3-13D). We concluded that L1-IP’s high sensitivity to 
detect germline insertions in single neurons, our robust 3’PCR validation method, and 
direct confirmation of <10% L1Hs allelic dropout, allows us to confidently search for 
somatic L1Hs insertions genome-wide in single neurons. 
We successfully validated 5 somatic L1Hs insertion candidates by 3’PCR, and 
these 5 were studied further by attempting to clone their full-lengths, and screening for 
their presence by 3’PCR across all single neurons sorted from the individual in which 
they were found. We successfully cloned the full-length of one of the five somatic 
insertion candidates (Figure 3-14A). This insertion was detected in our L1-IP data in 
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Figure 3-14. Identification of the first somatic L1 insertion in human brain. 
(A) Gel image of full-length (long-range) PCR cloning of the validated L1Hs somatic insertion shown 
in Figures 6C-E (L1-IP peak ID chr15_67625710_plus_0_0), in sample 1465-cortex 1-neuron #2. 
(B) Location of the somatic L1Hs insertion (L1-IP peak ID chr15_67625710_plus_0_0) in antisense 
orientation in intron 4 of the gene IQCH, and the corresponding L1-IP peak in 1465-cortex 1-neuron 
#2. The insertion’s target site duplication coordinates are chr15: 67,625,702-67,625,714 (hg19). A 5’ 
transduction (orange) identified the source L1Hs on chr8: 73,787,792-73,793,823. Representative gel 
images from a 3’PCR screen of 83 1-neuron samples from individual 1465 cortex (24 1-neuron 
samples shown). The two cortical 1-neuron samples (#2 and #77) found to have the insertion are 
shown. 1-neuron #77 was found to have the insertion only in the 3’PCR screen since it was not 
profiled by L1-IP. 3’PCR product sequencing and full-length cloning confirmed the insertion had 
identical 5’ and 3’ breakpoints and TSD in both neurons (#2 and #77). 
(C) Structure of the L1Hs somatic insertion (chr15_67625710_plus_0_0), cloned by full-length PCR. 
Pre-integration TSD coordinates are chr15: 67,625,702-67,625,714 (hg19). 5’ transduction (chr8: 
73,793,824-73,794,027) from upstream of the source L1Hs (L1Hs-KR-chr8_73787792) exhibited 
transcriptional splicing removing 103bp (chr8: 73,793,831-73,793,934) from the source sequence. 
Sequences of 5’ and 3’ junctions of the L1Hs somatic insertion show. Poly-A tail length (at least 71bp 
long) was not possible to determine exactly due to difficulty sequencing through homopolymeric 
regions. 
(D) Optimized 5’ PCR confirms the presence of the somatic insertion in unamplified bulk DNA at low 
level. 
evident by its stochastic amplification from different bulk DNAs of the same brain region. 
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intron 4 of the gene IQCH (IQ motif containing H, chromosome 15), in neuron #2 from 
the cortex of individual 1465, and is a full-length, intact 6.1kb L1Hs with all the 
hallmarks of a bona fide L1Hs insertion: a target site duplication (TSD) (13bp), a poly-A 
tail (~71bp), and a 5’ transduction (101bp) allowing us to trace its source to a full-length, 
population-polymorphic KR L1Hs on chromosome 8 (Figure 3-14B, C). The full-length 
sequence of the somatic insertion precisely matched the sequence of the source L1Hs. 
The insertion was found in 2/83 (2.4%) cortical and 0/59 caudate single neurons tested 
(Figure 3-14B). The insertion was detected at low-levels in L1-IP data of some unsorted-
50,000-nuclei samples, as expected for a low-level mosaic insertion. After further 
optimization, we were able to amplify the insertion from unamplified bulk samples with 
more specific primers against the 5’ junction of the insertion, definitively showing that 
the somatic insertion identified was not an artifact due to MDA (Figure 3-14D). Further 
characterization of the percent of mosaicism and clonal dispersion pattern of the somatic 
insertion in different brain regions of the individual is described elsewhere (see Gilad 
Evrony’s thesis). The remaining four candidates were each found by 3’PCR only in the 
single neuron in which they identified by L1-IP. Three of the four had poly-A tails by 
3’PCR product sequencing (the fourth had an indeterminate poly-A tail since the 
breakpoint was within a genomic poly-A). Our results illustrate the ability of single-cell 
sequencing to identify somatic L1Hs insertions and highlight the potential of single-cell 
sequencing to identify very low-level mosaic mutations in human tissue. 
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Discussion 
We have performed the first single cell, whole genome analysis to study somatic 
variants from normal human tissue. The method we developed allowed us to directly 
study human subjects without further experimental manipulations, such as tissue culture, 
cell transformation or iPS cell reprogramming. This ensured that we would capture 
genetic variants in vivo, free of common artifacts associated with in vitro manipulation. 
Our method is not limited to studies of the central nervous system, but widely applicable 
to any other organs, from which fresh-frozen post-mortem tissues are available. Most 
current human genetic studies heavily rely on DNA material from fresh blood; this 
approach inevitably misses somatic variants that are absent or present at only low levels 
in the hematopoietic system. Our method broadens the accessibility of tissue-specific 
somatic variants by making use of post-mortem tissues, which are generally available 
from public resource such as The NICHD Brain and Tissue Bank. We found that 
although it is difficult to isolate intact whole cells from frozen specimens, the nuclei 
integrity of these tissue specimens is largely preserved (with exceptions to be discussed 
in Chapter 4) and thereby is sufficient for genomic studies. However, for studies that 
require whole cells, such as single-cell mRNA sequencing, would still require fresh 
tissues.  
We performed by far the most comprehensive and rigorous quality control 
assessments among all single cell genomic studies (Navin et al. 2011; Hou et al. 2012; B. 
Xu et al. 2011; Fan et al. 2011; Wang et al. 2012; Zong et al. 2012; Lu et al. 2012). Using 
quantitative MDA, we confirmed the exact number of cells sorted into a well for 
subsequent whole genome amplification and quantified the external contamination of 
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reagents. We also carried out all the procedures with extreme caution by UV treatment of 
all the reagents (except for enzymes, dNTP and oligos), consumables (e.g. PCR striptubes, 
plates, microtubes, pipette tips, etc.) and equipments (e.g. pipettes), and performed all the 
procedures within sterile laminar flow hoods. We included negative controls by sorting 
fluorescent beads within each sample preparation; and indeed, we never detected positive 
product from negative control wells by multiplex PCR, demonstrating that our single cell 
preparations are free of external human contamination. The individual cell identities were 
further confirmed by forensic fingerprinting and SNP-chip concordance on a subset of 
randomly selected samples. The initial multiplex screen on all amplified samples allowed 
us to immediately exclude poor quality samples from downstream analysis. This cost-
effective screening method not only saved us money from sequencing bad samples, but 
also prevented potential data misinterpretation. Comprehensive analyses of allelic and 
locus dropout rates at various scales by different methods consistently pointed to an 
allelic dropout rate of ~10% and a locus dropout rate of no more than 2% for MDA 
amplified single cell samples. These quality control experiments led us to conclude that 
MDA single cell whole genome amplification is compatible with studies on a whole 
spectrum of somatic mutation types, except perhaps for small scale CNVs. This 
conclusion is further supported by our recent data from high-coverage (>30X) whole-
genome sequencing on MDA amplified single neurons. We believe that a standard and 
through quality-control pipeline is essential for all future single cell genomic studies to 
allow for informative comparisons across studies and across methods.  
In addition, we have optimized our protocol to be highly compatible with any 
high-throughput workflow such as robotic liquid handlers; therefore, systematic 
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assessments of large number of single cells is possible with our methods given the 
expected further reduction of sequencing cost.  
Our validation of a somatic L1Hs insertion with all the hallmarks of a bona fide 
retrotransposition event, including a 5’ transduction identifying its source, confirms that 
somatic L1Hs insertions are present in the normal human brain. The very low-level 
mosaicism of this insertion, and its detection only in cortical neurons, further suggests 
that it may have occurred during cortical development. Further characterization of this 
somatic insertion revealed that it is detectable in unamplified bulk DNA at an estimated 
percent of mosaicism between 0.1-0.2% only in a focal region of the cortex (data not 
shown), further confirming and highlighting the robustness of single cell sequencing in 
identifying low level mosaic somatic events.  
Although we successfully demonstrated the possibility of using single-cell 
sequencing to detect and quantify low-level somatic variants that would be otherwise 
missed by analyzing bulk DNA, we do realize a number of limitations of the current 
methods. First of all, all amplification methods introduce errors including point 
mutations/small indels and chimeras. Although Phi29 is considered a “high-fidelity” 
polymerase with 3’ à 5’ exonuclease activity resulting in error rates around 10-6- 10-5 
(Wang et al. 2012), with an over million-fold amplification (6pg to ~15ug), a significant 
amount of point mutations are expected to be accumulated. Moreover, chimeras are 
known to be introduced during MDA amplification due to mechanisms such as branch 
migration and template switching (Lasken & Stockwell 2007). In our experience, the 
false positive rate of somatic variants from MDA amplified single cell samples is 
extremely high (i.e. 5/81 validated for somatic L1 insertion); therefore, secondary 
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validation steps that separate real somatic variants from technical artifacts are crucial for 
any single cell studies. 
 
Materials and Methods 
Tissue sources 
Fresh-frozen post-mortem tissues of normal individuals and a trisomy 18 fetus 
were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at 
the University of Maryland (Baltimore, MD). All tissues were frozen at -80°C with post-
mortem intervals < 5 hours. Case UMB1465 was a 17 year-old male who died in a motor 
accident; case UMB4638 was a 15 year-old female who died in a motor accident; case 
UMB4643 was a 42 year-old female who died of cardiovascular disease; and case 
UMB866 was a 21 week-gestation fetus from an electively terminated pregnancy, with a 
47XY,+18 (trisomy 18) karyotype. All tissue samples were confirmed as deriving from 
the correct individual with AmpFlSTR Identifiler Plus fingerprinting (Applied 
Biosystems). 
Single-neuronal nuclei flow sorting and labeling 
Nuclei were isolated and labeled for flow cytometry based on Spalding, et al. 
(2005) and Matevossian and Akbarian (2008). All procedures were performed at 4°C 
unless noted. 100-200mg of tissue was homogenized in a dounce homogenizer in lysis 
buffer (0.1% Triton X-100, 11% sucrose, 5mM CaCl2, 3mM MgAc2, 0.1mM EDTA, 
10mM Tris-pH8, 50mM DTT) and ultra-centrifuged on top of a sucrose cushion (62% 
sucrose, 3mM MgAc2, 10mM Tris-pH8, 50mM DTT) at 13krpm in an SW-28.1 rotor 
(Beckman Coulter). The pellet was resuspended in PBS+3mM MgCl2 solution and 
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filtered through a 40µm cell strainer. Nuclear integrity, purity and concentration were 
assessed by light microscopy on a hemocytometer with light trypan blue staining. 
For labeling with NeuN for flow cytometry, 1.2µg each of NeuN antibody 
(Millipore, MAB377) was pre-incubated with Alexa-488 goat α-mouse and Alexa-647 
donkey α-rabbit antibodies (Life technologies) in 400µl PBS+3% BSA+3mM MgCl2 
solution at RT for 10 min. Initial experiments were performed with NeuN/Mef2c double-
labeling, and since all NeuN+ nuclei were also Mef2c+ (data not shown) subsequent 
experiments were performed only with NeuN labeling. For NeuN/Mef2c double labeling 
experiments, 1.2µg each of NeuN and Mef2c antibody (Abcam, ab64644) was used. 
Alexa-647 secondary antibody was still used in addition to Alexa-488 in NeuN-only 
experiments to provide background signal (FL-2) relating to nuclear size. 200-500×103 
nuclei were diluted in 1ml PBS+3mM MgCl2 solution and incubated with the antibody 
mix at 4°C for at least 30 mins. Nuclei in Figure S1B were labeled with Alexa488-
conjugated NeuN antibody (Millipore, MAB377). 
Single nuclei were sorted at a maximum flow rate of 3.0 with a FACSAria II cell 
sorter at the Dana-Farber Hematologic Neoplasia Flow Cytometry core into 96-well 
(qMDA experiments) or 384-well (sequencing experiments) plates. Sorting into 384-well 
plates always left a gap of one empty well in all directions between single cells. 1,000 
nuclei samples were sorted into microtubes. PBS+3mM MgCl2 sheath fluid and sample 
chambers chilled to 4°C were used to help preserve nuclear integrity. SSC-H vs. SSC-W 
and FSC-H vs. FSC-W doublet discrimination gates and a stringent ‘0/32/16 single-cell’ 
sort mask were used to ensure one and only one event was sorted per well. Initial 
experiments with DRAQ5 staining confirmed exclusion of doublets. Each sorted plate 
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contained negative (0 nuclei) and positive control (10 and 100 nuclei) wells. Amplified 
human DNA was never observed in negative control wells in quality control assays. 
Successful sorting of single nuclei into 384-well plates was monitored by quantitation of 
yield and with multiplex PCR (see below). Every plate’s sorting success rate per well 
was >80%, and the sorting success rate per well across all plates was 94%. 
RT-PCR and Western blots 
5,000 nuclei from each population were sorted into microtubes. RNA was 
extracted using RNeasy (Qiagen) and cDNA synthesized with the Superscript III First-
Strand Synthesis System (Life tech.), and in separate experiments protein lysates were 
used for western blots. RT-PCR primers were designed with Primer3 (Rozen & Skaletsky 
2000) to span introns. Antibodies used for western blots were NeuN (Millipore, 
MAB377), Olig2 (Millipore, AB9601), and HistoneH3 (Abcam, ab1791) at 1:1000 
dilution. 
Single-neuron genome amplification by MDA 
All work was carried out in a UV-treated laminar flow cabinet, and all surfaces, 
plastics and non-biologic buffers were UV-treated for at least 30 min. Reagents were 
added without touching the liquid surface to avoid losing parts of the single genome. 
Nuclei sorted into 384-well plates were sorted into 2.8µl lysis and denaturing buffer 
(200mM KOH, 5mM EDTA, 40mM DTT), and neutralized with 1.4µl neutralization 
buffer (400mM HCl, 600mM Tris-pH7.5). 15.8µl MDA reaction-mix was added to each 
well and incubated in a thermal cycler at 30°C for 16 hours (no lid heating), followed by 
3 min at 65°C. 
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MDA reactions (Dean et al., 2002) were optimized for hexamer, dNTP, and phi29 
polymerase concentrations by amplifying control human bulk DNA and assaying yield 
with Quant-iT Picogreen (Life tech.). All reaction conditions were confirmed to have 
high-molecular weight (>30kb) products by standard and alkaline gel electrophoresis 
(data not shown). Following optimization of MDA reaction conditions, MDA reagent 
concentrations used in reactions in this work were as follows: 1x RepliPHI phi29 reaction 
buffer (Epicentre), 50µM random hexamer 5′-dNdNdNdN*dN*dN-3′ (* = thiophosphate 
linkage) (IDT, Inc), 2mM each dNTP, 40U RepliPHI phi29 polymerase (Epicentre), and 
nuclease-free UV-treated water. Quantitative MDA reactions (Zhang et al., 2006) were 
monitored on a StepOnePlus real-time PCR instrument (Applied Biosystems) by addition 
of 0.1x SYBR Green I (Life tech.) and fluorescence was measured every 6 min for 7 
hours. 0.5µl of MDA reaction products was diluted 1:50 for quality control assays (see 
below) and initial Picogreen quantitation. The remainder of the DNA was purified with 
AMPure XP beads (Beckman Coulter), treated with 10U mung-bean nuclease (NEB) at 
30°C for 30 mins to debranch the MDA product structure (Zhang et al., 2006), cleaned-
up with the DNeasy Blood & Tissue 96 kit (Qiagen) skipping the tissue digestion 
protocol steps, and assayed for final yield with Picogreen. 
Single-neuron genome amplification by GenomePlex WGA4 
WGA4 single cell whole genome amplification was performed according to the 
manufacturer’s instructions (Sigma-Aldrich®), with slight modifications to the reaction 
volume and lysis conditions. All work was carried out in a UV-treated laminar flow 
cabinet, and all surfaces, plastics and non-biologic buffers were UV-treated at least 30 
mins. Nuclei sorted into 96-well plates were sorted into either 5µl proteinase K lysis 
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buffer provided by the manufacturer’s protocol or 4ul alkaline lysis and denaturing buffer 
(100mM KOH, 5mM EDTA, 40mM DTT), and neutralized with 1µl neutralization buffer 
(400mM HCl, 600mM Tris-pH7.5). Further fragmentation, adaptor ligation and PCR-
amplification were performed according to the manufacturer’s instruction with the 
reaction volume of all steps reduced by half. 
Amplified products were quantified by nanodrop and the amplification quality as 
well as external contamination was assessed by 1.5% agarose gel electrophoresis of 5% 
of the total product. 
MDA Amplified genome quality control 
Dilutions (1:50) of MDA reaction products prior to cleanup were used for quality 
control assays. Every MDA reaction well, including negative and positive controls, was 
assayed for successful sorting of nuclei and to confirm absence of non-human and human 
DNA contamination with 2 methods: (a) Picogreen quantitation to measure yield and 
confirm success of controls (negative control reactions produce ~ ½ the yield of single 
nucleus reactions) and to estimate the percentage of wells that were successfully sorted; 
(b) multiplex PCR for 4 arbitrarily chosen loci from different chromosomes in the human 
genome was performed to exclude human DNA contamination in negative control 
reactions, to independently determine which wells contained a successfully sorted 
nucleus, and to exclude failed nuclei amplifying < 3  loci, likely indicating loss of 
significant parts of the genome during sorting or amplification. 96.8% of the wells into 
which a cell had successfully been deposited passed our 4-locus multiplex PCR quality 
control (3 or 4 of 4 loci amplified). Negative control wells and wells into which a nucleus 
failed to be sorted always produced both low yield by Picogreen and none of the 
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multiplex PCR bands. Multiplex primers were designed with PrimerStation (Yamada et al. 
2006). Multiplex PCR reactions contained 5 µM of each primer, 1x HotStarTaq reaction 
buffer (Qiagen), supplemental 1.5mM MgCl2, 0.2 µl HotStarTaq polymerase (Qiagen), 
0.4mM dNTP, 2µl of 1:50 MDA reaction product, in 20µl reaction volumes. Thermal 
cycler conditions were: 94°C 15 mins, (94°C 1min, 68°C 1 min decreasing by 1°C every 
cycle, 72°C 1min, for 13 cycles), (92°C 1min, 55°C 1 min, 72°C 1 min, for 27 cycles), 
72°C 10 min. 
To further confirm the absence of any human DNA contamination and confirm 
the identity of sorted nuclei, additional quality control on a subset of 8-16 wells, 
including negative and positive controls, from each sorted plate, was performed using 
Identifiler muliplex genotyping of 16-microsattelite (STR) loci with the AmpFlSTR 
Identifiler Plus kit (Applied Biosystems) on a 3130xl Genetic Analyzer (Applied 
Biosystems). 1:50 dilution plates described above were further diluted to ~0.1ng/ul based 
on Picogreen quantitation for use in Identifiler asays. Unamplified bulk DNA genotypes 
were used as a reference. Loci homozoygous in an individual were excluded from 
preferential amplification (PA), low-amplification (LA), and allelic dropout (AD) 
calculations since they cannot be used to estimate per-allele PA, LA, and AD. 14 
heterozygous loci were included in analysis for individuals 1465 and 4643 and 11 loci for 
4638 (i.e. 11-14 heterozygous loci assayed in 92 single neurons = 1,183 loci assayed for 
the 1-neuron group). Genotypes of all samples were checked for concordance to the bulk 
reference genotype of the individual. Preferential amplification was defined as loci where 
the area under the trace of one allele was > 3x the area under the trace of the other allele. 
Low amplification was defined as callable alleles with traces of area < 1,000 fluorescence 
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units. Identifiler fingerprinting was performed on a subset of nuclei from every plate of 
nuclei sorted in this work. 
Affymetrix SNP6 microarray genotyping (performed by Expression Analysis, Inc.) 
was performed on bulk DNA from cortex and lung tissue from individuals 1465, 4638 
and 4643, and 3 single cortical neurons from individual 1465. Genotypes were called 
using the Affymetrix Genotyping Console with the Birdseed-v2 algorithm with standard 
settings. Genotypes called with confidence scores ≤ 0.01 in both the sample and reference 
were compared were used for analysis. Genotype concordance was calculated as: (# of 
loci with AA calls in both samples + # of loci with AB calls in both samples + # of loci 
with BB calls in both samples) / (total # of loci). The fractional allelic dropout (dropout 
rate) was calculated as: (# of heterozygous AB loci in the reference with AA or BB calls 
in the sample) / (2 × # of heterozygous AB loci in the reference). The fraction of 
discordant alleles was calculated as [(2 × # of loci with BB calls in the sample + # of loci 
with AB calls in the sample, where the reference is AA) +  (2 × # of loci with AA calls in 
the sample + # of loci with AB calls in the sample, where the reference is BB)] / (2 × # of 
AA + 2 × # of BB loci in the reference). Depending upon the number of loci passing the 
confidence score threshold, for single-neuron versus bulk DNA comparisons between 
250,000-350,000 loci were included for single-neuron versus bulk DNA comparisons in 
each comparison for genotype concordance, 60,000-75,000 loci for allelic dropout, and 
200,000-300,000 loci for discordant allele calculations.  
Whole-genome sequencing libraries 
Whole-genome sequencing libraries for low-coverage sequencing were prepared 
from 1µg of DNA with the NEXTflex DNA sequencing kit (Bioo Scientific), and 
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barcoded for multiplexed sequencing at the Harvard Biopolymers Facility (Harvard 
Medical School) on a HiSeq 2000 sequencer (Illumina).  
Sequencing copy number analysis 
Raw reads were trimmed of low quality-score sequence and mapped to hg19 with 
Bowtie with -v 2 -m 1 --best --strata settings (Langmead et al. 2009). Chromosome copy 
numbers (Figure 3-7B) for each chromosome were calculated as the fraction of reads in 
each sample aligning to the chromosome, normalized to the median fraction of reads 
aligning to the chromosome across all 8 neurons. For autosomal chromosomes, these 
median-normalized relative chromosome copy numbers were multiplied by 2 to obtain 
absolute chromosome copy numbers, since both individuals were confirmed to have 
46XY and 47XY,+18 karyotypes (i.e. 2 copies of each autosome except for chr18 in the 
trisomy 18 individual). The normal 46XY karyotype of the normal individual (UMB1465) 
was confirmed by comparison of 1465-bulk DNA low-coverage sequencing samples to in 
silico simulated reads from a 46XY genome (data not shown). The trisomy 18 individual 
(UMB866) was confirmed to have a 47XY,+18 karyotype from clinical karyotyping data 
at the NICHD Brain and Tissue Bank. Higher-resolution copy number normalization was 
performed by creating 6,000 (~500kb) bins spanning the entire genome with boundaries 
defined so that each bin contains an equal number of reads, BRef, in the reference sample 
(Navin et al., 2011). BRef was normalized to the reference sample’s total read depth, TRef. 
The number of reads in the sample being analyzed in each bin, n, defined by the reference 
were then counted (BSample,n) and normalized to the sample’s total read depth, TSample. For 
any bin 1…n, the relative copy number was calculated as . 
Replicate libraries from the 100-neuron #1 sample were highly reproducible (R2 > 0.9 for 
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all pair-wise comparisons of copy-number profiles) and therefore pooled for analysis. 
Samples for analysis were always excluded from the pooled reference samples to avoid 
falsely lowering noise levels. The same was done for 100-neuron #2 replicate libraries. 
Copy number profiles were normalized to the global median of all bins with copy 
number >0.5 since dropout leads to an upward shift of the global midline (dropout bins 
lead to a proportional increase in reads in normal copy number bins in a given sample; 
global median normalization corrects this by shifting down all data points by an equal 
amount), and then log2 transformed relative copy numbers for analysis in R and 
visualization with scripts modified from the aCGH package (Fridlyand & Dimitrov, 
2010).  
For GC normalization, GC content of each genomic bin is calculated and plotted 
against the log2 transformed copy numbers ratio (Figure 3-9A). LOWESS smoothing 
was then applied to both the GC content and log2 ratio, followed by computing the 
normalization factor of each sample by logistic regression. GC-normalized log2 ratios 
show no bias to GC content of the respective genomic bins (Figure 3-9B). The algorithm 
was adapted from Baslan et al. (2012). 
L1 insertion validation 
Batch primer design 
A custom primer design pipeline for L1Hs insertion validation was programmed 
in Excel, Galaxy, and Perl. L1-IP peak coordinates were used to define 750bp flanks 5’ 
and 3’ of the L1-IP peak, in order to design primers that flank the candidate insertion. 
The L1-IP peak 5’ flank coordinates used to search for primers were 800 to 50bp 
upstream of the 3’ end of the peak, and the 3’ flank coordinates used were 400 to 1150bp 
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downstream of the peak. For peaks matching KR insertions, the 3’ flank coordinates were 
the 750bp upstream of the KR insertion. These coordinates were used to extract genomic 
sequences both from an unmasked hg19 reference and an hg19 reference masked for non-
unique 20bp sequences using the Duke Uniqueness track available in the UCSC genome 
browser. Both sets of sequences were used in parallel to search for high quality PCR 
primers in each flank in Primer3, with the following settings: target product size range: 
301-850bp with preference for shorter amplicons, minimum primer size of 20bp, and a 
check for human repeat mispriming (remaining parameters are the default settings in the 
web version of Primer3). The batch primer design scripts then perform additional quality 
control on Primer3 primer results by checking the number of hits of each primer in the 
genome and the number of predicted PCR products using the Blat and in silico PCR 
functions of the UCSC genome browser. Primers with 1 genome hit and 1 predicted 
product were chosen from the non-uniqueness masked primer design results. Next, 
primers for peaks without primer pairs matching these criteria were chosen from the 
uniqueness-masked primer design results, again requiring at most 1 genomic match for 
the primers and predicted product. Primers for peaks without such primer pairs were then 
chosen allowing the L1-IP peak 3’ flank primer to have 2 genomic hits. Primers for peaks 
still remaining without adequate primer pairs were manually designed with the aid of the 
Duke uniqueness track and Primer3. All primers were purchased from IDT. 
3’ junction PCR and full-length (FL) PCR validations 
Two types of PCR were used for L1Hs insertion validation and characterization: 1) 
3’ junction PCR (3’PCR) with one primer specific to L1HS (L1Hs-AC-22) and the 5’ 
peak flank primer (upstream to the peak), used to verify the presence of the predicted 
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insertion; and 2) long-range full-length PCR (FL-PCR) with the 5’ and 3’ peak flank 
primers to clone the entire length of candidate insertions and also to determine the 
zygosity (homozygous vs. heterozygous). All PCR products were run on 1% agarose gels 
and images were analyzed by ImageQuant TL software (GE Healthcare) to quantify the 
product sizes, relative intensities and absolute peak heights of the bands in an unbiased 
manner. 
3’PCR: Positive 3’PCR reactions yield a single PCR amplicon within 150bp size 
of the predicted size. The predicted size was calculated as the distance from the 5’ flank 
primer to the 3’ end of the L1-IP peak plus 114bp, which is the distance of the AC primer 
location to the end of the L1Hs insertion, plus 50bp which is the approximate expected 
polyA tail length for recent polymorphic and disease-causing insertions (Beck et al. 2011; 
Hancks & Kazazian 2012). Peak coordinates do not necessarily precisely border the 
insertion in situations where seed sequences are not present adjacent to the insertion or 
low mappability prevents read mapping adjacent to the insertion, which leads to only 
approximate predicted sizes. The difference between observed to predicted band sizes 
was -1 ± 47 bp (SD) for 71 out of 76 insertions that validated in a PCR sensitivity screen 
(see below), supporting our ability to predict amplicon size within 150bp. Negative 
reactions yield no PCR product or in rare cases a band outside of the predicted size range. 
FL-PCR: For heterozygous insertions genotyped by FL-PCR, two products are 
expected: a smaller product within 150bp of the predicted size without an L1Hs insertion, 
and a product ranging up to 6kb larger than the smaller product, depending on the size of 
the L1Hs insertion. Some candidates validated by 3’PCR may still yield only one band in 
FL-PCR at the expected no-insertion size range, since even long-range optimized FL-
 
	  
114	  
PCR reactions can be biased toward smaller products. In this case, we conclude that the 
candidate insertion is heterozygous based on the presence of an amplicon corresponding 
to the absence of an insertion and 3’PCR validation of the presence of an insertion. 
Previously published PCR protocols for L1Hs validation (Ewing and Kazazian, 
2010; Iskow et al., 2010; Stewart et al., 2011) were adapted and optimized to maximize 
sensitivity and specificity for both unamplified bulk and MDA-amplified single-cell 
DNA: 
3'PCR master mix Amount 3’PCR program 
5X GoTaq flexi buffer 4ul Steps Temperature Duration Cycles 
MgCl2 (25uM) 1.2ul 1 95 5min  
dNTP (10uM) 0.4ul 2 95 30sec  
GoTaq Hot Start 
polymerase (Promega) 
0.2ul 3 60 30sec  
AC-22 primer 0.8uM 4 72 1min  
Primer 5'  0.8uM 5   35X 
DNA template  5ng 6 72 5min  
Total reaction volume 20ul 7 4 hold   
FL-PCR master mix Amount FL-PCR program 
10X LA Taq buffer 2ul Steps Temperature Duration Cycles 
dNTP 3.2ul 1 94 90sec  
LA Taq (Takara Bio) 0.2ul 2 94 20sec  
Primer 5'  0.5uM 3 61 20sec  
Primer 3'  0.5uM 4 68 8:30min  
DNA template  10ng 5   32X 
Total reaction volume 20ul 6 68 10min  
  7 4 hold   
 
PCR sensitivity and specificity calculations 
The sensitivity and specificity of the 3’PCR validation method was assessed by 
performing validation on 64 high-confidence known germline insertions found by L1-IP 
in bulk tissues (33 KR and 31 KNR). In a separate experiment, 3’PCR validation was 
performed on 12 high-confidence unknown (UNK) germline candidate insertions found 
Table 3-1. PCR protocols of 3’PCR and FL-PCR. 
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by L1-IP in bulk tissues. Among these 76 insertions (64 known and 12 unknown), 31 
were present in all 3 individuals in this study and 45 were absent from at least 1 of the 3 
individuals (polymorphic).  
Sensitivity: The sensitivity of the 3’PCR was 92% (70/76) for unamplified bulk 
DNA, 92% (70/76) for MDA-amplified unsorted (50 x 103 cells), and 93% (71/76) for 
MDA-amplified single-cell (one sample of each type assayed), demonstrating consistent 
sensitivity of 3’PCR for both unamplified and MDA-amplified DNA (Figure 3-13B). 2/6 
of the insertions that failed validation did not have any visible PCR product, and 3/6 had 
product of the wrong size. The PCR sensitivities for the KR, KNR, and UNK insertions 
were 91% (30/33), 94% (29/31), and 92% (11/12), respectively, in both unamplified bulk 
DNA and unsorted-50k-nuclei amplified DNA, and 91% (30/33), 97% (30/31), and 92% 
(11/12), respectively, in 1-neuron amplified DNA. For candidates that failed the initial 
3’PCR validation, up to 3 additional 5’ peak flank primers were tested to differentiate 
PCR failure from false insertion predictions of the L1-IP pipeline. The PCR sensitivity 
after an additional second set of primers increased to 97%, 97% and 96% in bulk DNA, 
unsorted nuclei and 1-cell, respectively. After testing failed candidates on up to four sets 
of primers, the final sensitivities were 100% for bulk DNA, unsorted-nuclei and 1-cell 
samples, confirming that the initial loss of sensitivity was due to faulty primers. 
Specificity: The specificity of the 3’PCR method for loci without predicted 
insertions was also determined by assaying for polymorphic L1Hs loci in individuals 
predicted not to have an insertion by L1-IP. These loci should not yield a band of the 
predicted size. The 45 polymorphic germline insertions were assayed in the individuals 
predicted by L1-IP to not have the insertions. The experiment was performed on one 
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sample each of bulk DNA, amplified unsorted-nuclei and single cell, from each of the 
individuals without the insertion. No false positive validations were observed in bulk 
DNA, unamplified-nuclei, and 1-cell samples (63 reactions each). 187/189 of the 
reactions had no band. 2/189 had a band >1kb larger than the predicted size in bulk and 
1-cell samples of one individual, and failed validation for this reason. The specificity of 
the 3’PCR was therefore 100%. 
L1Hs 3’PCR and FL-PCR single cell allelic and locus dropout rates 
3’PCR sensitivity for one single-cell in the above experiment was the same as 
bulk and unsorted-nuclei DNA. However, the above experiment was based on only one 
single-cell and 46% of assayed insertions whose zygosity could be determined by FL-
PCR were homozygous, such that this overall rate does not reflect the true AD and LD 
rates. Therefore, a more comprehensive assessment of AD and LD was carried out by 
3’PCR genotyping of 3 homozygous (for LD estimation) and 3 heterozygous (for AD 
estimation) insertions in each of 83 single-neurons from individual 1465. Low 
amplification in 3’PCR was defined as callable alleles with peak height < 10,000 
arbitrary fluorescence units. Peaks with height < 5,000 units were considered as allelic 
dropout as these are barely above background noise. 
TOPO-TA cloning and Sanger sequencing 
PCR products were sequenced either by direct Sanger sequencing of PCR 
products, or by TOPO-TA cloning (Life Tech.) of PCR fragments for subsequent Sanger 
sequencing. All Sanger sequencing was performed by Genewiz. Sequence traces were 
analyzed and assembled by Geneious.  
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Chapter 4: Chromosomal Copy Number Analysis of Single Neurons 
from Normal and Hemimegalencephalic Brains  
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Retrotransposition and Somatic Mutation in the Human Brain”, published in Cell, October 26, 2012; 
151(3):483-496. The text and figures were modified to fit the format of this dissertation. Xuyu Cai led all 
the analysis on single cell copy number with assistance from Gilad Evrony, Princess Elhosary, Ben Hills 
and Bhaven Mehta. Ann Poduri performed the initial copy number screening on HMG brains. Gilad 
Evrony and Ben Hills performed the qPCR experiments on HMG-1 brain.
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Summary 
This chapter summaries our efforts at copy number analysis of single-cell amplified 
genomes, both at the chromosomal level and down to 2Mb segmental CNVs. A quality control 
metric was developed to assess sample quality and amplification linearity of single-cell whole-
genome amplified samples. Two currently available methods for single-cell whole-genome 
amplification—including multiple displacement amplification (MDA) and GenomePlex Whole-
Genome Amplification 4 (WGA4)—are compared at various aspects for their applications to 
copy number analysis. Single cortical neurons from 3 normal individuals, 1 trisomy 18 fetus and 
1 hemimegalencephaly brain (HMG-1) are analyzed for somatic aneuploidy and segmental 
CNVs. We find that the majority of single cortical neurons analyzed, either by MDA or by 
WGA4, are euploid at the level of entire chromosomes, and even chromosome arms.  We use 
single cell analysis to accurately determine the precise chromosome anomaly associated with 
HMG, defining tetrasomy of chromosome 1q in a patient with HMG, rather than the trisomy that 
had been predicted based on analysis of bulk tissue.  We also find that few (<5%) cortical 
neurons from normal brain are grossly aneuploid at the level of chromosomes. 
 
Introduction 
In the previous chapter we have shown that single-cell whole-genome amplification by 
MDA successfully recovers ~90% of the genome, making it potentially amendable for studies of 
multiple types of somatic mutations, such as single-nucleotide variations (SNV), microsatellite 
repeats up to a few hundred basepairs, as well as L1 retrotransposons up to 6kb. Additional study 
has also demonstrated the successful use of single-cell MDA to study meiotic recombination in 
human sperm (Wang et al. 2012). However, copy number analysis on MDA amplified single 
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cells is known to be challenging given the inherent amplification noise and false positive 
dropouts introduced by MDA. Several array-based copy number studies of single cells amplified 
by MDA demonstrated the feasibility of applying single-cell MDA to copy number analysis, but 
also revealed significant challenges with signal normalization and false positive differentiation of 
these amplified samples (Vanneste et al. 2009; Cheng et al. 2011). We propose that next-
generation sequencing-based approaches will improve the performance of copy number analysis 
on MDA amplified single cells as it provides a wider dynamic range for signal detection, as well 
as more flexibility for data manipulation. In addition, it provides a more cost-effective way to 
analyze a large number of samples simultaneously.  
Technical Challenges 
Copy number analysis relies on the change of signal intensity from the genomic regions 
with altered copy numbers. Such signal intensities are measured by the hybridization signal at 
each probe through array-based methods and by the number of read counts of each specified 
genomic segment (named genomic “bins” or “windows”) through sequencing-based methods. 
Regardless of the methods, the key for successful single-cell copy number analysis is to have the 
amplified genome faithfully reflect the initial copy number states of the single-cell genome. This 
is defined as the amplification linearity or amplification uniformity. Non-linear amplification 
often occurs when amplifying from small copies of initial material, as any selective amplification 
in the initial rounds will become prominent copy number fluctuations in the end-product 
independent from the initial copy number states. Non-linear amplification leads to several 
technical artifacts, including 1) systematic amplification bias, 2) stochastic amplification noise 
and 3) false-positive dropouts. Systematic amplification biases give rise to regions that are 
consistently over or under-amplified specific to the amplification methods. One prominent factor 
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affecting systematic biases is the GC content, which can be corrected for by building-in GC-
normalization into the analysis pipeline. Additional systematic biases include secondary and 
tertiary structures of the genome, repetitive regions and perhaps nuclear compartmentation. 
Stochastic amplification noise is caused by regional over- or under-amplification, resulting in 
random fluctuation in copy numbers of each genomic bin around its true CNV state. Since 
stochastic amplification noise is expected to happen randomly, no normalization can be applied. 
However, assuming its randomness, the average of several consecutive data points should reflect 
the true CNV state of the region, as long as the size of a true CNV is significantly larger than the 
size of genomic region represented by each bin. A common computational tool to correct for 
stochastic noise is copy number segmentation, which computationally determines genomic 
regions with altered copy number states supported by multiple bins (Olshen et al. 2004). One 
advantage of sequencing-based methods over array-based methods is that not only the number of 
data points supporting each CNV can be changed; the number of genomic bins determined by the 
size of each bin is also able to be manipulated. Stochastic noise can be caused by amplification 
itself, as well as subsequent sequencing analysis and data manipulation; therefore, it is important 
to keep track of the two variables by comparing amplified and unamplified samples in parallel 
with the same downstream analyses. It is conceivable that the amplification noise directly 
correlates with the sensitivity, specificity and resolution of copy number calls, and thereby needs 
to be closely monitored throughout the analyses. Lastly, false dropouts can happen randomly 
throughout the amplified genome at various sizes. In general, single copy dropouts are more 
common than two-copy dropouts, and smaller sized dropouts are more common than larger sized 
dropouts. False dropouts are particularly harmful for single-cell copy number analysis as they are 
mixed with true deletions and are the major source of false positive errors. Therefore, assuming 
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each of the single cells analyzed contains a comparable number of true somatic deletions, the 
dropout statistics can be monitored and used to exclude poor quality samples flagged by a 
significantly increased number of dropouts. Taken together, the three above-mentioned factors, 
systematic amplification bias, stochastic amplification noise and false positive dropouts, need to 
be monitored and compared throughout the copy number analyses for the assessment of 
amplification methods and sample qualities. 
Alternative Amplification Methods for Single-Cell Copy Number Analysis 
An alternative method to MDA for single-cell whole-genome amplification is a PCR-
based method called GenomePlex WGA4 licensed by Sigma (See details in Chapter 3 Single cell 
whole-genome amplification). Several studies have successfully combined this method with 
next-generation sequencing to study CNVs in cancer single cells, as well as single cells isolated 
from in vitro human blastomeres at preimplantation genetic diagnosis (PGD) (Navin et al. 2011; 
Yin et al. 2013; C. Zhang et al. 2013). Although there has been no direct comparison prior to our 
study, WGA4 has been known to be the better method for copy number analysis with resolution 
potentially down to ~500kb (Navin et al. 2011; Baslan et al. 2012); however, its performance on 
non-cancerous postmortem tissue has yet to be addressed. The major drawback of the WGA4 
method is its low genome coverage (<10%), which prevents the analysis of other mutational 
types from the same amplified samples. This is the major motivation for us to explore the 
possibility of using MDA for large-scale copy number analysis, such as aneuploidy. Additionally, 
a newer method named multiple annealing and looping-based amplification cycles (MALBAC) 
was developed recently (Zong et al. 2012), after the completion of our current study. The 
MALBAC method claims to have superior performance on copy number analysis over MDA, as 
well as better genome coverage than WGA4. Therefore, it could potentially be used as an all-in-
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one method for single-cell somatic mutation detections. However, based on our data reanalysis, 
huge sample-to-sample variability was observed from single cells amplified by MALBAC, 
suggesting that further independent evaluation of the method may be required to assess its 
performance. 
Detection of Somatic Aneuploidy and CNVs from Normal Tissues 
Somatic aneuploidy and CNVs are most widely studied in the setting of cancers, via 
either traditional SNP-array from bulk samples or sequencing-based single-cell analysis 
(Beroukhim et al. 2010; Navin et al. 2011; Jacobs et al. 2012; Laurie et al. 2012). Bulk analysis 
allows for the characterization of the prevalence of different types of copy number alternations, 
such as segmental CNVs and chromosomal arm-level copy number alternations; previous bulk 
analyses have shown that segmental CNVs are often biased towards smaller sizes with a median 
size of 1.8Mb, whereas chromosomal arm-level CNVs are 30-fold more frequent than segmental 
CNVs at the matched size (Beroukhim et al. 2010). On the other hand, single-cell copy number 
analysis of tumor samples with high grade CNVs revealed multiple clonal populations with 
distinct copy number profiles, allowing for the tracking of tumor cell lineages (Navin et al. 2011). 
In contrast to the high prevalence of somatic CNVs affecting approximately ~30% of the genome 
in cancerous cells (Beroukhim et al. 2010), large CNVs are must less well-tolerated by normal 
cells. A recent study of tissue-specific somatic CNVs from normal individuals has revealed that 
the majority of events are below 50kb in size and show an average frequency between 2-6 events 
per tissue, accounting for only a negligible fraction of the genome (O’Huallachain et al. 2012; 
O’Huallachain et al. 2013). In addition, somatic aneuploidy at the chromosomal arm-level was 
not seen. Larger somatic CNVs (50kb to whole chromosome arm) can be detected from normal 
individuals at low mosaic states no greater than 1% on average; and the frequency increases with 
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age from 0.23% under 50 years to 1.91% between 75 and 79 years (Jacobs et al. 2012; Laurie et 
al. 2012). Compared to the low prevalence of somatic CNVs in terminally differentiated tissues, 
chromosomal abnormality seems to be much more common during early embryonic 
development. Large unbalanced chromosomal rearrangements were detected at frequency 
ranging from 30-80% of embryos at the preimplantation blastomere stage by a number of single-
cell copy number studies (Vanneste et al. 2009; van Echten-Arends et al. 2011; Yin et al. 2013). 
Such a high frequency suggests that early embryonic cell divisions are particularly error-prone 
with a high tendency towards chromosome missegregation and rearrangement; however, most of 
the abnormal cells seems to be under negative selection during further embryonic development, 
resulting in a much lower frequency of chromosomal abnormalities in adults. 
Somatic aneuploidy has been proposed as a mechanism in generating genetic diversity 
among post-mitotic neurons (See details in Chapter 1 Somatic variants in normal brains). 
However, based on our knowledge from studies on other tissues, we expect a rather low rate of 
aneuploid cells developing into neurons due to their expected proliferative disadvantages, unless 
there is an acquired mechanism to generate aneuploidies and/or unbalanced chromosomal 
rearrangments only at the terminal differentiation of neurons. Current evidence about somatic 
neuronal aneuploidies is solely based on interphase FISH probing a single or small number of 
chromosomes. Estimates of aneuploidy frequencies from different studies are also highly 
variable, ranging from 1.3%-40%, and rates seem to increase with age (Faggioli et al. 2011). 
Interphase FISH suffers from high false positive rates due to non-specific priming of the probes 
and offers an incomplete picture of the copy number state of the entire genome; therefore, more 
rigorious single-cell genome-wide copy number profiling would be necessary to assess previous 
observations and to potentially explaining experimental discrepencies. 
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Results 
Amplification linearity of single cell genomes 
 Although we have shown in Chapter 3 that MDA reliably amplifies single cell genome to 
a coverage ~90%, and is able to detect aneuploid single neurons with trisomy 18 (Figure 3-7), 
the stochastic amplification noise spanning + 1 copy number significantly increases the false 
positive rate and prevents us from studying sub-chromosomal segmental CNVs with this method 
(Figure 3-8A, C). We therefore explored an alternative single-cell whole-genome amplification 
method, GenomePlex WGA4, which was shown to amplify the single-cell genome more linearly 
albeit at significantly lower coverage (<10%) (Navin et al. 2011). To be able to compare the two 
methods directly, we developed a QC metric adapted from Affymetrix MAPD (Median Absolute 
Pairwise Difference) algorithm to measure the stochastic amplification noise of the two methods. 
MAPD measures the absolute differences between the copy number ratios of each adjacent bins, 
and then takes the median. This algorithm has been widely used as a quality assessment of SNP 
Array 6.0 copy number data, and a MAPD score >0.4 typically associates with poor quality copy 
number calls and high false positive rates (Affymetrix, Inc. 2008). We first measured the MAPD 
scores of 4 single-cell MDA samples, compared with 1 100-cell MDA sample together with two 
bulk unamplified samples from the same individual at different read depths to determine the 
effect of sequencing read depth on copy number data quality (Figure 4-1A). We found that 
MDA amplified samples give significantly higher MAPD scores compared to unamplified bulk 
samples, reflecting the stochastic amplification noise associated with MDA. A MDA amplified 
100-cell sample give a lower MAPD score than single cell samples, suggesting that the 
amplification of the single genome introduces another layer of amplification noise on top of 
MDA. Notably, the sequencing read depth, measured by number of reads per genomic bin, has 
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little effect on MAPD scores of MDA samples. In contrast, increased read depth helped to reduce 
the MAPD scores of bulk samples (Figure 4-1A). These data suggest that the copy number noise 
in MDA amplified samples is due to the genome amplification, instead of insufficient read depth 
for copy number profiling. The most cost effective read depth (~750 reads/bin, 4.5 
millions/sample, 0.07X genome coverage) was then chosen for following experiments. At this 
read depth, we are able to safely multiplex 32 single cell samples into 1 Illumina HiSeq lane for 
copy number analysis at ~500kb resolution.  
We then compared the amplification noise of GenomePlex WGA4 amplified single cells 
to MDA amplified single cells. Since we suspect that the tissue type and quality of the original 
sample may affect genome amplification quality, the comparison was limited to single cells 
derived from the same tissue source (UMB4643-cortex). Indeed, the MAPD scores of WGA4 
amplified samples were consistently lower than MDA amplified samples (Figure 4-1B). This 
result is consistent with the observed tighter distribution of copy number ratios by WGA4 
compared to MDA (Figure 4-1C). Therefore, we concluded that MAPD score is a reliable 
measurement of data quality of single-cell genome amplified samples, and that WGA4 is a better 
method for single-cell copy number profiling. We further compared the data quality of the two 
methods at different genomic bin sizes, including ~500kb, ~150kb and ~60kb, with normalized 
read counts for each bin. Since we didn’t sequence our WGA4 samples to high-enough read 
depth for this analysis, we used data from Navin et al. (2011) on 4 wildtype control single cells 
amplified by WGA4 to compare with our 4 wildtype cortical neurons amplified by MDA. We 
showed that with decreased bin sizes, MAPD scores increased for both amplification methods, 
suggesting that both methods introduce greater amplification noise at smaller local regions 
(Figure 4-2A). This is expected because larger bins contain many independently amplified 
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Figure 4-1. Comparison of amplification linearity between MDA and WGA4 by MAPD at ~500kb bin 
size. 
(A) MAPD score of 1-cell and 100-cell MDA amplified samples are various read depth compared to bulk 
samples. Increase of read depth (total number of reads per bin) does not bring down the MAPD score of MDA 
samples (N=4 for MDA single cells “MDA_1”; N=1 for MDA 100-cell “MDA_100”; N=2 for bulk; error bar = 
+ SD).  X-axis represents the number of reads per bin and the Y-axis represents the MAPD score. 
(B) Histogram of MAPD distribution of single neurons from 4643 cortex, amplified by either MDA or WGA4. 
Bulk DNA from 1465 cortex is used to define the baseline of MAPD (N=21 for WGA4; N=32 for MDA; N=2 
for bulk). WGA4 amplified samples consistently have smaller MAPD, with average at 0.184+0.026, compared 
to MDA amplified samples, with average at 0.340+0.047. There are two outlier cells from MDA amplified 
samples with high MAPD score. Average reads per bin is 734+14 for bulk, 735+118 for MDA and 313+40 for 
WGA4 samples (Error = + SD). The red dash lines denote the mean MAPD scores of each method. 
(C) Copy number profiling at 6,000 bins  (~500kb bin size) of representative samples from Figure 4-1B. Bulk, 
MDA amplified single neuron and WGA4 amplified single neuron are shown respectively from left to right. 
MDA sample has the highest noise spanning +/- 1 copy number; copy number distribution of WGA4 samples is 
tighter compared to MDA, spanning +/- ~0.5 copy. Y-axis denotes the copy number ratio (CNR) respect to 
euploid genome. Therefore copy number ratio 1 stands for copy number 2, 0.5 stands for copy number 1 and 1.5 
stands for copy number 3. 
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fragments; therefore, over or under amplification at a small region within a large genomic bin is 
unlikely to change its overall copy number; whereas these stochastic nonlinearly amplified 
fragments are more likely to influence the copy number of smaller genomic bins which includes 
fewer independent fragments. Notably, the MAPD score of bulk samples do not change with bin 
sizes, confirming that the increase of MAPD in amplified samples is not due to binning artifacts. 
Furthermore, although MDA samples always give higher MAPD score and higher amplification 
noise, this defect can be corrected by increasing genomic bin size at the cost of copy number 
resolution. The MAPD score of MDA samples at ~500kb bin size is similar to WGA4 samples at 
~60kb bin size (0.33+0.02 and 0.33+0.01, respectively; error = +SD); therefore, the choice of 
~500kb bin size for copy number profiling on MDA amplified samples is adequate.  With this 
approach, we should reliably detect copy number changes at megabase scale from MDA 
amplified single cells, evident by the successful detection of trisomy 18 from single neurons in 
our earlier experiments (Figure 3-7B). Since we used WGA4 data from others (Navin et al., 
2011) for the comparisons in Figure 4-2A, we also compared the data quality of our WGA4 
samples from cortical neurons and cultured lymphocytes with cancer and normal samples from 
Navin et al. (2011) to show that the MAPD scores from all 4 tissue types are comparable, with 
slightly higher average and wider distribution in our samples (Figure 4-2B). These data also 
demonstrate that MAPD score only measures stochastic data noise, but is not altered by 
biological CNV states since the cancer samples with high copy number changes have the same 
average MAPD score with its normal control (compare “cancer” and “control”). Therefore, 
MAPD is a superior quantitative measurement of the overall linearity of genome amplification 
compared to the measurement of “uniformity” on the amplified genomes used in another study 
(Zong et al. 2012). We also noticed that three outlier cells from the lymphocytes samples, 
	   130	  
presumably due to poor amplification, can be readily differentiated by their increased MAPD; 
therefore, in addition to measuring data quality across different methods, MAPD can also used as 
QC metrics to exclude poor quality samples from copy number analysis (discussed in the 
following section). 
The other challenge in copy number profiling on single-cell amplified genomes is locus 
dropouts, in which regions fail to amplify or amplify poorly in a stochastic manner. These 
regions, if large enough, will be falsely recognized as genomic deletions of either one or both 
copies. We therefore quantified the fraction of the genome that “dropped out” by 1 and 2 copies 
at ~500kb bin size. For MDA-amplified single neurons from 4643 cortex, a median of 1.23% of 
the genome is dropped out by 1 copy and 0.23% of the genome is dropped out by 2 copies 
(Figure 4-3). For WGA4-amplified single neurons, a median of 0.32% of the genome is dropped 
out by 1 copy and 0% of the genome is dropped out by 2 copies (Figure 4-3). In contrast, zero 
bins were dropped out as either 1 or 2 copies from bulk samples. The median is used to quantify 
dropout rates because there are outlier cells in both sample sets that skew the mean. Since both 
sample sets were derived from the same tissue with the same germline genotype, we can 
conclude that the increased dropout rate seen in MDA samples compared to WGA4 is due to 
MDA amplification. However, the 0.32% of the genome dropped out by 1 copy in WGA4 
samples consists of a mixture of true somatic heterozygous deletions and artifactual locus 
dropout due to WGA4 amplification. On the other hand, the 0% dropout by 2 copies from 
WGA4 samples holds great promise on detecting somatic homozygous deletions at megabase 
scale. In addition, we found outlier cells with large number of dropouts from both MDA and 
WGA4 amplified samples (Figure 4-3); the biological significance of these cells will be further 
discussed in the following sections.  
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Figure 4-2. Effects of bin sizes on MAPD scores of both methods at normalized read depth. 
(A) Average MAPD score of bulk, MDA amplified and WGA4 amplified single cell samples are 
plotted against various bin sizes, including 500kb (6,000 bins in total), 150kb (20,000 bins in total) and 
60kb (50,000 bins in total). MAPD scores of both MDA and WGA4 amplified samples increase as bin 
size get smaller, whereas the MAPD score of bulk sample remains unchanged with changing bin sizes, 
suggesting that both amplifications introduce more prominent noise at smaller local regions (N=2 for 
bulk; N=4 for MDA single cells “MDA_1”; N=1 for MDA 100-cell “MDA_100”; N=4 for WGA4 
single cells “WGA4_1”; error bar = + SD).  
(B) Histogram of MAPD distribution of single cells from different tissue types amplified by WGA4. 7 
breast cancer single cells (“cancer”) and 4 normal control cells for the cancer study (“control”) were 
from Navin. et al. (2011). 24 single neurons from 4643 cortex (“Brain”) and 24 cultured wildype 
lymphocytes (“Lymph”) are from our study. MAPD scores are generally comparable among all 4 
tissue types, with slightly wider distribution of lymphocyte samples. Average MAPD score of the 4 
tissue types are 0.184+0.026, 0.152+0.006, 0.147+0.026 and 0.212+0.053 respectively from top to 
bottom (error = +SD). The average read depth per bin of the 4 tissue types are 313+40, 275+34, 
451+176 and 258+30 respectively from top to bottom (error = +SD). 
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In conclusion, we developed a QC metrics to assess the single-cell genome amplification 
linearity of two independent methods and concluded that both methods are suitable for copy 
number analysis of single cells at the chromosomal level whereas only WGA4 should be used for 
segmental CNVs analysis. The QC metric based on MAPD score reliably measures the stochastic 
noise of copy number profiles and is not altered by biological CNVs states of the sample. 
Therefore, it can be further applied to all single cell samples as a quality control assessment to 
exclude poor quality cells from further analysis to minimize the effect of amplification bias on 
the estimation of somatic CNV prevalence.  
Chromosomal copy number analysis of single neurons from normal human brains 
Following out analysis of CNV quality, both MDA and WGA4 amplified samples were 
used to study the prevalence of somatic aneuploidy in wildtype cortical neurons. A total of 139 
single cells were analyzed, including 97 single cortical neurons from 3 normal adults 
(UMB1465, UMB4638 and UMB 4643), 18 single neurons from a trisomy 18 fetus (UMB866) 
and 24 cultured single lymphocytes derived from a normal adult GM21781 (Table 4-1). With a 
QC threshold of MAPD <= 0.45, 82 single neurons from normal individuals, 9 single neurons 
from the trisomy 18 individual and 24 single, wildtype lymphocytes were included in the 
chromosomal copy number analysis. All WGA4 amplified samples (26 single neurons and 24 
single lymphocytes) passed the QC threshold; however, the sample qualities of MDA amplified 
samples are highly variable, depending on the individual (Figure 4-4A). We suspect that the 
quality of the tissue source could be the cause of the variation; this highlights the importance of 
applying a QC metric for all amplified single cell samples prior to any copy number analysis. In 
addition, 4 samples that failed the initial multiplex PCR screen were sequenced and included in 
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Figure 4-3. Locus dropout of MDA and WGA4 amplified single cells at ~500kb bin size. 
 (A) Histogram of number of bins with Log2CNR < -2 of single neurons from 4643 cortex, amplified 
by either MDA (blue) or WGA4 (red) (N=21 for WGA4; N=32 for MDA). The median 2 copy dropout 
of WGA4 samples are 0 out of 6000 bins, with 1 outlier sample of >500 bins dropped out. The median 
2 copy dropout of MDA samples are 13.5 out of 6000 bins, contributing to ~0.23% of the genome. 
(B) Histogram of number of bins with Log2CNR < -1 of single neurons from 4643 cortex, amplified 
by either MDA (blue) or WGA4 (red) (N=21 for WGA4; N=32 for MDA). The median 1 copy dropout 
of WGA4 samples are 19 out of 6000 bins, contributing to 0.32% of the genome, with 1 outlier sample 
of >800 bins dropped out. The median 1 copy dropout of MDA samples are 73.5 out of 6000 bins, 
contributing to ~1.23% of the genome. 
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          Table 4-1. Summary of all single cells analyzed for chromosomal copy numbers.  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Individual Karyotype Tissue type Cell type  Amplification 
method 
# of cells 
analyzed 
# of cells passed QC 
(MAPD <= 0.45) 
# of euploid 
cells 
# of aneuploid 
cells  
UMB1465 46XY Cortex Neuron MDA 7*  6 6 0 
UMB4638 46XX Cortex Neuron MDA 32 20 19 1 
UMB4643 46XX Cortex Neuron MDA 32 30 30 0 
UMB4643 46XX Cortex Neuron WGA4 26 26 24 2 
UMB866 47XY, 18 Cortex Neuron MDA 18 9 0 9** 
GM21781 46XY Cultured 
lymphocytes 
Lymphocyte WGA4 24 24 24 0 
    TOTAL 139 115 103 12 
* 4 of these single cells were sequenced at >30X coverage 
** trisomy 18 
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Figure 4-4. MAPD QC metric for MDA single-cell chromosomal copy number analysis. 
 (A) Histogram of the MAPD scores of MDA-amplified single cells from 4 different tissue sources. N-
18 for UMB866 cortex; N=7 for UMB 1465 cortex; N=32 for UMB 4638 cortex and N=32 for 
UMB4343 cortex. The red dash lines denote the mean MAPD score of each tissue sources. 
(B) Histogram of the MAPD scores of MDA-amplified single cells from all 4 individuals either passed 
(“P”, green) or failed (“F”, red) the initial multiplex PCR screen. N=86 for passed and N=3 for failed 
multiplex PCRs. All samples that failed the multiplex PCR appeared as poor quality outliers based on 
their MAPD scores. 
(C) Histogram of the MAPD scores of MDA-amplified single cells from all 3 normal individuals either 
called as “euploid” (green) or aneuploid (red) prior to QC filtering. N=71 in total; N=56 for “euploid” 
and N=15 for “aneuploid”. With a QC threshold of MAPD <= 0.45, 56 samples passed the threshold 
and 15 samples failed. Among the samples passed the threshold, 54/56 are “euploid” and 2/56 are 
“aneuploid”. Among the samples failed the threshold, 2/15 are “euploid” and 13/15 are “aneuploid.” 
The red dash line denotes the QC threshold at MAPD <= 0.45. 
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the analysis to confirm whether the multiplex PCR helps to distinguish poorly amplified samples. 
Indeed, all samples that failed the multiplex PCR appear as outliers with high MAPD scores 
(Figure 4-4B); however, multiplex PCR is not sufficient to filter out all poor-quality samples 
since a few samples that passed the multiplex PCR screen also appeared as outliers with high 
MAPD scores, further suggesting that additional QC is necessary for copy number analysis. We 
relaxed the QC threshold of MAPD from 0.4 to 0.45 to include more cells for the analysis with 
minimal loss of specificity.  
Among the 71 MDA amplified single neuron samples from normal individuals, 56 of 
them passed the QC threshold, and 2 out of the 56 neurons have aberrant chromosomal copy 
numbers (Figure 4-4C). On the other hand, 13/15 samples that failed the QC appeared to have 
noisy copy number profile with multiple chromosome gains and losses, confirming that the 
MAPD is a powerful tool on differentiating false positive copy number aberration caused by 
poor amplification. 9 out 18 trisomy 18 cells passed the QC, with an average copy number of 
3.01+0.17 at chromosome 18, demonstrating the high sensitivity of method on detecting copy 
number changes at the chromosomal level from single cells amplified by MDA (Table 4-1 and 
Figure 4-5B). The two cells with copy number aberrations are MDA_4638ctx_24 and 
MDA_4643ctx_14 (Figure 4-5C, D, respectively). MDA_4638ctx_24 has a grossly aberrant 
genome with copy numbers alternating between 0, 1 and 2 (Figure 4-5E). Multiple 
chromosomes (Chr2, Chr6, Chr11 and ChrX) or chromosome arms (Chr10q, Chr12q, Chr21p) 
have a discrete copy number 1, and additional chromosomes have copy numbers alternating 
between 0 and 1 (Chr3, Chr4p, Chr5, Chr17) (Figure 4-6). The other aberrant neuron, 
MDA_4643ctx_14 has a noisy copy number profile overall with a borderline MAPD score at 
0.44 and an intermediate copy number of chromosome X at 1.4 (Figure 4-5D).  The copy  
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Figure 4-5. Copy number profiles of MDA amplified single neurons at ~500kb bin size. 
 (A-D) Genome-wide copy number profiles with segmentation of 4 representative single neurons. (A) 
represents an euploid neuron; (B) represents a positive control neuron with copy number gain at Chr18;  
(C) represents a neuron with grossly aberrant genome and (D) represents the other neuron called as 
“aneuploid” with a intermediate copy number at ChrX (CNR=0.7, CN=1.4). X-axis represents all 6,000 
genomic bins arranger by their genomic positions by chromosomes. Log2 transformed Y-axis denotes the 
copy number ratio (CNR) respect to euploid genome.  
(E-F) Copy number density plot of the two “aneuploid” single neurons in Figure 4-5C-D, respectively, 
Neuron MDA_4638ctx_24 showed clear discrete copy numbers at CN=0, 1, 2; whereas neuron 
MDA_4643ctx_14 showed a major peak around CNR=1 and an small peak representing ChrX between 
CNR=0.5 and 1.0. X-axis represents the segmented mean copy number ratio (CNR). 
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 number ratio density plot showed a major peak around ratio 1.0 and a small peak at 0.7, 
consistent with the predicted copy number of chromosome X at 1.4 (Figure 4-5F). Based on the 
trisomy 18 samples, the standard deviation of altered copy number is 0.17; therefore, copy 
number 1.4 at chromosome X of a female cannot be considered as a full copy number loss, and 
so may be a technical artifact. 
24 single lymphocytes and 26 single neurons amplified by WGA4 were also analyzed for 
chromosomal copy number. All 50 samples passed the QC threshold of 0.45 although the 
distribution of MAPD score of the WGA4 samples showed 3 outlier samples from GM21781 
lymphocytes (Figure 4-2B). However, despite their significantly nosier copy number profiles 
with increased number of copy number changes at a sub-chromosomal scale (Compare Figure 4-
7B to Figure 4-7A), all 3 outlier samples are still called as euploid in the copy number analysis, 
further confirming that the MAPD score faithfully reflects the data quality and the QC threshold 
used in the chromosomal copy number analysis is adequate. On the other hand, it also suggests 
that for segmental CNV analysis, a more stringent QC threshold would be necessary. 2 out of 26 
neurons from 4643-cortex (WGA4_4643ctx_30 and WGA4_4643ctx_22) exhibit alternated copy 
numbers at multiple chromosomes (Figure 4-7C, D, respectively). WGA4_4643ctx_30 exhibits 
grossly imbalanced chromosomal number, with copy numbers alternating between 0, 1 and 2, 
similar to what has been observed for MDA_4638ctx_24 (Figure 4-7C, Figure 4-8C and Figure 
4-5C, E). Multiple chromosomes exhibited copy numbers ranging from 0 to 1 (Chr14, 15, 16 and 
ChrX) and additional chromosomes exhibited alternating copy numbers from 1 to 2 (Chr1, Chr7, 
Chr9, Chr11, Chr17, Chr19) (Figure 4-7C and Figure 4-8C).  WGA4_4643ctx_22 exhibited 4 
copy number states, with multiple chromosomes exhibiting copy number gains (Chr4, Chr7, 
Chr16, Chr7 and ChrX) and multiple chromosomes with alternating  
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Figure 4-7. Copy number profiles of WGA4 amplified single cells at ~500kb bin size. 
Genome-wide copy number profiles with segmentation of 4 representative single cells.  
(A) represents an euploid neuron with low MAPD score (MAPD=0.15);  
(B) represents a euploid single lymphocytes with a MAPD score appeared as an outlier among WGA4 
samples (MAPD=0.27);   
(C) represents a neuron with grossly aberrant genome and large homozygous deletions; and  
(D) represents the other neuron called with grossly aberrant genome and no homozygous deletions, but 
copy number gains at chromosomal level.  
X-axis represents all 6,000 genomic bins arranger by their genomic positions by chromosomes. Log2 
transformed Y-axis denotes the copy number ratio (CNR) respect to euploid genome.  
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Figure 4-8. Copy number ratio density plot of WGA4 amplified single cells at ~500kb bin size. 
Copy number ratio density plot of the four single cells presented in Figure 4-7, respectively.  
(A-B) Euploid single cells showed single peak at CNR=1 and additional peak at CNR=0.5 for male 
sample  (GM21781).  
(C-D) Neuron WGA4_4643ctx_30 showed clear discrete copy numbers at CN=0, 1, 2; and neuron 
WGA4_4643ctx_22 showed 4 overlapping peaks presumably representing copy numbers at CN=1, 2, 
3, 4.  
X-axis represents the segmented mean copy number ratio (CNR). 
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copy number between 1 and 2 (Figure 4-7D and Figure 4-8D). However, WGA4_4643ctx_22 
did not show loss of both copies of any chromosomes as observed in the other two aberrant cells.  
In conclusion, we analyzed 82 single cortical neurons from 3 normal individuals with a 
quality control threshold at MAPD <= 0.45. 79 out 82 neurons are euploid, accounting for 96.3% 
of the population (95% confidence interval: 89.8%-98.8%). We did not identify any aneuploid 
neuron with discrete copy number change of a single chromosome. This result puts an upper 
bound at 4.5% for the prevalence of aneuploid neurons with single chromosome gain or loss in 
normal individuals. Instead of detecting canonical aneuploid neurons as expected, we identified 3 
aberrant neurons with genome-wide copy number imbalances. This observation is unlikely to be 
a technical artifact specific to a certain genome amplification method since we identified similar 
aberrant cells from both MDA and WGA4 amplified samples. This observation is also not 
limited to a specific individual as we identified them from both individuals with more than 10 
single neurons analyzed. However, we cannot rule out other technical reasons that may lead to 
the observation of these cells. Further discussion on the possible causes of these aberrant cells is 
carried out in the Discussion section.  
Segmental CNVs of single neurons from normal human brains 
Segmental CNVs are defined as copy number gains and losses at sub-chromosomal scale. 
Although they can also be large in size, their molecular mechanism is distinct from aneuploidy. 
Large CNVs, up to a few megabases, are also one of the most common genetic causes of 
neurodevelopmental disorders (Sanders et al. 2011; F. Zhang et al. 2009). We performed 
genome-wide copy number profiling on the 24 euploid single neurons amplified by WGA4, to 
identify somatic CNV candidates down to 2 megabase in size. The four different CNV states 
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(CNV0, CNV1, CNV3 and CNV4) were analyzed separately across all the samples since the 
specificity and sensitivity of each CNV state is different.  
As discussed in the previous section, additional quality control assessments are applied to 
the WGA4 amplified samples for segmental CNV analysis. In addition to the amplification noise 
measured by MAPD, locus dropout introduced by nonlinear amplification can also lead to false 
positive CNV calls. Since all these single neurons are derived from the same tissue, we expect 
the CNV states of them to be similar, potentially with a low level of somatic variations. We 
measured the number of bins at ~500kb size that were dropped out by copy number 1 
(log2GCNR < -1) across all samples and found the median to be 26.5; however, a few samples 
exhibit as outliers with > 100 bins dropped out by copy number 1 (Figure 4-9A). We therefore 
conclude that such increase in dropout rate is unlikely to be physiological but more likely to be a 
technical artifact caused by the whole genome amplification. Samples with >100 apparent CNV 
1 were then excluded from further segmental CNV analysis. In fact, the 6 samples excluded have 
the 6 highest MAPD scores among all 24 samples, supporting the interpretation that the excluded 
samples have relatively poor quality compared to the rest, and again demonstrating the direct 
correlation between MAPD score and sample quality in multiple aspects (Figure 4-9B).  
 18 single cortical neurons that passed the dropout quality control were then included in 
the segmental CNV analysis, which identifies genomic segments with at least 5 consecutive 
genomic bins and a size larger than 2Mb. For copy number gains, 0 candidate were identified at 
CNV4, and 5 candidates were identified at CNV3 (Table 4-2, Appendix Table 4-1). Since 
mapping and binning artifacts can lead to false positive copy number gains, the candidates were 
then BLATed using UCSC genome browser. 3 out 5 candidates are BLATed to centromeres, 
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Figure 4-9. Locus dropout by copy number 1 of WGA4 amplified single neurons at ~500kb bin 
size. 
 (A) Histogram of number of bins with Log2CNR < -1 of euploid single neurons from 4643 cortex, 
amplified WGA4 (N=26). The median 1 copy dropout of WGA4 samples are 26.5 out of 6000 bins, 
with several outlier samples of >100 bins dropped out. Red dash line denotes the median MAPD score 
of all 24 samples. 
(B) Histogram of the MAPD scores of all 24 samples either passed the “CNV1” (red) and failed the 
“CNV1” with more than 100 bins dropped out (green). Red dash denotes the median MAPD scores at 
0.18. 
MAPD	  
A 
B 
Number	  of	  bins	  at	  CNV1	  
	  Sample_ID Metho
ds 
Bincount
.med 
log2MAP
D 
dropout
_-­‐1 
dropout
_-­‐2 
n.seg
ments 
dropout1
_filter 
CNV4 CNV3 CNV1 CNV0 
WGA4-­‐3_7 WGA4 179 0.25 144 3 251 >100 NA NA NA NA 
WGA4-­‐3_8 WGA4 180 0.25 147 13 262 >100 NA NA NA NA 
WGA4-­‐3_9 WGA4 194 0.25 282 20 310 >100 NA NA NA NA 
WGA4-­‐3_10 WGA4 155 0.26 106 12 162 >100 NA NA NA NA 
WGA4-­‐3_11 WGA4 113 0.30 105 8 105 >100 NA NA NA NA 
WGA4-­‐3_12 WGA4 355 0.18 9 0 30 <100 0 0 0 0 
WGA4-­‐3_13 WGA4 288 0.19 57 4 80 <100 0 0 5 0 
WGA4-­‐3_14 WGA4 322 0.19 26 0 55 <100 0 0 1 0 
WGA4-­‐3_15 WGA4 285 0.19 3 0 40 <100 0 0 0 0 
WGA4-­‐3_16 WGA4 309 0.16 6 0 36 <100 0 0 0 0 
WGA4-­‐3_17 WGA4 327 0.17 30 1 120 <100 0 0 6 0 
WGA4-­‐3_18 WGA4 405 0.22 62 2 93 <100 0 0 1 0 
WGA4-­‐3_19 WGA4 309 0.20 51 1 76 <100 0 0 2 0 
WGA4-­‐3_20 WGA4 365 0.19 19 0 80 <100 0 0 1 0 
WGA4-­‐3_21 WGA4 307 0.18 18 0 63 <100 0 0 3 0 
WGA4-­‐3_23 WGA4 302 0.18 7 0 45 <100 0 0 0 0 
WGA4-­‐3_24 WGA4 315 0.23 131 10 99 >100 NA NA NA NA 
WGA4-­‐3_25 WGA4 316 0.15 0 0 27 <100 0 0 0 0 
WGA4-­‐3_26 WGA4 344 0.15 5 0 50 <100 0 0 0 0 
WGA4-­‐3_27 WGA4 319 0.17 3 0 29 <100 0 0 0 0 
WGA4-­‐3_28 WGA4 280 0.22 59 0 125 <100 0 0 4 0 
WGA4-­‐3_29 WGA4 246 0.15 2 0 52 <100 0 0 0 0 
WGA4-­‐3_31 WGA4 328 0.16 27 0 206 <100 0 0 3 0 
WGA4-­‐3_32 WGA4 298 0.14 17 0 97 <100 0 0 1 0 
       Average 0 0	   1.5 0 
       Median 0 0 1 0 
Table 4-2. Summary of all single cells analyzed for chromosomal copy numbers.  
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suggesting mapping artifact. The remaining 2 candidates were further validated by data 
reanalysis at 50,000 bins to test for binning artifacts and both of them no longer showed as copy 
number gain with 50,000-bin reanalysis, suggesting binning artifact. Therefore, there are no 
candidate CNV identified for copy number gains >2Mb. For copy number losses, 0 candidates 
were identified at CNV0 (i.e., homozygous deletion), and a total of 31 candidates were identified 
at CNV1 for heterozygous deletion across all samples (Table 4-2). Similarly, all 31 candidates 
were validated by BLAT and reanalysis at 50,000 bins to check for mapping and binning 
artifacts, respectively. All candidates were BLATed to mappable regions making mapping 
artifacts unlikely. 4 out 31 candidates no longer showed copy number loss in reanalysis with 
50,000 bins. Among the remaining 27 candidates that were detected by both 60,000 and 50,000 
bins, 19 of them appeared in chromosomes with additional segments of copy number losses, 
although some of these segments did not pass the arbitrary 2Mb minimal size requirement 
(Figure 4-10A). These candidates may be false positive, reflecting poorly amplified 
chromosomes, but could alternatively represent a recently characterized biological condition 
named chromothripsis, which involves gross chromosomal rearrangements and multiple copy 
number changes within a single chromosome. The other 8 candidates are isolated heterozygous 
copy number losses present in chromosomes that are otherwise euploid (Figure 4-10B); these 
candidates are more likely to be real though amplification dropout of specific loci cannot be 
ruled out.  
From the previous study of somatic L1 insertion candidates, we learned that candidates 
that are shared by more than 1 cell are much more likely to be fully validated unless proven to be 
systematic artifact; one the other hand, all the false positive candidates are typically unique 
events. All 27 CNV candidates identified in this analysis are unique, suggesting that they are 
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Figure 4-10. Representative chromosomes of with segmental CNV candidates. 
(A) Chr4 from neuron WGA4_4643ctx_13. Multiple segmental copy number losses are observed within 
the same chromosome. 
(B) Chr4 from neuron WGA4_4643ctx_17. A single segmental copy number loss is observed within the 
same chromosome. 
X-axis represents the genome bins within each chromosome; Y-axis presents the copy number CN of 
each bin. Blue line denotes the segmented mean copy number and red line denotes the segmented copy 
number calls (in integers) of each chromosome. Calling confidence is generally higher when the blue 
approaches the red line.  
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either false positives or real somatic variants present at low percent mosaicism. Furthermore, we 
checked if any of the CNV candidates localize to one of the known de novo CNV “hot spots” 
from previous studies (Sanders et al. 2011) and we identified none. Collectively, our data 
showed that large somatic CNVs are not common at the single neuron level, with an average of 
1.5 and a median of 1 CNV per neuron. More importantly, all the CNVs candidates identified are 
exclusively in the CNV1 state, which is known to be the most prominent type of amplification 
artifact (Figure 4-3 and Figure 4-8). Therefore, we expect the above estimated rate to be an 
overestimation given the difficulty in differentiating true variants from amplification dropout.  
In general, copy number analysis of single cells at sub-chromosomal scale remains 
extremely challenging due to the technical limitations of amplification noise and locus dropout. 
Our analysis is unable to identify any convincing CNVs shared by multiple neurons or within the 
CNV “hotspot” regions previously identified down to 2Mb resolution from a total of 18 single 
neurons analyzed. This study sets an upper bound of large CNVs at copy number state 0, 3, and 4 
to be no more than 6.6% at 95% confidence (0 events identified from 18 samples at 3 different 
states, CI = 0-6.6%) from the 18 samples analyzed. We expect the confidance interval to narrow, 
leading to a lower statistical upper bound when more samples analyzed in the future. We are 
unable to precisely define the rate of somatic CNV1s due to the inability of separating bona fide 
events from false positives, highlighting the limitation of current single cell amplification 
methods.  
Chromosomal copy number analysis of single brain cells from hemimegalencephaly 
In addition to the somatic copy number variants in normal human brains, we also studied 
the role of a somatic CNV in hemimegalencephaly, a brain overgrowth syndrome that is 
previously described to be caused by brain-specific somatic mutations (Poduri et al. 2012; Lee et 
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al. 2012). Two hemimegalencephaly cases were previously identified to have non-integer copy 
number increase of chromosome 1q, suggesting mosaic copy number gains in some but not all 
the cells from the affected tissue (Figure 4-11A, B). For one of the two cases affected brain 
tissue remained available (HMG-1). Copy number evaluation of SNP data showed increased 
signal for the entire q arm of chromosome 1 in the brain sample (Figure 4-12A, B), with an 
estimated copy number of 2.41 (SD 0.12). No other chromosomes displayed abnormal copy 
number (Figure 4-12A). Quantitative PCR (qPCR) confirmed the 1q copy number gain with the 
calculated copy number being 2.68 (SD 0.16), 2.76 (SD 0.20), and 2.73 (SD 0.13) at 1q21.3, 
1q31.1, and 1q42.2, respectively (Figure 4-12C). High-resolution karyotype and qPCR of 
peripheral blood cells in the patient did not reveal any evidence of copy number increase of 1q in 
these nonbrain cells (Figure 4-12C and data not shown). 
Single-cell copy number analysis was then performed on both the neuronal and non-
neuronal populations from the affected brain tissue of HMG-1. Due to the poor tissue quality 
evident by the abnormal FACS scatter plot of HMG-1 (data not shown), neuronal versus non-
neuronal 100-cell samples amplified by MDA were first analyzed for the presence of 
chromosome 1q copy number gains. An intermediate copy number gain of chromosome 1q was 
detected in both neuronal and non-neuronal cells (Figure 4-13A). The estimated copy number at 
chromosome 1q of neuronal and non-neuronal cells are 2.35 and 2.7, respectively. These 
estimates are in largely in agreement with previous estimates by SNP chip and qPCR (Figure 4-
12), and are consistent with our similar study on somatic point mutation on AKT3 (Figure 1-3), 
which affects both the neuronal and non-neuronal cells. The data suggest that the mutations 
occurred in a progenitor that gives rise to both neurons and glia. The higher chr1q copy number 
in non-neuronal cells suggests that a higher proportion of glial cells carrying the mutation 
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Figure 4-11. Copy number screening and MRI of hemimegalencephaly brains. 
(A) Initial copy number analysis of Affymetrix 100K SNP data from 6 cases of HMG shows the trisomy 
of 1q in HMG-1 and HMG-2. The additional two cases were evaluated using Affymetrix 6.0 data (not 
shown). Dark pink indicates copy number 3, and light pink copy number 2 (normal). A diagram of 
chromosome 1 is presented (adapted from www.genome.ucsc.edu); note that there are no SNP probes in 
the centromeric regions. 
(B) The first column shows an example of coronal T2-weighted and axial T2-weighted MRI images 
showing the brain of a normal 1 year old. Note the symmetric size of the right and left hemispheres, 
labeled R and L to denote standard MRI convention. The middle column shows a representative image of 
HMG-1. MRI before surgery showed left-sided hemispheric enlargement, abnormal cortical thickness 
and configuration, and enlarged left lateral ventricle in the coronal T2-weighted and axial T2-weighted 
images. The right hemisphere is smaller and appears normal. The right column shows representative MRI 
image after left hemispherectomy surgery, there is cerebrospinal fluid (CSF) where the abnormal 
hemisphere had been, seen as bright signal in coronal and axial images taken at approximately the same 
plane as the preoperative images. 
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Figure 3. Mosaic Mutations in Hemimegalencephaly: Trisomy of Chromosome 1q and an Activating Point Mutation in AKT3
(A) Copy number for all of the chromosomes is shown for HMG-1; the estimated copy number for 1q is 2.41 (SD 0.12), consistent with mosaic trisomy 1q.
Chromosome 1p, as well as the other autosomes, has normal copy number of 2, and chromosomes X and Y each show copy number of 1. (B) Copy number
evaluation of Affymetrix 6.0 data shows the gain in copy number at chromosome 1q for HMG-1, with the x axis representing nucleotide position along chro-
mosome 1 and the y axis denoting copy number. (C) Assuming a copy number of 2 for all regions in the DNA derived from leukocytes (white columns), the
calculated copy number from the brain tissue (black columns) was 2.68 (SD 0.16) at 1q21.3, 2.76 (SD 0.20) at 1q31.1, and 2.73 (SD 0.13) at 1q42.2. (D) The AKT3
c.49G/A, p.E17K heterozygous mutation is present in the sequencing traces from brain-derived DNA (first row) and absent in the traces from leukocyte-derived
DNA from HMG-3 (second row). The arrows point to AKT3 nucleotide position 49. Cloning results indicate that the mutation is present in 8/46 (17.4%) of the DNA
reads from a brain tissue sample, suggesting that the mutation exists in the heterozygous state in 35% of the cells; traces from two clones are shown in the third
and fourth rows; the trace in the third row shows the results of sequencing from a clone with the AKT3 c.49G/Amutation present (A), and the bottom row shows
the results from a clone without the mutation but rather with the reference allele present (G).
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Figure 3. Mosaic Mutations in Hemimegalencephaly: Trisomy of Chromosome 1q and an Activating Point Mutation in AKT3
(A) Copy number for all of the chromosomes is shown for HMG-1; the estimated copy number for 1q is 2.41 (SD 0.12), consistent with mosaic trisomy 1q.
Chromosome 1p, as well as the other autosomes, has normal copy number of 2, and chromosomes X and Y each show copy number of 1. (B) Copy number
evaluation of Affymetrix 6.0 data shows the gain in copy number at chromosome 1q for HMG-1, with the x axis representing nucleotide position along chro-
mosome 1 and the y axis denoting copy number. (C) Assuming a copy number of 2 for all regions in the DNA derived from leukocytes (white columns), the
calculated copy number from the brain tissue (black columns) was 2.68 (SD 0.16) at 1q21.3, 2.76 (SD 0.20) at 1q31.1, and 2.73 (SD 0.13) at 1q42.2. (D) The AKT3
c.49G/A, p.E17K heterozygous mutation is present in the sequencing traces from brain-derived DNA (first row) and absent in the traces from leukocyte-derived
DNA from HMG-3 (second row). The arrows point to AKT3 nucleotide position 49. Cloning results indicate that the mutation is present in 8/46 (17.4%) of the DNA
reads from a brain tissue sample, suggesting that the mutation exists in the heterozygous state in 35% of the cells; traces from two clones are shown in the third
and fourth rows; the trace in the third row shows the results of sequencing from a clone with the AKT3 c.49G/Amutation present (A), and the bottom row shows
the results from a clone without the mutation but rather with the reference allele present (G).
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Figure 4-12. Mosaic copy number gain at chromosome 1q of HMG-1. 
(A) Copy number for all of the chromosomes is shown for HMG-1; the estimated copy number for 1q is 
2.41 (SD 0.12), consistent with mosaic trisomy 1q. Chromosome 1p, as well as the other autosomes, has 
normal copy number of 2, and chromosomes X and Y each show copy number of 1. 
(B) Copy number evaluation of Affymetrix 6.0 data shows the gain in copy number at chromosome 1q 
for HMG-1, with the x axis representing nucleotide position along chromosome 1 and the y axis denoting 
copy number. 
(C) Assuming a copy number of 2 for all regions in the DNA derived from leukocytes (white columns), 
the calculated copy number from the brain tissue (black columns) was 2.68 (SD 0.16) at 1q21.3, 2.76 
(SD 0.20) at 1q31.1, and 2.73 (SD 0.13) at 1q42.2. 
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compared on neurons, perhaps reflecting their ability to continue to proliferate. The variable 
copy number estimates ranging from  2.41 to 2.76 may reflect the difference in the percent of 
cells carrying the mutation from different cortical regions sampled and/or the slight difference in 
neuronal versus glial composition of the sampled regions. 
Chromosomal copy number analysis was then performed on single neurons isolated from 
the HMG-1 brain. Due to the poor tissue quality, which had gone through multiple freeze-thaw 
cycles before the analysis, most of the cells were amplified poorly and did not pass the MAPD 
QC threshold. Among all 45 single neurons sequenced, only 8 samples passed the threshold of 
MAPD <= 0.45; and 1 of 8 neurons was positive for chromosome 1q copy number gain (Figure 
4-13B). Surprisingly, instead of detecting a trisomic chromosome 1q (CN=3) as previously 
assumed, tetrasomic chromosome 1q (CN=4) was detected from this single neuron, highlighting 
the importance of single cell copy number analysis in revealing the nature of mosaic copy 
number variations. Additional cells from both NeuN+ and NeuN- populations with MAPD 
scores that failed the QC threshold nonetheless independently confirmed the observation of 
tetrasomy 1q (Figure 4-13C). Tetrasomy 1q was previously described a mosaic state from 
embryos with nasopharyngeal teratomas, a rare neonatal neoplastic condition (Beverstock et al. 
1999), providing further evidence for the pathogenic role of this CNV in driving over-
proliferation. The previously identified tetrasomy 1q case exists as an isodicentric chromosome 
1q (47, XX, +idic(1)(q10)), making it stably transmitted through cell division. Therefore, it is 
highly likely that the tetrasomy 1q cells from HMG-1 brain also represents an isodicentric 1q; 
interphase FISH analysis on the HMG-1 brain is to be carried out to confirm the finding. 
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Figure 4-13. Single-cell copy number profiling of HMG-1. 
(A) 100-cell neuronal versus non-neuronal cells from HMG-1 brain. Both show copy number increase at 
chromosome 1q. 
(B) Representative single neurons from HMG-1 that passed the QC threshold. HMG-1_NeuN+_14 
shows CN=4 at chromosome 1q; whereas HMG-1_NeuN+_31 shows CN=2 at chromosome 1q. 
(C) Additional single cells that failed the QC threshold from both neuronal and non-neuronal population 
of HMG-1 brain but show tetrasomy 1q.  
X-axis represents all 6,000 genomic bins arranger by their genomic positions by chromosomes. Log2 
transformed Y-axis denotes the copy number ratio (CNR) respect to euploid genome.  
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Discussion 
This chapter presents the first rigorous comparison of two independent single-cell 
whole genome amplification methods used for single cell copy number analysis. We 
conclude that WGA4 is a more reliable amplification method for single-cell copy number 
analysis, consistently producing amplified product with less stochastic amplification 
noise as well as less stochastic locus dropouts than MDA. We suspect that this advantage 
in amplification linearity is mostly due to the initial fragmentation of the genome into 
~400kb fragments. Compared with the amplification fragments up to 50Mb in size by 
MDA, the 100-fold smaller fragment size allows more fragments to be independently 
amplified within any given genomic region, making the under or over amplification of 
fractions of the fragments less important to the overall copy number of the genomic 
region. This is evident by the increased stochastic noise and dropout by increased 
genomic bin sizes (Figure 4-2, and data not known). However, the gain of amplification 
linearity is at an expensive cost of genomic coverage since only ~10% of the initial 
fragments are successfully amplified, making the method unsuitable for studies of any 
other type of mutations (Navin et al. 2011; C. Zhang et al. 2013). Moreover, due to the 
pre-amplification fragmentation, WGA4 yields non-overlapping small fragments, which 
makes it incompatible with PCR based secondary validation. This is another lethal 
drawback of WGA4 since single-cell amplification is known to create a large number of 
technical false positives, secondary validations such as cloning of the breakpoints are 
crucial for making confident discoveries.  
MDA poses significant advantages on the studies of a whole spectrum of somatic 
mutations types and is amendable for various secondary validations as discussed in 
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Chapter 3 and here we demonstrate that MDA can also be used for copy number analysis, 
at least at the chromosomal level. We achieved 100% sensitivity is detecting trisomy 18, 
which is 74Mb in size, from single cortical neurons. Trisomy 18 is one of the smallest 
chromosomes in the genome and copy number 3 is known to be most challenging to 
detect by any copy number algorithm. With such technical sensitivity, we can 
comfortably conclude that we will be able to detect most of the somatically aneuploid 
neurons if they are as common as previously suggested using other methods (Kingsbury 
et al. 2005).  
From the 82 single cortical neurons, derived from 3 normal individuals, that we 
analyzed, we did not find any aneuploid neurons in which copy number alternations were 
limited to just one or two chromosomes, such as might result of chromosomal 
missegregation during mitosis due to multipolar spindles(Yang et al. 2003). In contrast, 
in the 3 out 82 neurons that showed chromosomal imbalances, they affected multiple 
chromosomes with copy number gains and losses at the whole chromosome or 
chromosome arm level, as well as alternating copy numbers within a single chromosome, 
a characteristic feature of chromosome “shredding” (Figure 4-5, 6, 7). These cells, if 
physiological, would not result from simple chromosomal missegregation, but rather 
would suggest more catastrophic events that produce global chromosomal 
rearrangements. No obvious mechanism is currently known to explain the observation. 
Chromotriphisis, a recently described phenomenon that leads to massive chromosomal 
breakage and rearrangements may be the most plausible biological explanation (Forment 
et al. 2012). However, the currently characterized chromotriphisis events are mostly 
restricted to a single chromosome and rarely affect multiple chromosomes at once 
	   155	  
(Stephens et al. 2011). Although we cannot conclude definitely whether the observed 
aberrant cells are physiological, we successfully ruled out several obvious technical 
causes of the observations. 
Regarding the 2 cells that showed large apparent homozygous deletions affecting 
multiple chromosomes (WGA4_4643ctx_30 and MDA_4638ctx_24), other groups have 
made similar observation. Baslan et al. (2012) who developed the first protocol of 
performing single-cell copy number analysis with WGA4 has described a similar 
observation and referred to it as “genome sector loss” (GSL), characterized by large 
homozygous deletions and patterns consistent with chromosomal “shredding”. They 
observed ~5% of single cells with “genome sector loss” from a variety of sample sources, 
including cultured cells and postmortem samples from normal and malignant. Therefore, 
regardless its biological significance, this observation is not limited to the brain. It is also 
not a simple reflection of a specific whole-genome amplification method or lysis 
condition since similar observations have been made in both WGA4 and MDA amplified 
cells, as well as cells lysed by both proteinase K digestion (WGA4) and alkaline lysis 
(MDA and WGA4).  
One potential technical cause of gross chromosome loss is loss of chromosomes 
during the nuclear sorting step, as both studies that report widespread chromosome loss 
used nucleus sorting as opposed to other single cell isolation methods. Nuclei are known 
to be fragile and thereby it is possible that a small fraction of the nuclei are shredded 
during the sorting process, leading to random loss of genomic segments. To test this, 
whole cells could be sorted or microfluidic devices used for cell/nuclei isolation for 
parallel analysis. It is also possible that the grossly abnormal cells are undergoing 
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apoptosis, although a ~5% frequency of apoptotic neurons in normal individuals seems to 
be too high. Postmortem apoptosis could also be a potential explanation; however, similar 
observation from cultured cells makes it less likely.  
The other type of genome-wide chromosomal imbalance observed in our study, 
from a single neuron amplified by WGA4 (WGA4_4643ctx_22), does not exhibit 
homozygous genomic deletions, but instead shows chromosomal or sub-chromosomal 
copy number alternations covering four copy number states (CN=1, 2, 3, 4). The 
observation of some chromosomes with copy number > 2 makes it possible that a mitotic 
non-neuronal nucleus is accidently sorted or is attached to a neuronal nucleus. A recent 
study of single cell copy number profiling in S-phase cells reveal that DNA replication 
introduces (pseudo) false-positive copy number variations and the DNA-replication 
domain varies depending the stage of S-phase (Van der Aa et al. 2013). Alternatively, 
this cell can indeed be a partial tetrasomy cell that has undergone mitotic slippage 
followed by genome-wide chromosomal rearrangements. Such a result may also explain 
why earlier studies using interphase FISH technique detects cells with copy number 
ranging from 1-4 with probe against a single chromosome. In this case, the frequency of 
neurons with genome-wide chromosomal imbalance is estimated to be 1.2% (95% CI: 
0.02%-6.6%).  
Segmental CNV analysis of single cells is the most challenging aspect of single 
cell genomics, due to the lack of biological hallmarks for secondary validation. Our 
current results have suggested that CNVs at copy number 0, 3, or 4 larger than 2Mb are 
rare. However, due to the lack of positive controls, we cannot directly assess the 
sensitivity of our method at these 3 CNV states. The lack of positive controls reflects the 
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fact that CNVs at this large size barely occur in the germline of healthy individuals and 
none of the 3 normal individuals analyzed have germline CNVs larger than 2Mb that 
could be used as positive control. Alternatively, disease-causing, large CNVs can be used 
as positive controls in the future to assess the sensitivity and limitation of the method.  
An average of 1.5 events/cell of heterozygous deletion (i.e. CNV1) larger than 
2Mb was detected. These candidates should be further validated by an LOH test, which is 
not possible with the current data due to the ultra low sequencing depth. More than half 
of the heterozygous deletions are localized to chromosomes with additional deletions, 
suggestive of either poor amplification of the whole chromosome or chromothripsis 
(Appendix Table 4-1). Further higher coverage sequencing and LOH analysis could 
differentiate the two possibilities. Nevertheless, this CNV frequency is likely to be a 
significant over-estimation of the true frequency since some CNV calls probably 
represent false-positive dropouts. The true specificity is impossible to assess with the 
current method due to the lack of secondary validation that can be applied independent of 
the amplification bias and the lack of gold standard negative controls since the genome of 
every single cells can be different. 
 The identification of somatic mosaic tetrasomy 1q, which likely represents an 
isodicentric 1q, and that drives the over-proliferation of neural progenitors to cause 
hemimegalencephaly is an important finding in epilepsy genetics. It points to a second 
molecular mechanism, besides the PI3K-AKT-mTOR activating mutations, that can 
cause this non-malignant overgrowth syndrome. More interestingly, both of the PI3KC2B 
and AKT3 genes are localized to chromosome 1q; therefore, it’s tempting to hypothesize 
that the dosage increase of these two genes is sufficient to hyper-activate the pathway to 
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provide proliferative advantages is the affected cells. It also likely explains why somatic 
chromosome 1q copy number gains are highly enriched in cancer cells (Beroukhim et al. 
2010). Although aneuploidy are often regarded as anti-proliferative, here we provided an 
exceptional example of aneuploid cells that show pathogenic proliferative advantages, 
providing insights into the ongoing debate about whether aneuploidy can be a causal 
driver of cancers (Siegel & Amon 2012). 
 
Materials and Methods 
Copy number analysis pipeline 
The copy number analysis pipeline is adapted but modified from Baslan, et al. 
(2012). The data analysis flowchart is presented in Figure 4-14.To create bin boundaries, 
20 million 50bp simulation reads against hg19 reference and mapped with bowtie -v 2 -m 
1 --best --strata settings (Langmead et al. 2009). Boundaries of 6,000, 20,000, and 50,000 
genomes bins are generated with variable sizes to ensure equal number of reads inside 
each bins. The average bin size of 6,000, 20,000 and 50,000 are 500kb, 150kb and 60kb, 
respectively. Generating equal-read instead of equal-size genomic bins controls for the 
mappability of the genome so that each bin receives a comparable number of reads and 
thereby a similar data variance from random sampling. The percent of GC-content of 
each calculated bin was then measured for later GC normalization. All sequence reads are 
first demultiplexed by CASAVA allowing for 1 mismatch in the 6-bp index sequences. 
Sequence reads are further trimmed based on the FASTQC score allowing at least 38bp 
reads for bowtie mapping with the same setting. Mapped stats are reviewed to samples 
with at least 80% uniquely mapped reads for MDA and 40% uniquely mapped reads for 
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• Adapted from Baslan et al., 2012
50bp SE reads: 
Trim and map with Bowtie Mapping stats QC
Calculate RPM per bin
hg19 simulated 50bp reads
Map with Bowtie
Create equal-read bins
Calculate GC-content per bin GC-normalized CNR
Segmentation 
(alpha=0.05, nperm=5)
MAPD QC
Dropout QC
Chromosomal-level 
aneuploidy
Segmental CNV AnalysisConfirm with different bin sizes
Figure 4-14. Illustration of the scCNV data analysis pipeline. 
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WGA4 are allowed to proceed forward. The low mapping percentage of WGA4 samples 
is due to the additional adaptors added to the amplicons. Then the number of reads in 
each bin is counted (RPBi) and normalized by the total number of reads of the particular 
sample (RPMBi).  
The copy number ratio (CNR) is then calculated by: CNRi = RPBi/average(RPBi). 
Chromosomal copy number is then calculated as previously described in Chapter 3. Any 
chromosome with a copy number (CN) > 1.5 or <0.5 is called as copy number gain and 
loss, respectively. In parallel, the GC-normalized CNR (GCNR) (see detailed in Chapter 
3) is calculated for each bin, and the data set is subject to segmentation with parameters 
alpha=0.05 and number of permutation (nperm)=5 using the DNAcopy package 
(Venkatraman & Olshen 2007). A quality control step on amplification noise measured 
by MAPD score is applied to all the samples passed the mapping stats QC (see details in 
next section). Samples with MAPD score <= 0.45 are allowed to proceed to chromosomal 
copy number analysis and segmentation. We found a strong correlation between 
chromosomal copy number alternations and high MAPD scores, suggesting that poor 
quality samples with high MAPD scores tend to produce false positive results and 
thereby should be excluded from further analysis (Figure 4-4). After segmentation, the 
copy number profiles of each sample are plotted by the GCNR value in gray and 
segmented GCNR (seg.GCNR) value in blue of each genomic bin across the genome. 
The aneuploidy calls on a chromosomal level are further validated with the segmentation. 
Again, all trisomy 18 cells that passed the QC threshold showed copy number gain at 
chromosome 18 after segmentation. The three cells with chromosomal imbalance are 
further analyzed at every single chromosome to reveal the pattern of copy number 
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alternations. For segmental CNV analysis, only WGA4 amplified single neurons are used. 
An additional quality-control step was incorporated by counting the number of bins with 
a copy number loss at 1 or more (log2GCNR <= - 1) from each sample. A threshold of 
100 bins/genome with copy number <= 1 is used to eliminate poor quality cells with 
increased technical dropouts from further analysis. Segmental CNVs with size larger than 
2Mb are called of the segmentation data based on the following criteria: CNV0 when 
seg.log2GCNR < -1.5; CNV1 when -1.5 <= seg.log2GCNR < -0.6; CNV2 when -0.6 <= 
seg.log2GCNR <= 0.4; CNV3 when 0.4 < seg.log2GCNR <= 0.8 and CNV4 when 
seg.log2GCNR > 0.8. All the CNV candidates were first called with 6,000 bins and then 
validated by rerunning the pipeline at 50,000 bins; only the candidates that are called by 
both analyses are retained as the final candidates. In parallel, all the candidates are 
BLATed against the UCSC hg19 reference genome and some of the candidate regions are 
turned out to be unmappable regions such as centromeres and telomeres. These 
candidates are also excluded from the final list as they are caused mapping and binning 
artifacts.  
MAPD QC metrics 
The MAPD QC metric was developed by adapting the Affymetrix multiple 
absolute pairwise differences algorithm (Affymetrix, Inc. 2008). MAPD = 
median(|log2GCNRi+1 - log2GCNRi|) where i stands for individual bins. A MAPD 
threshold of 0.45 is used for all single cell genome amplified samples because it appears 
to be the border line where samples with noisy copy number profiles start to cause false 
positive aneuploidy calls (Figure 4-4). 
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Copy number screen, SNP-chip and qPCRs 
We obtained eight samples of flash-frozen brain tissue resected during focal 
epilepsy surgery for HMG. DNA was extracted by using standard methods and was then 
digested, amplified, and hybridized to Affymetrix 100K SNP arrays for six of the 
samples (Affymetrix). In the original arrays (e.g., 100K), copy number was assessed 
based on intensity of signal from each SNP. For the Affymetrix 6.0 arrays, copy number 
probes are included in addition to the full array of SNPs, and both are used for 
quantitation. The Gaussian- smoothed signal log2-ratio of all probe intensities normalized 
to a reference of 270 normal HapMap samples was calculated by Affymetrix Genotyping 
Console with standard settings. Additional DNA from HMG-1 and two other samples 
was assessed by using the Affymetrix 6.0 SNP array. The software dChipSNP was used 
for analysis. 
For HMG-1 and HMG-2, we performed qPCR in cases in which copy number 
change was detected. Primers were designed to 1q44 and 1p21.1. DNA from two control 
individuals (Promega) was used for comparison. We repeated qPCR in an additional 
specimen from HMG-1 for confirmation by using primers targeting 1p (1p13.3, 1p32.3, 
and 1p36.2) and 1q (1q21.3, 1q31.1, and 1q42.2). 
Leukocytes were obtained from six of the cases; DNA was extracted by using 
standard methods and was used for SNP analysis as above. For HMG-1, we performed 
SNP analysis and clinical karyotype to assess for the presence of mosaic copy number 
gain at 1q in peripheral blood leukocytes (evaluating 50 cells to detect even a low level of 
mosaicism). 
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Chapter 5: Conclusions and Future Directions
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Genetic Diversity and Diseases 
 
This dissertation, along with the dissertation of Gilad Evrony, serves as a proof-
of-principle study on how to systematically identify and quality genetic variabilities 
within a human brain, and it provides a foundation for future work on study of functional 
consequences of various types of somatic mutational events during neurodevelopment 
and aging. In this study, we show that the individual genomes of single neurons are 
indeed variable, with low frequency of somatic mutations acquired during the process of 
neurogenesis. We demonstrate that both L1 retrotransposition and aneuploidy—the two 
mutation types that were proposed to have increased prevalence in the human brain 
cells—are in fact rare with little evidence of brain specific elevation. Therefore, they are 
unlikely to serve as an obligated generator of genetic diversity within the human brain. 
However, our work presents only an incomplete survey of a subset of somatic mutations. 
Therefore, it is still possible that other types of somatic variants could be actively 
generated during human brain development, to diversify the genome of brain cells. To 
date, the only known mechanism for such genetic diversification is the V(D)J mechanism, 
which functions exclusively in the immune system (Jung et al. 2006). However, there is 
no clear evidence suggesting a similar mechanism active in the CNS; therefore, a CNS-
specific increase in genomic diversity seems unlikely based on current knowledge.  
On the other hand, neurons are the post-mitotic cells that live for decades. They 
are expected to accumulate DNA damages caused by endogenous (e.g. ROS) and 
environmental insults throughout individual’s lifespan. During this process, additional 
somatic mutations continue to be accumulated. Their functional consequences are 
unlikely to be obvious in the early stages of individual’s lifetime; however, these variants 
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and damages are accumulative, so they would become more and more likely to alter 
neuronal function with aging. Such a mechanism coincides with the development of 
neurodegenerative diseases with aging. Although genome-wide assessment of increased 
genetic variability during aging has not been available, studies on specific disease-
relevant loci have provided ample evidence on the ongoing somatic mutagenesis in 
human brains. For example, the length of the CAG repeats causing Huntington’s disease 
(HD) continues to expand in postmitotic neurons. Further evidence showed that such an 
ongoing mutagenesis are regulated in a regional-specific fashion with neurons from 
striatum harboring the highest genomic instability (Gonitel et al. 2008). Performing 
single-neuron whole-genome sequencing from young versus aged brains, one can 
immediately start asking questions such that whether there is any type of somatic 
mutations overrepresented during the aging process and whether there is any particular 
genomic regions (“hotspots”) susceptible for a given type of somatic variant. More 
importantly, the functional consequences of these potential genetic variants can be 
studied to definitively study the correlation between genomic instability and 
neurodegenerative diseases. Single-cell sequencing technique has become a valuable tool 
to interrogate these questions as each of the somatic variants occurred post-mitotically are 
unique to the individual neuron and hence cannot be easily identified by bulk sequencing. 
 
Aneuploidy 
The accumulation of aneuploid neurons during neurogenesis as well as during the 
aging process has been proposed as one of the major contributors to genetic variations 
within the human brain. Additionally, PGD single-cell screens on cleavage stage 
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blastomeres used for IVF procedures have revealed an unexpected high frequency of 
aneuploid cells and mosaic aneuploid embryos, ranging from 30%-80% based on a 
number of studies (van Echten-Arends et al. 2011; Vanneste et al. 2009; Yin et al. 2013). 
Assuming this is not an IVF-specific artifact, it suggests that many of us are developed 
from mosaic embryos. Although it is known that most aneuploid cells—with a few 
exceptions including trisomy and tetrasomy 1q—confer proliferative disadvantages; and 
therefore, they are likely to be outcompeted during embryonic development. It is still 
tempting to ask to which degree does our normal body can tolerate aneuploidy mosaicism 
and whether this is determined at a tissue/organ-specific manner. Two organs have been 
shown to harbor high levels of tissue-specific aneuploidy: one of which is the brain. 
Previous studies reported up to 30% aneuploidy within mouse neural progenitors and up 
to 10% within matured neurons from mouse and human adult brains (Rehen et al. 2001; 
Rehen et al. 2005). The hepatocyte in liver is the other cell type that has been observed to 
have high frequencies of aneuploidy; and the frequency appears to increase during aging 
and in response to toxic stresses (Duncan et al. 2010; Duncan et al. 2012). Despite the 
overall reduction of fitness to aneuploid cells, acquired aneuploidy has been proposed as 
a fast adaptive mechanism to external stresses under short-term selective pressure (Tang 
& Amon 2013). Conceivably, the very early stages of embryonic development could be 
highly stressful and therefore results in an extremely high rate of aneuploidy. 
In the context of brain development and aging brains, a high frequency of 
aneuploid cells among the neural progenitors presumably reflects the replicative-related 
stress during neurogenesis. On the other hand, those aneuploid progenitors are expected 
to be less proliferative compared to their wildtype competitors; therefore, they are more 
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likely to be outcompeted, or alternatively, terminally differentiate into neurons and 
survive. If the latter case were true, we would expect to see high prevalance of aneuploid 
post-mitotic neurons as some of the previous studies suggested (Rehen et al. 2005; 
Westra et al. 2008; Yurov et al. 2007). However, based on our comprehensive genome-
wide chromosomal copy number profiling of 82 cortical neurons from 3 normal brains (at 
age of 17, 15, and 42), we are unable to identify a single neuron with discrete 
chromosomal copy number alternation limited to one or two chromosome, as predicted 
outcome of mitotic missegregation. Instead, we identified three neurons with genome-
wide chromosomal imbalances. Two out of the three neurons harbor large homozygous 
deletions, a phenomenon independently described by Baslan et al. (2012). Since both 
studies used nucleus sorting to isolate single cells, we suspect that these two single 
neurons with large homozygous deletions are probably technical artifacts associated with 
nucleus sorting. The one additional aberrant neuron harbors multiple chromosomal gains 
and losses with 4 distinct copy number states (CNV1, 2, 3, 4). It can either be a mitotic 
cell falsely sorted or a partial tetraploid neuron that had gone through major catastrophic 
events, leading to unbalanced genome-wide chromosomal rearrangements. In any case, 
the frequency of such aberrant cells remains low (1/82); and therefore they are unlikely 
pose functional impact on the development of normal human brains. Nevertheless, it 
would be interesting to follow up on the molecular mechanism of grossly aneuploid 
neurons. One potential mechanism, analogous to the polyploidy/aneuploid hepatocytes, 
predicts the aneuploid neuron as a result of a progenitor cell undergone mitotic slippage 
followed by random multipolar division (Tang & Amon 2013). Alternatively, the grossly 
altered genome can be a secondary effect of misregulated cell division in the first place 
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(Ganem & Pellman 2012; Crasta et al. 2012). It is also interesting to note that multiple 
previous studies have observed an increase of aneuploid brain cells during aging (Yurov 
et al. 2007; Iourov et al. 2009; Kingsbury et al. 2006). Although the absolute 
quantification of aneuploid rates based on the interphase FISH studies can be indirect and 
inaccurate, the consistent relative increase of aneuploidy frequency in aged brains is 
informative. These observations together all suggest that increased chemical stress level 
(e.g. ROS) during aging of the human brain can lead to the accumulation of aneuploid 
cells. Further single cell copy number analysis on aged brain (age >70) could test whether 
the frequency of grossly aneuploid cells (analyzed at the age at 42) increases in an older 
brain. And if this is the case, it coincides with the previous observation shown by 
interphase FISH, and it suggests that the “aneuploid” cells detected by interphase FISH 
are instead more likely to be cells with unbalanced genome-wide chromosome 
rearrangements. The last piece of the puzzle is that how would a post-mitotic neuron turn 
into an aneuploid cells without going through further cell division?  Further mechanistic 
insight into the formation of the cells with genome-wide chromosomal imbalances would 
be required to answer the question. 
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ID	   Chrom	   Start	   End	   Num.
bin	  
Size	  
(MB)	  
Num.sampl
es	  shared	  
Copy	  
number	  
Comment	  
CNV1_1	   4	   95514470	   98688435	   8	   3.17	   1	  (13)	   1	   multiple	  dropouts	  
CNV1_2	   4	   108959992	   113614987	   11	   4.65	   1	  (13)	   1	   multiple	  dropouts	  
CNV1_3	   4	   116309137	   119638575	   8	   3.33	   1	  (13)	   1	   multiple	  dropouts	  
CNV1_5	   17	   9022233	   11365374	   6	   2.34	   1	  (13)	   1	   multiple	  dropouts	  
CNV1_6	   17	   56463429	   58563209	   5	   2.10	   1	  (13)	   1	   multiple	  dropouts	  
CNV1_7	   20	   43683943	   45958956	   6	   2.28	   1	  (14)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_8	   2	   82924718	   85207231	   6	   2.28	   1	  (17)	   1	   multiple	  dropouts	  
CNV1_9	   3	   10144745	   12434756	   6	   2.29	   1	  (17)	   1	   multiple	  dropouts	  
CNV1_10	   4	   156172930	   160256493	   10	   4.08	   1	  (17)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_11	   5	   112878401	   115198557	   6	   2.32	   1	  (17)	   1	   multiple	  dropouts	  
CNV1_12	   7	   150460160	   154011942	   8	   3.55	   1	  (17)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_13	   10	   130418442	   132609109	   6	   2.19	   1	  (17)	   1	   multiple	  dropouts	  
CNV1_15	   18	   7880279	   10169561	   6	   2.29	   1	  (18)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_16	   14	   99679698	   102844929	   8	   3.17	   1	  (19)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_17	   15	   47905237	   52033465	   10	   4.13	   1	  (19)	   1	   multiple	  dropouts	  
CNV1_18	   5	   33629556	   37072917	   8	   3.44	   1	  (20)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_20	   8	   14091831	   16323312	   6	   2.23	   1	  (21)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_21	   14	   64196851	   66531916	   6	   2.34	   1	  (21)	   1	   look	  real,	  remains	  in	  50k	  
CNV1_22	   19	   20152682	   22376604	   5	   2.22	   1	  (21)	   1	   multiple	  dropouts	  
CNV1_23	   2	   64143115	   66916655	   7	   2.77	   1	  (28)	   1	   multiple	  dropouts	  
CNV1_25	   6	   103749166	   106972538	   8	   3.22	   1	  (28)	   1	   multiple	  dropouts	  
CNV1_26	   11	   7990609	   11273782	   8	   3.28	   1	  (28)	   1	   multiple	  dropouts	  
CNV1_27	   14	   55414198	   58198919	   7	   2.78	   1	  (28)	   1	   multiple	  dropouts	  
CNV1_28	   3	   4637443	   9639508	   12	   5.00	   1	  (31)	   1	   multiple	  dropouts	  
CNV1_29	   3	   122844551	   125094833	   6	   2.25	   1	  (31)	   1	   multiple	  dropouts	  
CNV1_30	   10	   118456139	   120693419	   6	   2.24	   1	  (31)	   1	   multiple	  dropouts	  
CNV1_31	   23	   49039875	   53019359	   7	   3.98	   1	  (32)	   1	   look	  real,	  remains	  in	  50k	  
Appendix Table 4-1. Summary of segmental CNVs identified from WGA4 amplified single neurons.  
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